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ABSTRACT 
 
Silicon is an essential element in human nutrition, with the symptoms of a 
silicon-deficient diet being abnormal bone development (Carlisle, 1972). 
Similarly, animals and bone forming osteoblast-like cells in vitro show an 
increase in bone growth when supplemented with the soluble, bioavailable 
form of silicon, orthosilicic acid [Si(OH4)] (Carlisle, 1988). Certain bioactive 
glass compositions can form a strong chemical bond with bone, doing so by 
dissolving to form a solution that includes orthosilicic acid which re-
polymerises to form a hydrated silica gel layer that adsorbs growth factors, 
supports cell growth and acts a nucleation bed for bone mineral (Hench, 1980). 
Bioactive glass degradation products alone have also been shown to 
significantly enhance the activity of osteoblasts in vitro (Xynos et al, 2001).  
 
Pure, crystalline silicon is not soluble in water or body fluids, but when 
electrochemically etched with hydrofluoric acid, nanoscale silicon hydride-lined 
pores are formed through the material which render it soluble in aqueous 
solutions, yielding orthosilicic acid (Canham, 1996). Porous silicon has 
therefore been proposed as a novel orthopaedic biomaterial, acting in a similar 
way to bioactive glasses. In addition, the long, narrow pores can be filled with 
pharmaceuticals, creating a dissolvable drug delivery material with release 
kinetics that are easily controllable by adjusting the pore morphology and drug 
loading density (Anglin et al, 2008). 
 
This research aims to evaluate porous silicon (pSi) as a therapeutic biomaterial 
for bone tissue engineering applications in the form of a composite with the 
biodegradable polymer, polycaprolactone (PCL). pSi microparticles were 
incorporated into a polycaprolactone matrix and the composites characterised 
in terms of the ability to generate orthosilicic acids under various conditions. It 
was found that the composites released silicic acids at a rate proportional to the 
loading proportion of pSi, with 8% composites (20mg pSi in 230mg PCL) 
eluting ~400 ng.ml-1 Si per day. At this composition, pSi increased the amount 
of calcium phosphate formed on the composite in a simulated body fluid and 
this had the morphology and molar ratio of biological apatite (Ca:P § 1.5). 
 
The addition of 8% pSi to polymers enhanced the electroconductivity of 
hydrogels by two orders of magnitude and did not significantly affect 
mechanical strength. The release profiles of small molecules such as gentamicin 
and large hydrophobic proteins such as alkaline phosphatase were enhanced by 
pre-loading sample drugs into pSi rather than directly loading drugs into PCL. 
Crucially, the molecules retained their activity following release. Other proteins 
such as bovine serum albumin were adsorbed onto the surface silica gel layer, 
suggesting a method for localising growth factors onto biomaterial surfaces. 
 
Osteoblasts responded well to 8% pSi-PCL composites, producing significantly 
more collagen and glycosaminoglycans in vitro. Collagen in the extracellular 
matrix (ECM) was also significantly more highly crosslinked as determined by 
the pyridinium content of ECM lysates and was more mineralised than the 
ECM on PCL alone. The breakdown products of pSi also significantly 
enhanced the osteoblastic phenotype of cells in vitro. This research 
demonstrates that porous silicon can be added to polymer-based materials to 
enhance their effectiveness as biomaterials for orthopaedic tissue engineering.                               
 ix
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Chapter One 
1.1. Bone biology. 
 
The aim of the research presented here is to assess porous silicon as a bioactive 
agent which can be added to polymer-based implants to increase their 
osteoconductivity (bone-bonding ability). A supporting aim was to further 
elucidate the mechanisms and biochemistry of the effect silicon (in the form of 
silicic acids and silica) has on osteoblasts in vitro and determine a bioactive range 
of soluble silicic acids. 
 
The following sections outline the normal structure and formation of bone in vivo, 
provide a brief history of orthopaedic biomaterials and summarise the emerging 
recognition of the importance of silicon in bone formation, repair and in 
functional biomaterials. 
 
 
1.1.1. Bone structure  growth and repair. 
 
Bone is a dynamic biological tissue comprising organic and inorganic matrix 
components, living cells and haematopoietic elements forming a functional and 
load-bearing structure for support of the body. Although a rigid composite 
material, through the combined action of osteoblasts (which deposit organic 
matrix) and osteoclasts (which degrade bone tissue), bone is continually reshaped 
and remodelled to increase strength in response to changing stresses throughout 
life. This remodelling action also allows fractures in bone to heal as damaged bone 
can be removed and replaced, reforming a strong structural tissue over a period of 
several weeks (Sommerfeldt & Rubin, 2001). 
 
These repair mechanisms are very well documented and allow for physicians to 
enhance the rate and degree of bone repair through the inclusion of bone grafts 
or artificial strengthening materials during the healing process. As approximately 
500,000 bone repair operations are performed annually in the United States, 
improvements in clinical treatment of complex fractures, incidents of bone loss 
and joint prostheses are continually being sought (American Academy of 
Orthopaedic Surgeons, 2009). 
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1.1.1.1. Structure and biology. 
 
Bone is a complex composite material which is structurally organised in several 
hierarchical levels during formation and exists in various forms depending on the 
material properties required. Two main types of bone, cortical (or compact) and 
trabecular (cancellous or spongy) bone comprise the majority of osseous tissue 
found in the adult body. A third type, woven bone, is found during development 
and in some areas of a restoring fracture site, as it is able to form quickly and de 
novo without a preliminary collagenous matrix on which to build (Sommerfeldt & 
Rubin, 2001). Woven bone is structurally weak, lacking the high orders of 
organisation found in other types of bone and is gradually replaced by compact or 
trabecular bone as the site matures (Sommerfeldt & Rubin, 2001). 
 
Many bones are composed of combinations of these three types of tissue, 
depending on the location and stresses particular to the bone. Long bones, for 
example, consist of an outer layer or collar of cortical bone for strength with an 
inner medullary core of trabecular bone supporting the haemopoetic (bone 
marrow) matrix and allowing transfer of stresses such as those in the femoral head 
(fig. 1.1). Cranial and maxillo-facial bones are often plates, consisting of a 
sandwich of trabeculae surrounded by cortical-type bone (fig. 1.2). 
Fig. 1.1. A. Human femur in section revealing trabecular bone distributed along 
lines of tension and compression and, B. Stress trajectories in the human femur 
(from Thompson, 1992). 
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Fig. 1.2. Cross section of the maxilla, showing the typical arrangement of cranio-
facial bones as dense, cortical-type plates with larger bones having trabecular 
cores (from Gray 1858). 
 
Cortical bone is very dense, forming in sites where large loads are borne and 
providing support for locomotion and other motor functions. Cortical bone is 
arranged in osteons, a series of concentric rings surrounding the central Haversian 
canal, which contains blood vessels that are linked laterally by Volkmanns canals 
(fig. 1.3). Osteocytes surrounded by osseous matrix are found in lacunae (spaces) 
within these rings and are linked by long cellular processes through a series of 
pores known as canaliculae with an average diameter (in humans) of 259nm 
(Liyan et al, 2005), enabling the exchange of nutrients, growth factors and factors 
responsible for maintaining calcium levels within the body. 
 
In contrast, trabecular bone density is only 5 - 60% and forms the inner core of 
most long bones and cranial plates. Trabeculae are rod or plate-like, in general no 
greater than 200 Ƭm in thickness and about 1000 Ƭm long.  Although lacking the 
regular composition of cortical bone osteons, Jee (1983) denotes the trabecular 
packet as the basic structural unit of trabecular bone based on the fact that it is 
the basic remodelling unit, just as the osteon is the basic remodelling unit of 
cortical bone. Trabecular packets are regions of osteoclast activity, creating a 
lacuna typically 50Ƭm deep and 1mm long which is re-ossified by osteoblasts. As a 
product of osteoclastic remodelling, trabecular packets only exist on the surface of 
secondary (mature) bone, are comprised of lamellae and joined to the adjacent 
bone by cement lines similar to those seen in cortical bone.  
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Fig 1.3. Images of cortical bone showing the concentric rings system surrounding 
longitudinal Haversian canals and interconnecting Volkmanns canals  osteocyte 
lacunae are visible as black dots. Narrow canaliculi connect osteocyte lacunae, 
allowing for exchange of nutrients, waste and extracellular messages (from 
Khoury & Esterhai, 2006).  
 
 
Unlike osteons, trabeculae in general do not have a central canal with a blood 
vessel, although unusually thick trabeculae contain a blood vessel and some 
osteon like structure with concentric lamellae (Barou et al, 2002). Depending on 
the location and age of the bone, several types of trabeculae form, varying in 
thickness and interconnectivity and degree of anisotropy (fig. 1.4).  
 
This latter characteristic - the formation of trabecular structures along lines of 
stress to add further support to bones bearing higher loads in certain directions 
such as vertebrae, demonstrates the ability for osteoclastic remodelling to enhance 
bone strength.   
 
Both cortical and trabecular bone are surrounded by the periosteum - an envelope 
of fibrous connective tissue. In addition to providing blood supply and 
noinceptive (pain-sensing) innervation to the bone surface, the periosteum is the 
main store of osteoprogenitor cells and osteoblasts, thereby being particularly 
important in fracture repair.  
 
 5 
Chapter One 
 
 
Fig. 1.4. Tomography models based on scans of trabecular bone from different 
sites (37 year old male), showing a) illiac crest, b) femoral head, c) Lumbar spine 
(LS4) and d) lumbar spine (LS2). These images illustrate the adaptability and 
anisotropic growth of trabecular bone in response to specific forces at each site 
(from Muller & Ruegsegger, 1997). 
 
 
The periosteum is strongly bound to the bone matrix by strong collagenous 
Sharpeys fibers that penetrate the circumferential surface and interstitial lamellae 
(Kuroiwa et al, 1994). The inner medullary cavity of long bones is similarly lined 
by a thinner vascular layer, the endosteum, which also provides a source of 
osteoprogenitor cells and blood supply (Menton et al, 1982).  
 
 
1.1.1.2. Cell types in bone metabolism. 
 
Bone is a complex, highly ordered tissue which is dynamically remodelled by a 
variety of cell types throughout life. These cells can be classified into two main 
types, which have distinct lineages, and are responsible for a) bone deposition and 
homeostasis, or b) bone resorbtion. As a dynamic and continually adapted tissue, 
these cells are often both present and active concurrently, for example in a healing 
wound site or on either side of a trabeculum which is undergoing remodelling 
(fig. 1.5). 
 
In addition to the cells responsible for bone metabolism, most long bones contain 
bone marrow which contains haemopoetic cells and adipocytes.  
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Fig. 1.5. Osteoblasts and osteoclasts on trabecula of lower jaw of calf embryo. 
From Grays Anatomy, 1858. 
 
 
1.1.1.3. Bone formation and metabolism. 
 
The cells responsible for deposition of bone matrix and homeostatic regulation of 
bone metabolism derive from osteo-progenitor cells of a mesenchymal lineage 
(Modder & Khosla, 2008; Liu et al, 2009). These pre-osteoblastic cells are found in 
large numbers, forming sheets in the inner part of the periosteum and the 
endosteum. Osteoprogenitor cells have been shown to attach to laminin-1, 
inhibiting the subsequent attachment of other cell types in rat calvarial in vitro 
cultures (Roche et al, 1999). 
 
Osteoprogenitor cells and pre-osteoblasts are dividing cells, providing a source of 
osteoblasts for bone remodelling and repair following bone damage. 
Osteoprogenitor cells are also stimulated to differentiate into either osteoblasts or 
chondroblasts by the relative vascularisation of the tissue (Cormack, 1984). Upon 
receiving signals for differentiation, the pre-osteoblasts mature, losing the ability 
to divide and increasing the expression of osteoblastic markers such as Type I 
collagen and alkaline phosphatase (Leung et al, 1993).  
 
Once differentiation initiates, osteoblasts begin to produce extracellular matrix 
components and allied substances involved in mineralisation of the osteoid, 
maturing into osteoblasts and potentially then osteocytes. The differentiation of 
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osteoprogenitor cells and pre-osteoblasts into mature, active osteoblasts is 
characterised by several morphological changes in the cells structure and 
appearance, coupled to the expression of a variety of molecular markers, some of 
which are unique to the osteoblast (page 11). Mature osteoblasts are active 
secretary cells with prominent golgi apparatus and rough endoplasmic reticulum 
(Cormack, 1984) and are connected to each other and to underlying osteocytes via 
gap and adherens junctions (Cross, 1993). 
 
Osteocytes are osteoblasts which become surrounded by osseous matrix and 
differentiate, changing from a bone deposition phenotype to one of bone 
homeostasis and maintenance of calcium levels (Teti & Zallone, 2009). After bone 
deposition, 10-20% of osteoblasts become encased in this way, becoming smaller 
and losing many of the intracellular organelles they possessed as osteoblasts - the 
remaining osteoblasts undergo apoptosis (Nijerwerde et al, 1996). 
 
Osteocytes are well connected to each other and to osteoprogenitor cells and 
osteoblasts via extensive cellular processes which connect through tunnels in the 
osseous matrix known as canaliculi, such that nutrients, waste and intercellular 
messages can be exchanged via gap and adherens junctions. Osteocytes are 
sensitive to parathyroid hormone and calcitonin, indicating that part of their role 
is in maintaining plasma calcium levels and thereby governing the bodys stores of 
this element (Billah, 1996). 
 
The osteocyte lacuna is typically 10-20Ƭm in diameter and both lacuna and 
canaliculi are filled with an annular fluid, thought to be a gel-like matrix composed 
of proteoglycans and other matrix molecules (fig. 1.6). This matrix resists fluid 
flow and assists in the osteocyte response to mechanical load which is though to 
be a major regulatory factor in bone remodeling (Weinbaum et al, 1994). 
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Fig. 1.6. Osteocytes in cortical bone after propyl-butadienylpyridiniumbromide 
dye (RH 414)-H2O staining and laromin C- embedding. Bar = 30 µm (from Meyle 
et al, 2002). 
 
 
1.1.1.4. Bone resorbtion. 
 
Osteoclasts are multinucleated cells that degrade and resorb bone and arise from 
haemopoetic cells of the monocyte/neutrophil lineage (specifically CFU-GM), 
rather than from the osteoprogenitor lineage (Vaananen et al, 2000; Billah et al, 
1996). Osteoclasts can be histologically stained using acid phosphatase (Evans et 
al, 1980) and represent only a small percentage of the bone cell population, far 
fewer than osteoblasts (Nijerwerde et al, 1996).  
 
Osteoclasts lie in small conical cavities called Howship's lacunae, formed from the 
digestion of the underlying bone and sealed by the attachment of the osteoclast's 
plasmalemma which is ruffled to increase surface area (Holtrop & King, 1977; fig. 
1.7). The osteoclast releases hydrogen ions (H2O + CO2 Ⱥ HCO3- + H+) into the 
cavity, acidifying and dissolving the mineralized bone matrix into Ca2+, H3PO4, 
H2CO3 and H2O. H
+ ions are pumped against a high concentration gradient by 
proton pumps, specifically a unique vacuolar-ATPase (Chatterjee et al, 1992). 
Additionally, several hydrolytic enzymes including collagenase and cathepsin K 
are released into the lacuna via lysosomes to degrade the organic matrix. Debris, 
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calcium and protease products are endocytosed by the cell allowing for processing 
of the vesicles in the cytoplasm before excretion. Regulation of osteoclastic 
differentiation and activity is by several hormones, including parathyroid hormone 
(PTH), calcitonin and interleukin 6 (IL-6) (Greenfield et al, 1999).  
 
                           A 
 
 
 
 
 
 
  B 
 
 
 
 
 
Fig. 1.7. A. Schematic of osteoclast action at a resorbtion lacuna. The sealing 
zone creates a border under which protons are pumped against a high 
concentration gradient to erode the inorganic phase of bone. The organic matrix 
is degraded by collagenases and other proteolytic enzymes (Vaananen et al, 2000). 
B. (inset) A resorbing osteoclast on bone showing distinctive phenotype and 
resorbtion trail (from the website of the Bone Research Organisation, 2008). 
 
 
A familiar example of osteoclastic activity is in orthodontic tooth straightening 
using braces. Pressure exerted on the periodontal ligament of the tooth (by the 
braces) causes osteoclasts to absorb the bone which is then re-laid by osteoblasts 
to coincide with the reduced pressure on the opposite side of the tooth. 
Imbalances in osteoclastic activity can result in osteoporosis (osteoclast 
overactivity, reviewed in Liu et al, 2003), Pagets disease (Hasenhuttl, 1962) or 
osteopetrosis (insufficient activity, reviewed in Helfrich, 2003) 
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1.1.2. Molecular biology of the osteoblast. 
 
Osteoblasts are characterised both by their morphology and by their expression of 
various unique molecular markers secreted in the formation of organic 
extracellular matrix (osteoid) and in regulating its subsequent mineralisation. The 
expression of these molecular markers varies over time in response to the tissue 
site and exogenous mediators of activity. The differentiated and actively secreting 
osteoblast expresses the following proteins. 
 
1.1.2.1. Collagen. 
 
Type I collagen is the most abundant type of collagen in the human body, being 
predominant in skin, lung and scar tissue and comprising ~90% of the organic 
component of bone (Nigg & Macintosh, 2000). The distribution and orientation 
of collagen is highly organised on several levels, reflected in the high tensile 
strength of bone (also see fig 6.1). The serially regulated structure of collagen is 
shown in fig. 1.8. 
 
Fig. 1.8. Hierarchical organisation of collagen from the atomic scale to the 
microscopic, showing the beginning of mineralisation as the gaps between 
tropocollagen (TC) molecules act as nucleation sites for apatite crystals. From 
Buehler, 2007. 
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The tropocollagen superhelix is approximately 300 nm long and 1.5 nm in 
diameter and is comprised of three alpha polypeptide strands which individually 
are 'left-handed' and wind together in a right handed fashion to form a triple helix 
structure that is stabilised by extensive hydrogen bonding. 
 
Collagen is rich is three particular amino acids: glycine, proline and 
hydroxyproline. Crucially to the structural role of collagen, glycine (the smallest 
amino acid with no side chain) is required as every third amino acid in the chain 
since the assembly of the triple helix puts this residue at the interior of the helix. 
Similarly, the side chains of proline and hydroxyproline always point out of the 
main axis of the helix, allowing for hydrogen bonding between adjacent helices. 
 
Tropocollagen subunits spontaneously self-assemble into even larger 
macromolecules in the extracellular environment which are referred to as collagen 
fibrils (Hulmes, 2002), and are 10-300nm in diameter. Each tropocollagen subunit 
in the fibril is staggered from the next by 67nm (approximately a quarter of the 
length of a single subunit), giving the fibril a distinctive banded appearance when 
viewed using high-power microscopy (fig. 1.9). Fibrils can associate with various 
other proteins at this stage, including proteoglycans and other collagen types to 
form larger fibrillar bundles (fibres), which become increasingly covalently 
crosslinked as the tissue matures (Perumal et al, 2008). 
 
Fig. 1.9. A highly magnified electron micrograph of collagen fibrils stained with 
phosphotungstate, the cross striation can be resolved into several distinct bands 
due to the arrangement of the tropocollagen molecules within the fiber. From 
Encyclopedia Britannica (2009),  micrograph by B.R. Olsen (Department of Cell 
Biology, Harvard Medical School, Boston, Massachusetts, USA). 
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Collagen fibrils can therefore be extremely heterogeneous in order to fulfil 
particular molecular and biomechanical roles, and so it is striking that type I 
collagen is bone is so highly organised.  
1.1.2.2. Bone sialoprotein II.  
Bone sialoprotein II (BSP-II) is a large (72-80 KDa), flexible protein which is 
expressed during early matrix mineralisation, eventually comprising up to 8% of 
the organic mass of bone (Fisher et al, 1990). BSP is highly modified by post-
transcriptional sulphation, phosphorylation and glycosylation, to the extent that 
up to 50% of the mature protein is comprised of these modifications, rendering 
the molecule highly heterogeneous. The function of BSP is not entirely clear, 
although Hunter and Goldberg (1996) propose that the protein acts as a 
nucleation site for apatite and mediates the extent of crystal growth along the 
collagen fibril depending on the particular post-transcriptional modifications. 
 
1.1.2.3. Osteopontin. 
 
Osteopontin is a multifunctional 41 KDa protein secreted by numerous cells 
(such as myoblasts and macrophages, in a addition to osteoblasts and pre-
osteoblasts) with roles in mineralisation and cell adhesion (Reinholt et al, 1990) 
particularly of osteoclasts in bone remodelling. 
 
Osteopontin expression is stimulated by calcitriol, a modified form of vitamin D3 
and leads to the recruitment of immune cells, such as neutrophils (Koh et al, 2007) 
and autoimmune inflammatory responses in rheumatoid arthritis (Ohshima et al, 
2002).  
 
Osteopontin interacts with a large number of ubiquitously expressed cell surface 
receptors such as various integrins (Yokosaki et al, 2005) and CD44 (Weber et al, 
1996) indicating an important role in both pathological and physiological 
processes involving leukocytes such as inflammation and bone remodelling. 
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1.1.2.4. Osteonectin.  
 
Osteonectin is a 32.5 KDa protein which is post-translationally modified to 
become a 40-44 KDa glycoprotein with four distinct domains, two of which 
selectively bond calcium ions (Maurer et al, 1995). 
 
Osteonectin binds strongly to hydroxyapatite (Romberg et al, 1986) and 
extracellular matrix proteins including collagens I, III, V, VIII (Sage et al, 1989), 
IV (Mayer et al, 1991), thrombospondin (Clezardin et al, 1988) and platelet-derived 
growth factors (PDGF-AB and PDGF-BB) (Raines et al, 1992). The role of 
osteonectin in bone remodelling therefore appears to be in initiating the 
calcification of collagen fibrils (Pacifici et al, 1990).  
 
1.1.2.5. Osteoadherin. 
 
Osteoadherin is a bone-specific keratan sulfate-containing 85 KDa glycoprotein 
that binds osteoblasts via their ơvƢ3 integrin (Wendel et al, 1998). In bone 
trabeculae, osteoadherin is found in a disulfide-bonded complex with osteonectin. 
 
1.1.2.6. Osteocalcin. 
 
Osteocalcin is a 5.8 kDa protein which is highly conserved between species, 
transcriptionally regulated by vitamin D3 and modified (by ƣ-carboxylation) by 
vitamin K (Lee et al, 2000). Osteocalcin is the most abundant and well-studied of 
the non-collagenous proteins comprising osteoid (where it is adsorbed onto the 
mineral phase) and serves as a clinical marker for studies of bone metabolism, but 
despite this its exact function and role in bone is slightly unclear (Lee et al, 2000).  
 
Studies of osteocalcin knockout mice by Ducy et al (1996) exhibit a normal 
phenotype until about 6 months, after which bone production is markedly 
increased, suggesting osteocalcin has a role in maintaining bone turnover. 
Research on osteoclast recruitment and differentiation by osteocalcin-replete 
matrix particles (Glowacki et al, 1991) supports this, indicating that osteocalcin 
acts as a matrix-embedded signal for osteoclasts. In addition, studies in animal 
 14 
Chapter One 
models have shown that bone regulates glucose metabolism and fat mass via the 
uncarboxylated form of osteocalcin (Lieben et al, 2009) 
 
Interestingly, plasma levels of osteocalcin are found to oscillate in a 24-hour 
period (Gundberg, 1985) with maxilla and mandible concentrations of osteocalcin 
varying the most over a day (Gafni et al, 2009) and indicating that bone 
remodelling occurs in a circadian pattern throughout the day. 
 
1.1.2.7. Alkaline phosphatase. 
 
Alkaline phosphatases are a family of widely expressed proteoglycan enzymes 
which exist in numerous tissues including liver and mucosa in addition to bone. 
Bone-specific alkaline phosphatase is identifiable by being post-transcriptionally 
modified to exhibit N-acetylglucosamine and N-acetylneuraminic acid 
Glycosaminoglycan motifs which can be precipitated by wheat lecithin to provide 
a measure of bone-specific alkaline phosphatase activity and therefore quantify 
bone metabolism for clinical applications (Leung et al, 1993).  
 
Alkaline phosphatase is essential to the mineralisation of bone, recruiting 
inorganic phosphate from plasma to combine with calcium to form apatite 
crystals. As discussed later (page 18), alkaline phosphatase is secreted by 
osteoblasts in vesicles which accumulate high concentrations of inorganic 
phosphate and localise to the mineralisation front of the growing or repairing 
bone (Anderson, 1969).  
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1.1.3. Mineralization of bone matrix. 
 
Extracellular matrices in all tissues are highly regulated and organised structures, 
and in bone the organisation of collagen, proteins and glycosaminoglycans 
forming the osteoid results in the tensile strength of the mature tissue. 
 
Bone however is a composite material and derives its compressive strength and 
hardness from carbonated calcium phosphate crystals in the osteoid matrix. 
Sources give slightly differing values for this mineral proportion of bone mass, 
from 60% (Cormack, 1984) to 75% (Henrickson, 1997). 
 
Phase pure hydroxyapatite (also referred to as apatite or hydroxyapatite, HA) is a 
crystalline mineral with the formula Ca5(PO4)3(OH), although the formula 
Ca10(PO4)6(OH)2 is more commonly used to acknowledge that two molecules 
comprise a single crystal, forming a hexagonal dipyramidal structure.  
 
Apatites exist commonly in nature and are ranked at 5 in Mohs hardness scale, 
flanked by iron (4.5  less hard) and titanium (6  harder). Although bone mineral 
is almost universally referred to as apatite, the molecular ratios of hydroxyapatite 
and bone mineral differ. In bone, the molar Ca:P ratio is ~1.5, in contrast to 1.67 
for crystalline HA (Landis and Glimcher, 1978). This is due to bone apatite being 
carbonated, with carboxyl groups substituting phosphate in the crystalline matrix. 
 
 
Fig. 1.10. Schematic illustration of the hexagonal bone HA unit cell found in 
bone (A) and the growth of the crystal (B), which is primarily along the c axis 
(longitudinally) but also along the a and b axes (width and thickness). (From 
Boivin, 2007). 
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In bone, hydroxyapatite crystals align along collagen fibrils, with the proposed 
nucleation site being the 35nm gap between N- and C- termini of the fibrils 
comprising the fiber (Buhler, 2007). However, it has been noted (Kristofferson et 
al, 2005) that a more primitive pattern of calcification is observed in juvenile 
epiphsyeal calcification, with crystalline deposits forming in a circle surrounding a 
central nucleation point. Bone mineralization in adults and non-woven types of 
bone is far more regular and organised, with a periodic distribution of 64-70nm 
and with the c-axis of the crystals being aligned (Robinson and Watson, 1952).  
 
 
Fig. 1.11. A region of the extracellular matrix of growth cartilage from the tibia of 
a 3-week old adult chicken, showing the mineralisation of the matrix (arrows). 
Collagen fibrils (C) and proteoglycan aggregates (PG) are visible in this early stage 
of bulk epiphyseal mineralisation (bar = 500nm), from Christofferson and Landis, 
1991. 
 
 
Cortical and trabecular bone are shown to have some differences in mineral 
crystal organisation during development. Apatite crystals of 1-3 month old calves 
were shown by Kuhn et al (2008) to be larger (186 ± 3Å) than those found in 
trabecular bone (145 ± 5Å), with higher crystallinity and a correspondingly more 
apatite-like Ca:P ratio (1.61, cortical compared to 1.51, trabecular  hydroxyapatite 
is 1.66).  
 
 17 
Chapter One 
Whilst the organic osteoid is secreted by the osteoblasts, mineralization of the 
matrix is by the deposition of inorganic calcium and phosphate ions from the 
surrounding extracellular volume. It is thought that mineralisation is not a passive 
process and that extracellular vesicles have a role in the deposition of apatite 
crystals (Anderson, 2003).  
 
These vesicles, first described by Anderson (1969), are 40-400nm in diameter, 
circular and trilammellar, with the main internal constituents being alkaline 
phosphatase and rod- or platelet-shaped particles of calcium phosphate and are 
localised in the mineralizing regions of bone. The role of the vesicles has not been 
fully elucidated but may form a mechanism for concentration of Ca and P ions. 
 
In addition to the organic and mineral phase, bone is a highly hydrated tissue, 
with estimates of cortical bone being 10-20% water and trabecular bone being 30-
50% water (in dogs) according to Boivin (2007). 
 
 
Fig. 1.12. A. High resolution electron micrograph showing a single bone apatite 
crystal (Hodgkinson, 1991). B. Stress-strain response of a mineralised collagen 
fibril and an unmineralised fibril (pure collagen) showing the much greater tensile 
strength of the mineralised collagen. The saw toothed profile of the mineralised 
fibre results from intermolecular slip of tropocollagen in the fibril (From Bueler, 
2007). 
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1.1.4. Mechanism of fracture repair. 
 
Bone fractures heal naturally in the majority of cases due to the innate ability for 
bone to remodel itself and the mechanism of repair is a well-studied process. 
Following a fracture, healing progresses in four distinct stages: 
 
1. Inflammation and hematoma formation 
2. Neovascularisation and formation of soft callus (fibrocartiallge) 
3. Hard callus formation (woven bone) 
4. Remodelling 
 
Immediately following a fracture, blood released from ruptured vessels in the 
bone and periosteum pools and coagulates, forming a haematoma. Over a period 
of several days, neovascularisation brings a new blood supply to the fracture site 
and macrophages invade the haematoma, endocytosing the damaged tissue. 
Concurrently, osteoclastic activity increases and fracture surfaces are abraded in a 
relatively large area surrounding the fracture site. Amongst the numerous cell 
types invading the site are fibroblasts which lay down type III collagen, providing 
temporary extracellular matrix for supporting neovascularisation  this network of 
blood vessels, fibroblasts, leukocytes and collagen in known as granulation tissue. 
 
As the damaged tissue is endocytosed and removed from the site, fibroblasts, 
chondrocytes and osteoblasts begin formation of a callus. Composed of collagen 
and osteoid, the callus is very weak for the first 4-6 weeks and often requires 
support in the form of an external plaster cast or internal fixing pins, 
intramedullary nails or plates. Lacking the higher order ultrastructure of 
cortical/trabecular bone, this woven bone is generally much weaker, but as a 
temporary supportive structure serves to bind the outer surfaces of the fracture 
site during healing (Dutton, 2004). 
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Fig. 1.13. Bone healing following a fracture proceeds through four distinct stages. 
Following inflammation, granulation tissue forms consisting of a fibrillar network 
and new blood vessels (I). A fibrillocartilagenous matrix forms to stabilise the 
wound (II) which subsequently becomes calcified, resulting in the formation of a 
bony callus (III). Over an extended period of time, the callus and surrounding 
bone are remodelled to restore the strength and function of the original bone. 
Redrawn from Sfeir et al (2005). 
 
 
Once the fracture has been stabilised and is capable of bearing moderate loads, 
axial stresses caused by the bones return to function cause osteoid to be laid 
down where it is needed and resorbed from the external callus. It is known that 
piezoelectric currents caused by compressing and decompressing bone matrix are 
somehow responsible for guiding remodelling, although the molecular biology 
behind this is presently unclear (Supronowicz et al, 2002). 
 
 
Fig. 1.14. Microtomography images of trabecular calluses. In trabecular bone 
microfractures caused by localised overloading, formation of a callus of woven 
bone allows the site to strengthen quickly and provides attachment sites for 
trabeculae and anastomosing spicules. From the University of Dortmund (2009). 
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1.2. Biomaterials and tissue engineering. 
 
Throughout the history of surgery materials have been used in enterprising ways 
to solve medical problems and improve the quality of life for patients. In previous 
centuries materials were often chosen more for their familiarity or availability than 
for their biological compatibility, and so catgut and nylon sutures became 
predominant in surgery just as the use of stainless steel became universal in bone 
fixation.  
 
Many modern and almost all historical biomaterials do not necessarily integrate 
fully with the body, examples including ivory tooth replacements, dental fillings, 
stainless steel bone prostheses and artificial heart valves. However, advances in 
the understanding of how materials function in the body and widespread 
investment in new technologies has revolutionised the opportunities for 
employing modern materials in novel functional roles. 
 
Bioresorbable polymers have been particularly important in modern tissue 
engineering and surgical procedures, providing resorbable matrices for supporting 
tissue growth and allowing temporary fixation of medical devices without the 
requirement for surgical removal. Most resorbable polymers are aliphatic (open 
chain) polyesters with hydrolysable ester linkages which degrade to generate 
relatively non-toxic waste products such as carbon dioxide and water. 
 
Tissue engineering encompasses the implantation of biomaterials to restore 
function to tissues following disease or injury. Biomaterials can be implanted as 
porous scaffolds to support tissue ingrowth from surrounding tissue, or 
cellularised in vitro prior to implantation. Uses for such materials are diverse, from 
vascular grafts (Kannan et al, 2005) to maxillo-facial reconstruction (Schliephake, 
2009).  
 
The need for advanced, biocompatible materials for tissue engineering becomes 
evident following an analysis of current techniques used for such treatments. 
Currently, most vascular grafts are performed using autologous (patients own) 
saphenous veins (Dashwood & Loesch, 2009), but this technique has associated 
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complications following the necessary vein harvesting operation. A rise in the 
alternative use of Dacron (a resorbable polymer) mesh tubes for this operation 
has met with considerable clinical success (Kannan et al, 2005).  
 
Similarly, maxillofacial and mandible reconstruction techniques often utilise bone 
harvested from three main sources: autologous bone, typically from the iliac crest; 
allograft bone from human cadavers; and xenografts from animal bone. Each of 
these procedures has associated difficulties, from the pain and morbidity of 
harvesting autograft bone to immune rejection and infection through using 
allografts and xenografts. 
 
The use of non-toxic and resorbable materials which can be seeded with the 
patients own cells prior to implantation resolves these problems, but difficulties 
include a lack of surgical expertise in their usage, regulatory restrictions and issues 
regarding implant design and standardisation which are still unresolved for the 
majority of applications.  
 
Examples of successfully applied tissue engineering are now appearing in the 
literature in greater numbers, including the artificial collagen-cell seeded bladder 
constructs (Atala et al, 2006) which have met with significant clinical success and 
raised public awareness of tissue engineering. Designs for the engineering of 
specific tissues share similar criteria, such as for supporting cell attachment and 
activity, but differ in terms of mechanical and morphological properties. Bone-
specific materials for example must allow for osteoconduction (from surrounding 
tissue), osteoinduction (development of bone matrix throughout the implant) and 
neovascularisation to develop healthy bone. During this process, the material 
must also support mechanical loads as the bone returns to function. 
 
Clearly substantial challenges remain for developing synthetic biomaterials for 
tissue engineering, but the advantages of using advanced materials for regenerative 
medicine are considerable. Technological advances in rendering polymeric 
materials more biocompatible through the inclusion of relevant bioactive agents 
such as Bioglass® and eluted or surface-bound growth factors have enhanced the 
ability for tissue regeneration (Chouzori & Xanthos, 2007). 
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1.2.1. Bioglass® and the response of osteoblasts to silicate biomaterials. 
 
Since the discovery by Larry Hench in the 1960s that certain glass compositions 
can form a strong chemical bond to living bone, research has focussed on the 
properties of these materials which are responsible for their biocompatibility 
(Bosetti et al, 2001; Hench et al, 2000, 2001; Oliviera et al, 2002). 45S5 Bioglass® 
has a low silica content with a sodium flux and the calcium to phosphorous ratio 
of hydroxyapatite, the inorganic component of bone. This composition effectively 
induces the attachment and proliferation of osteoblasts around the implant site, 
leading to inclusion of the Bioglass® material into a callus of reconstructing bone 
supported by the implant, and strengthens the site against lateral movements and 
shearing forces. Further, as Bioglass® is bioresorbable, the implant is gradually 
dissolved and excreted as its ionic constituents. 
 
Bioglass® is termed a class A bioactive material as it induces both extracellular and 
intracellular effects at the interface between implant and host tissue (class B 
bioactive materials illicit only extracellular responses, such as osteoconduction of 
bone growth along an interface). It has been established that twelve reaction 
stages are involved in the regeneration of bone by Bioglass®-based implants, 
including surface and genetic effects (Hench, 2001). 
 
Implantation of a Bioglass® scaffold into a target site initiates the process of bone 
regeneration with stages 1-5 occurring at the materials surface within 24 hours of 
exposure to body fluids. Rapid release of soluble ionic species into the interfacial 
area results in the formation of Si-OH bonds and the formation of orthosilicic 
acid (Si(OH)4). As this collects in increasing concentration around the surface of 
the implants, orthosilicic acid polycondenses into larger polymeric silicic acids, 
ultimately precipitating out of solution to form a hydrated silica gel (Hench, 2001). 
 
Simultaneously, amorphous Ca, PO4 and CO3 ions are adsorbed out of solution 
onto the surface of the implant and crystallise into hydroxyapatite, 
Ca10(PO4)6(OH)2. The silica gel/hydroxyapatite layer adsorbs biological molecules 
from the surrounding tissue fluid, including growth factors, proteins and 
regulatory glycosaminoglycans, stimulating migration of macrophages and 
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osteoprogenitor cells into the region (Chai & Leong, 2007). Hydroxyapatite 
crystals in the silica gel reaction layer enhance attachment of filipodia and 
stimulate synchronised proliferation of osteoblasts which produce various growth 
factors and morphogens (Oliveira et al, 2008). 
 
Osteoprogenitor cells have been found to colonise the surface of class A 
biomaterials within 48 hours and begin production of extracellular matrix 
components including type I collagen which quickly becomes mineralised, leading 
to maturation of osteocytes after 6-12 days of in vitro culture (Loty et al, 1999). 
Expression levels of insulin-like growth factor (IGF) axis system proteins, 
responsible for regulating certain key growth factors, are shown to increase by 300 
to 500% over controls after only a few hours of exposure to the chemical extracts 
of 45S5 Bioglass® (Valerio et al, 2003). 
 
Osteoblasts cultured in vitro on Bioglass® show a distinct morphology compared 
to cells grown on control substrates such as thermanox. As shown by Xynos et al 
(2001), osteoblasts grown on 45S5 Bioglass® for 2 days maintained a more 
compact shape, with numerous filipodia, dorsal ridges and microvilli, 
characteristic of cell activation and an osteoblastic phenotype. In contrast, cells 
grown on bioinert substrates for the same period were flattened, forming 
confluent sheets  features normally attributed to non-differentiated cell types. 
Analysis of cells cultured on Bioglass® reveals that the number of osteoblasts in 
the S and G2-M phases of the cell cycle (respectively DNA replication and cell 
division) were double that of cells grown on bioinert substrates (Hench, 2001).  
 
Interestingly, cells grown on Bioglass® also exhibit much higher levels of apoptosis 
 typically between 5 and 7 times more cells being apoptotic after 2 days than 
control groups cultured on bioinert materials (Gough et al, 2003; 2004). This 
apparent regulation of cell cycle illustrates the effectiveness of Bioglass® as a 
biologically active material, capable of effecting the intracellular, genetic processes 
of osteoblasts.  cDNA microarray analysis of 1,176 genes by Xynos et al (2001) 
demonstrated that the ionic products of 45S5 Bioglass® dissolution increased the 
levels of 60 transcripts twofold or more and reduced the levels of five transcripts 
compared to controls. Markedly up-regulated genes included RCL (a c-myc 
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responsive growth related gene), cell cycle regulators such as G1/S specific cyclin 
D1, and apoptosis regulators including calpain and DAD1. Other significantly up-
regulated genes include the cell surface receptors CD44 and integrin ฀1, and 
various extracellular matrix regulators including metalloproteinases-2 and -4 and 
their inhibitors TIMP-1 and TIMP-2. In total Ca and Si ions in solution were 
shown to up regulate more than 200 genes by more than 150%. 
 
Although cells grow more slowly on Bioglass® in the initial stages in vitro, cellular 
morphology and growth are much more osteoblastic in phenotype, indicating that 
these cells are responding in a similar way as they would in natural bone repair. 
This is supported by evidence that cells grown on Bioglass® synthesise alkaline 
phosphatase and osteocalcin, a non-collagenous extracellular matrix protein 
associated with the onset of mineralization, after 6 days in culture. After this 
period, osteoblasts have self-assembled into 3-dimensional structures known as 
bone nodules, comprised of cells and mineralised extracellular matrix  this is 
similar to the in vivo rate of nodule formation. 
 
1.2.2. Silicon in biomaterials. 
 
The importance of silicon incorporation in biomaterials has been appreciated for 
some time, particularly following studies of the dissolution products on 
osteoblasts directly in vitro by Xynos et al (2001). Despite this interest and 
numerous advanced techniques being employed to determine the inorganic 
crystallography of the silicon-hydroxyapatite interface and the reactions of silicon 
with cell and matrix components, no clearly descriptive theory exists. However, 
numerous theories have been tested experimentally and as none of these are 
exclusive, it could be that a combination of any or all of these explain the 
essentiality of silicon in osteogenesis and the enhancing effect silicon appears to 
have when incorporated into biomaterials.  
 
The current theories can be broken down into those which suggest a role for 
silicon in adjusting the crystal microstructure of hydroxyapatite or its 
bioavailability and those which suggest that silicon affects the conformation and 
organisation of collagen and the osteoblast extracellular matrix. 
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 1.2.3. Silicon substitution in hydroxyapatite. 
 
Whilst bone mineral is generally referred to as hydroxyapatite, the molar Ca:P 
ratios found in bone are slightly different to phase pure HA (Landis and 
Glimcher, 1978). This results from the ionic substitutions for calcium and 
phosphate in the matrix with numerous other atoms and small molecules, such as 
magnesium and strontium for Ca2+ (Ratner et al, 2004) with the majority of 
substitutions found in healthy bone being carbonate (0.79 mmol.g-1), sodium (0.32 
mmol.g-1) and magnesium (0.17 mmol.g-1) (Boivin, 2007).  
 
In addition to carbonate, the hydroxyl residues can be replaced by chloride and 
fluoride (Boivin, 2007). This ionic substitution results from the relative instability 
of hydroxyapatite as a mineral and the large surface area of the crystal which is in 
contact with extracellular fluid (Boivin, 2007). 
 
The mechanism of increased bioactivity of Si-substituted HA biomaterials has 
been studied extensively (Porter et al, 2004), yet no clear explanation exists. 
Frequent observations are made in the literature to the reduced grain size and 
solubility of Si-substituted HAs (Gibson et al, 2002), however, the grain size and 
solubility of carbonated HA is greater than Si-HA but shows much lower 
bioactivity (Porter et al, 2004).   
 
Research has shown that increasing dietary silicon content in humans is associated 
with increased bone mineral density (BMD) in the cortical bone of hip in all 
subjects except post-menopausal women (Jugdaohsingh et al, 2004). Large 
differences in hip BMD (up to 10%) between the highest (Si > 40 mg.day-1) and 
lowest (Si < 14 mg.day-1) groups were observed, demonstrating both the 
importance of silicon in bone and showing the concentrations of bioavailable 
silicon that physiologically stimulate bone growth. 
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1.2.4. Silicon function in the osteoid. 
 
In addition to silicon being substituted into the mineral phase of bone, research 
by Schwarz (1973) demonstrated that silicon is essential to the normal 
development of the glycosaminoglycan network, helping to stabilise the complex 
polysaccharide structures and forming crosslinks via silanolate (R-O-Si-O-R and 
R-O-Si-O-Si-O-R) bonds which regulate the structure and function of these 
molecules. 
 
Almost concurrently, Carlisle demonstrated that silicon-supplemented embryonic 
chick bones showed a 100% increase in collagen content over silicon-low bones 
after 12 days in culture (Carlisle, 1974), whilst more recently Reffitt et al (2003) 
demonstrated that type I collagen synthesis increased in osteoblastic cells cultured 
in the presence of orthosilicic acid concentrations of 10 and 20 ƬM. Type I 
collagen mRNA has also been shown to increase significantly in osteoblasts 
seeded with orthosilicic acid concentrations from 5 to 50 ƬM (Arumugram et al, 
2004).  
 
Fig. 1.15. Four-week old chicks showing normal growth with silicon-replete diet 
(left) and abnormal growth following a silicon-deficient basal diet (right), from 
Carlisle (1988). 
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Symptoms of silicon deficiency have been targeted by several researchers as a 
method for identifying biological processes with an apparent requirement for Si. 
Of these, abnormalities in skeletal development and adult brain diseases emerge as 
the most silicon-dependant mechanisms (Birchall, 1995). Studies of skeletal 
development in Si-deficient chicks reveal reduced circumference of leg bones with 
thinner cortex and reduced flexibility (Elliot et al, 1991). Fig. 1.15 shows four-
week old chicks fed a silicon-replete diet and a silicon-deficient diet, illustrating 
the profound physiological effects on development of Si-deficiency. Deficient 
chick skulls are abnormally shaped (also true of Si-deficient rats - Schwarz et al, 
1973) with the cranial bones appearing flatter than normal, lacking the typical 
striated trabecular matrix and instead having a less organised, nodular pattern of 
growth characteristic of immature or woven bone. 
  
Carlisle (1973) found that Si is localised in the active bone growth areas of young 
mice and rats (co-localised with osteoblasts) and increases together with the 
concentration of calcium in osteoid tissues. As bone matures, the level of 
(detectable) silicon diminishes as calcium levels approach those of fully 
mineralised bone. This indicates that silicon may have a role in development of 
organic matrix and the subsequent initiation of calcification.  
 
This is further evidenced by the concentrations of glycosaminoglycans and 
collagen, which are depressed in Si-deficient animals whilst the mineral 
composition of bone is largely unaffected. Extracts of these glycosaminoglycans 
show that they are associated with silicon in several types of tissue (Shwarz et al, 
1973), whilst other research has indicated that silicon is associated with organic 
phosphorus prior to calcification (Singh et al, 1985). These results indicate that 
silicon may have a role in co-coordinating glycoprotein phosphorylation reactions 
with collagen prior to growth of hydroxyapatite crystals. 
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1.3. Silicon. 
 
Silicon is the eighth most abundant element in the solar system (Suess et al, 1956), 
and comprises 27.7% of the earths crust by weight, second only to oxygen 
(46.6%) (Lutgens et al, 2000). In fact, silicon dioxide and silicates constitute the 
vast majority of minerals found on earth, in various crystalline, lithogenic forms 
being found as sand, amethyst, agate, quartz, rock crystal, chalcedony, flint, jasper, 
and opal in combination with other elements. Despite this abundance silicon is 
rarely found in biology, occurring as a trace element in higher animals and 
forming just 0.02% by weight of the human body (Emsley, 1998).  
 
 
Fig. 1.16. Phytoliths from A. Lagenaria siceraria (bottle gourd), B. neotropical tree 
species and C. the squash Cucurbita maxima [from D. R. Piperno Phytoliths: A 
Comprehensive Guide for Archaeologists and Paleoecologists (AltaMira Press, 
Lanham, MD)]. D shows the 31st plate from Ernst Haeckel's Kunstformen der Natur 
(1904), depicting the silica frustules of radiolarians classified as Cyrtoidea. 
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Silicon in the form of silica is found in greater abundance in plants where it is 
used to strengthen cell walls in the form of phytoliths, and in the frustule 
surrounding marine algae, the diatoms and radiolarians (fig. 1.16). 
 
1.3.1. The biogeochemical cycle of silicon. 
 
Orthosilicic acid is the only form of silicon biologically available to higher animals 
(Sripanyakorn et al, 2005). It is formed by the action of acidified water on silica 
and silicate rocks exposed to terrestrial rain/groundwater or the action of 
seawater on marine rock and animal debris. The example mechanism of Albite (a 
simple feldspar) degradation by acidified water is illustrated in fig. 1.17.A. which 
results in the formation of silicic acid and Kaolinite (i), a mineral which can be 
further reduced to liberate more soluble silicic acid (ii). Silicic acid can also be 
produced by the action of water on pure silica such as quartz or glass as described 
in fig. 1.17.B. 
 
A 2NaAlSiO3O8  + 2H
+ + 9H2O     Æ  Al2Si2O5(OH)4 + Si(OH)4 + 2Na+
 Albite     Kaolinite 
 
Al2Si2O5 + 6H
+ Æ 2Si(OH)4 + 2H2O     
  
B SiO2 + 2H2O Æ Si(OH)4       
   
Fig. 1.17. A. The reduction of albite by acidified water to kaolinite releases soluble 
orthosilicic acid. Kaolinite can react further with H+ to produce more orthosilicic 
acid, illustrating a mechanism for silicic acid generation, from Worland (1997). B. 
The direct dissolution of silica in water to form orthosilicic acid.  
 
 
Soluble silicic acids are absorbed by higher animals from four main sources: 
1. Directly from silicic acid-containing drinking water. 
2. From eating plants containing phytoliths. 
3. From eating animals. 
4. (In man) from drinking beverages made from plants. 
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The orthosilicic acid content of bottled mineral water is <10mg.l-1 in the majority 
of samples tested (77%) by Giammarioli et al (1996), compared to an average of 
19.2mg.l-1 found in beer (Sripanyakorn et al, 2004). This is due to the brewing 
process involved in making beer in where plant phytoliths (which are found in 
large quantities in barley husks) spend some time macerated in contact with 
acidified, agitated water, allowing more silicic acid to pass into solution.  
 
This effect is so great than in the average western diet beer (and bananas) forms 
the main source of bioavailable silicon for men (Jugdaohsingh, 2002). The silicon 
content of meat (food) animals is minimal, particularly as silicon in vertebrates is 
concentrated in the non-eaten tissues such as bone and aorta (Martin, 2007). The 
main routes by which silicon enters the human food chain are summarised in fig. 
18.  
 
Fig. 1.18. Simplified schematic of part of the biogeochemical silicic acid cycle 
showing the main routes of bioavailable silicon ingestion for omnivorous humans. 
 
 
 
1.3.2. Polymerisation of orthosilicic acid. 
 
Orthosilicic acid remains in its monomeric state for long periods in solution at 
25°C when the concentration is lower than about 2x10-3 M (Iler, 1979). At pH 8.5, 
10% of orthosilicic acid is ionised which rises to 50% at pH 10. Polymerisation of 
 31 
Chapter One 
silicic acids is precipitated by the presence of hydroxyl groups when only 
fractional ionisation is present  high proportions of ionisation and therefore 
alkaline pH inhibits polymerisation of silicic acids (Al Mutaz et al, 2002). 
 
Polymerisation occurs through condensation of silanol groups, formation of 
connecting siloxane bonds and partial dehydration as illustrated in fig. 1.19 
(Kashutina et al, 2008).  
 
 
SimO(m-1)(OH)(2m+2)  +  SinO(n-1)(OH)(2n+2)  Æ  Si(m+n)O(m+n-1)OH(2n+2m+2)  +  H2O 
 
Fig. 1.19. A. Polymerisation of orthosilicic acid and, B. formation of polysilicic 
acids through condensation (from Kashutina et al, 2008). 
 
 
Polymerisation continues following the formula mSiO2.nH2O eventually forming 
colloidal particles of hydrated silica which can bond to organic molecules or form 
complexes with inorganic compounds such as aluminium and calcium oxide 
(Comb, 1996). As colloidal particles are formed, silanol groups dissociate to 
release H+, leaving the silica colloid negatively charged (Kashutina et al, 2008).  
 
In radiolarians and diatoms, silica frustules are formed by the organism increasing 
the concentration of aqueous orthosilicic acid [Si(OH)4] in membrane-bound 
compartments known as  silica deposition vesicles (SDVs) which polymerises to 
form biogenic silica. Transport of silicic acids against the concentration gradient 
into these compartments is by cell membrane-bound silicon transporters, such as 
those of the sit (silicon transporter) family in diatoms (Lopez & Coradin, 2003), 
which are shown to be sodium dependent. In addition, glycoproteins enriched 
with hydroxy amino acids are shown to associate with silica OH groups in the cell 
wall (Lopez & Coradin, 2003).   
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1.3.3. Technological applications of silicon. 
 
Silicon is widely known as a semiconductor and through its use in integrated 
circuits (microchips) forms the technological basis of the modern world. In 
addition, 55% of the worlds total silicon production is used in aluminium-silicon 
alloy cast parts, particularly for the automotive industry, with a further 40% of 
total global consumption of silicon being turned into silicones for diverse uses, 
such as in waterproofing and in breast implantation.  
 
The remaining 5% of elemental silicon is processed into high-purity 
monocrystalline wafers for electronics using the Czochralski method of pulling a 
growing crystal from a hot melt of silicon (fig. 1.20.A). Silicon produced in this 
way for electronics purposes is commonly doped by addition of other elements 
(boron, phosphorus, arsenic or antimony) to produce n- or p-type wafers  even 
so, the purity of silicon in the wafer is 99.9999% (Widman & Dietrich, 2000). 
 
Monocrystalline silicon wafers have a regular diamond cubic crystal structure with 
a lattice spacing of 5.430710 Å (0.5430710 nm). When cut into wafers (using a 
diamond-coated blade), the crystal surface is aligned in one of several orientations, 
defined by the Miller index with [100] or [111] faces being the most common 
(OMara et al, 1990) and which have a bearing on the wafers anisotropic structural 
and electrical properties. 
 
After cutting from a cylindrical block,  a silicon wafer must be cleaned and 
polished with acids, and it is through experimental techniques in this process that 
porous silicon was first discovered. 
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A      B 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
Fig. 1.20. A. Silicon monocrystal grown using the Czochralski method (© Dave 
King, Dorling Kindersley,  From The Science Museum, London). B. Mirror finish 
silicon wafer (NASA Glenn Research Center). 
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1.4. Porous silicon. 
 
Porous silicon was accidentally discovered in 1956 at the Bell laboratories in the 
US as an undesired product of experimental methods for polishing and shaping 
silicon surfaces for use as semiconductors (Canham, 1997). Under certain 
conditions the combination of acid etching under an anodic current resulted in 
the formation of a thick black, red or brown film on the materials surface. As this 
was regarded as a failure for the purposes of polishing wafer surfaces, the 
discovery was not further pursued until Leigh Canham reasoned that the resulting 
porous silicon may exhibit quantum confinement effects (Nash et al, 1994).  
 
This effect occurs as the nano-scale holes in the acid-etched silicon wafer restrict 
the motion of electrons, particularly at the surface of the holes. As the size of the 
restricting hole decreases relative to the wavelength of the confined electrons, the 
energy of the electron increases. Coupled with the semiconducting properties 
which silicon naturally possesses, this leads to various unique physical properties 
that can be exploited for various applications, particularly in opto-electronic 
sensing (Parkhutik, 2000). 
 
In addition to these novel electronic properties, the enormous surface area of 
silicon exposed by the pores relative to the volume (on the order of 500m2/cm3) 
coupled with the covalently bonded hydrogen presented on the pore surfaces 
renders porous silicon soluble in water and aqueous media  a property which is 
unique for a pure silicon material (Canham, 1995).  
 
Fig. 1.21. Porous silicon surface of a silicon wafer (BioSilicon, from pSiVida 
webpages). 
 35 
Chapter One 
1.4.1. Fabrication. 
 
Several techniques for porosifying silicon are available, but the commonest 
method (used to produce pSi for this investigation) is through the anodisation of 
an 8 inch silicon wafer (200mm diameter, 725Ƭm thick). A platinum cathode and 
a silicon wafer anode are both immersed in a hydrogen fluoride electrolyte. A 
direct current is passed through the cell which corrodes the anode wafer, 
producing an even, porous layer (fig. 1.22). The addition of >15% ethanol to the 
electrolyte solution serves to dissolve hydrogen released during the reaction and 
homogenise the concentration of hydrofluoric acid within the developing pores, 
resulting in more uniform pore geometry (Halimaoui, 1997).  
 
 
  A                                         B 
 
 
 
 
                   C 
 
 
 
 
 
 
 
Fig. 1.22. The effect of etching current density on pore morphology in pSi. 
FESEM cross-section views of n+-type silicon wafers made porous by anodization 
carried out at A. 18 mA.cm-2 , B. 36 mA.cm-2, C. 182 mA.cm-2 in the dark in an 
ethanoic-HF bath. Channels vary from tortuous to straight with increasing current 
density, as does pore diameter from A. 6nm, B. 10nm, C. 30nm. From Pichonat 
& Gauthier-Manuel, 2006.  
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The pore diameter and depth can be controlled by HF concentration, with longer, 
narrower pores produced by concentrated HF solutions (Seo et al, 1994). Pore 
diameter is initially determined by the area of the surface oxide layer and so the 
OH- content of the electrolyte is also important (Seo et al 1994). Pore width is 
classified into three sizes, less than 2nm as nanoporous, between 2nm and 50nm 
as mesoporous and larger than 50nm as macroporous (Feng et al, 1994).  
 
Once the wafer is fully etched the porous silicon must be dried by either 
supercritical drying, freeze drying or pentane drying. Water drying can be 
employed, although the high capillary stress forces incurred cause the porous 
wafer to crack, particularly when the wafer is etched beyond a certain critical 
thickness (Bellet, 1997). Although this is a major issue for opto-electronic 
applications, the microparticles required for biomaterials uses can be dried using 
water. 
 
 
1.4.2. Degradation in water. 
 
Due to the large surface area of Si-H (500m2.cm-3) on the surface and interior 
spaces of pSi, porous silicon is soluble in water and aqueous solutions, dissolving 
along the mechanism given in fig. 1.23. 
 
Si + 4H2O Æ Si(OH)4 + 2H2 
 
Fig. 1.23. Orthosilicic acid is liberated from the surface of the decomposing pSi 
in addition to hydrogen gas. 
 
 
1.4.3. Biological activity. 
 
Porous silicon has been shown to have good biocompatibility, supporting the 
growth in vitro of several cell types including osteoblasts (Whitehead et al, 2008), 
neurones (Johannsen et al, 2008) and hepatocytes (Alverez et al, 2008).  
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Low et al (2009) show that implantation of porous silicon under the conjunctiva 
of the rat eye results in the material becoming surrounded with a thin fibrous 
capsule after 8 weeks, with no erosion of surrounding tissue, inflammatory 
response or neovascularisation. When injected intravenously into mice, Park et al 
(2008) also demonstrated good in vivo compatibility: pSi particles were observed in 
liver, kidneys and spleen with normal tissue morphology. Macrophages were 
observed in liver at day one following injection implying that the small particles 
are endocytosed and naturally degraded, but after 4 weeks all tissues were normal. 
 
Porous silicon is being studied by various groups for biological applications in 
drug delivery (Serda et al, 2009) and radioisotope intratumoral brachytherapy for 
treatment of inoperable cancers with a typically poor prognosis, such as pancreatic 
and hepatocellular carcinoma (Zhang et al, 2005). In this latter case, small particles 
of 32P-loaded porous silicon are injected into a tumour, which disperse to provide 
localised but very concentrated radiotherapy. pSi particles are cleared by 
degradation and excretion via the kidneys (Canham, 2001). 
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1.5. Aims of the investigation. 
 
The overall aim of the research presented here is to assess porous silicon as a 
potential bioactive material which can be added as a bioactive agent to increase 
the osteoactivity of polymer-based prostheses for bone tissue engineering. A 
secondary aim was to further elucidate the mechanisms and biochemistry of the 
effect silicon (in the form of silicic acid and silica) has on osteoblasts in vitro.  
 
Therefore, the research aims can be summarised as follows, each of which outline 
the themes for the following chapters: 
 
1. Examine the behaviour of porous silicon-polymer composites in 
simulated body fluids in terms of degradation and rate of silicic acid 
release from the material. 
2. Evaluate the response of human osteoblasts to pSi-PCL surfaces, 
degradation products and orthosilicic acid solutions in vitro. 
3. Assess pSi-PCL composites as delivery vehicles for active pharmaceuticals. 
4. Determine the physical, mechanical and electrical properties of pSi-
polymer composites. 
5. Characterise pSi-PCL behaviour in simulated physiological models. 
6. Consider the potential applications of pSi-based biomaterials and test 
relevant examples.  
Throughout this investigation, appropriate materials were used for outside 
reference, particularly bioactive glass  polymer composites and unmodified pure 
polycaprolactone. These were used to compare pSi-composites to other 
biomaterials with existing applications in orthopaedics and tissue engineering. 
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Characterisation of Porous Silicon  
Polycaprolactone Composites 
 
Chapter Two 
2.1. Introduction. 
 
Porous silicon exhibits many of the same characteristics as Bioglass®, being able to 
release silicic acids into aqueous solution and form a surface layer of 
hydroxyapatite in simulated body fluid (Canham, 1996). Like Bioglass®, the 
mechanical properties of porous silicon are poor, and so a composite material was 
developed to exploit the bioactive properties of pSi within a strong but degradable 
polymer matrix. 
 
The polymer that was ultimately chosen for this composite was polycaprolactone 
(PCL), a biodegradable aliphatic polyester which has existing uses in tissue 
engineering (Sahoo et al, 2002) and drug delivery  (Sinha & Trehan, 1999), and is 
FDA approved for human in vivo use (Rohner et al, 2003). Alternative 
biodegradable polymers were also trialed, and are discussed in this chapter. 
 
To test pSi  PCL composites for tissue engineering applications, a standardised 
method for manufacturing reproducable materials was required, with the 
following necessary design criteria: 
 
 Fully homogenous pSi dispersal through polymer matrix. 
 Similar proportions of crystalline/amporphous PCL phases for equivalent 
samples. 
 Easily measurable surface area, volume and mass. 
 Consistent high densities (lack of pores, voids or excessive surface 
topography). 
 
Following the fabrication of reproducible composites, the prospective biomaterial 
was characterised via a number of accepted techniques relevant to the material. 
For pSi-PCL, this included quantification of silicic acid release (the proposed 
source of bioactivity) under varying simulated physiological conditions; 
measuements of biodegradation; and evaluation of calcium phosphate deposits on 
the material from acellular simulated body fluids.  
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This section of the research encompasses the initial tests for bioactivity performed 
on the composite. The aims of this chapter therefore were to: 
 
 Develop a method for forming a pSi-polymer composite. 
 Compare biodegradable polymer-pSi composites to determine the most 
suitable for the proposed orthopaedic applications. 
 Evaluate pSi-degradation and silicic acid release from the composite. 
 Evaluate calcium deposition on the matrix in acellular simulated body 
fluids. 
 Compare the performance of the pSi composite to similar composites in 
the literature, eg. Bioglass®-polymer composites. 
 
 
2.1.1. Choice of biodegradable polymer. 
 
Research in materials science since the 1950s has focussed extensively on 
synthetic polymers derived from crude oil fractions, developing a huge array of 
plastics with diverse properties for numerous applications. Of these, a 
comparitively small number have so far been used for internal clinical applications 
 these generally being hard and unreactive plastics developed to act as removable 
sutures, casings for sensors, or as inert components of internal prostheses such as 
the ultra high molecular weight polyethylene (UHMWPE) acetabular cups used in 
total hip replacements. 
 
However, certain synthetic plastics are more amenable to modern biomedical 
science, possessing properties which make them desirable for inclusion within the 
body. Of these, aliphatic polyesters such as polylactides (PLA), polyglycolide 
(PGA) and poly-ƥ-caprolactone (PCL) are being developed for therapeutic 
applications including biodegradable sutures, cranial burr plugs and also as devices 
for drug delivery (Sahoo et al, 2002). Another major class of biodegradable 
polymers under investigation are polyhydroxyalkanoates which are biologically 
synthesised naturally by bacteria and by genetically modified plants (Poirer et al, 
1992). 
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2.1.1.1. Polylactic acid.  
 
PLA is an aliphatic (open chain) polyester derived from lactic acid. It can be easily 
produced in a high molecular weight form through ring-opening polymerization 
using a stannous octoate catalyst. 
 
Fig. 2.1. Ring opening polymerization of lactide to polylactide. 
 
 
Due to the chiral nature of lactic acid two distinct forms of polylactide exist: poly-
L-lactide (PLLA) is the product resulting from polymerization of lactic acid in the 
L form. PLLA has a crystallinity of 13 - 37%, a glass transition temperature 
between 50-80° C and a melting temperature between 173-178°C (Park & Cima, 
1996). The polymerization of a mixture of both L and D forms of lactic acid leads 
to the synthesis of poly-D,L-lactide (PDLLA) which is fully amorphous, 
possessing no crystalline regions (Ajioka et al, 1995).  
 
Polylactic acid can be processed like most thermoplastics into fibre (using 
conventional melt-spinning processes, for example) and films. PLA is currently 
used in a number of biomedical applications, such as sutures, dialysis media and 
drug delivery devices, but it is also evaluated as a material for tissue engineering 
(Sahoo et al, 2002).  
 
Importantly for these applications, polylactides are biodegradable by hydrolysis of 
their ester bonds under physiological conditions, generating decreasing-weight 
polymer fragments which, at a certain size limit, are able to move out of the 
material and be excreted (Wise, 1995). The rate at which these materials degrade 
in this way is related to their proportional crystalinity, with the more amorphous 
poly-D-lactides degrading more quickly. Therefore by varying the monomer ratios 
in the poly-D,L-lactide copolymers, the degradation rate can be controlled (Wise, 
1995). 
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PLA is particularly attractive as a sustainable alternative to petrochemical-derived 
products, since the lactides from which it is ultimately produced can be derived 
from the fermentation of agricultural by-products such as corn starch or other 
starch-rich substances like maize, sugar or wheat. PLA is more expensive than 
many petroleum-derived commodity plastics, but its price has been falling as more 
production becomes available.  
 
 
2.1.1.2 Polyglycolide.  
 
Dimerisation of glycolic acid into glycolide forms the monomer for 
polymerisation of polyglycolide, the simplest linear aliphatic polyester. The 
resulting polymer has a glass transition temperature between 35-40°C and melting 
point of 225-230ûC (Chujo et al, 1967). It is highly crystalline (around 45-55%) and 
thus insoluble in most common organic solvents except for highly fluorinated 
solvents such as hexafluoroisopropanol (HFIP; Hariharan & Pinkus, 2006). 
 
 
Fig. 2.2. Ring opening polymerisation of glycolide to polyglycolide. 
 
 
 
PGA was the first material to be used as a synthetic, absorbable suture (marketed 
as Dexon in the 1960s by Davis and Geck, Inc.) and has been authorized for the 
production of implantable medical devices including mesh for wound closure in 
severely ruptured spleen (Vandershot et al, 1993; Louredo et al, 2005). Due to the 
high degree of crystalinity, pure PGA homopolymers have a high elastic modulus 
(~7 GPa) and are too stiff for use as sutures unless braided or co-polymerised 
with other monomers.  
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Degradation of the homopolymer occurs rapidly in vivo, with 50% loss of strength 
after 2 weeks and 100% loss of strength after 4 weeks, although the material is not 
fully absorbed until 4-6 months post-implantation (Kim et al, 2005). Degradation 
results in the production of glycolic acid which is non-toxic and easily broken 
down into CO2 and water. 
 
PGA/Polylactide co-polymers have been researched extensively as a way of 
tailoring the physical properties of the material. Vicryl, a 90/10 PGA/PLA co-
polymer was marketed by Ethicon as a braided absorbable suture which degrades 
completely in 3-4 months. This is shorter than polyglycolide homopolymer and 
the material is slightly stronger initially (Bourne et al, 1988). The differences in 
degradation rate are considered to be due to the greater vulnerability to hydrolytic 
attack of the amorphous regions than the crystalline regions  co-polymers 
containing 25-70% mole percentage PGA are fully amorphous. A 70/30 L-
lactide/glycolide copolymer is marketed as Lactomer (injection moulded surgical 
staples) by US Surgical (Hirashima et al, 1985). 
 
 
2.1.1.3. Polycaprolactone.  
 
PCL is a biodegradable polyester with a low melting point of around 60°C and a 
glass transition temperature of about -60°C (Sinha et al, 2004). PCL can be 
prepared by ring opening polymerization of ƥ-caprolactone using a catalyst such as 
stannous octoate. 
 
Fig 2.3. Ring-opening polymerisation of ƥ-caprolactone to polycaprolactone. 
 
 
Polycaprolactone is used as an absorbable suture material in Europe and is under 
evaluation as a drug delivery device in the form of porous microspheres (Williams 
et al, 2005; Venugopal et al, 2005; Quinn et al, 2004; Sinha et al, 2004). PCL is semi-
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crystalline with a low modulus (0.4GPa) and degrades slowly (>2 years for full 
absorbtion), although this can be dramatically reduced by inclusion of co-
polymers such as poly-D,L-lactide (PDLLA). PCL co-polymerised with glycolide 
is marketed as a monofilament suture by Ethicon, Inc. (Somerville, NJ), under the 
trade name Monacryl. Co-polymers of ƥ-caprolactone and L-lactide are 
elastomeric when prepared from 25% e-caprolactone, 75% L-lactide and rigid 
when prepared from 10% ƥ-caprolactone, 90% L-lactide. 
 
As with other biodegradable aliphatic polyesters, PCL degrades via hydrolytic 
cleavage of ester linkages within the polymer, forming smaller oligomers which 
results in the weakening of the material. Studies have demonstrated that polymer 
fragments with WM more than 8 KDa are unable to diffuse out through the 
semicyrstalline matrix, accounting for the slow rate of PCL absorption in vivo. As 
the average molecular weight of PCL used for tissue engineering research is 65-80 
KDa, each oligomer must be cleaved several times before diffusible lengths are 
generated. The sole metabolites of PCL are ƥ-hydroxycaproic acid, water and CO2, 
although small polymer fragments are removed from the implant site by 
macrophages and giant cell phagocytosis (Lam et al, 2008). 
 
 
2.1.1.4 Poly-3-hydroxybutyrate.  
 
Polyhydroxyalkanoates (PHA) are a family of polyesters first isolated and 
characterised by the microbiologist Maurice Lemoigne in 1926. Poly-3-
hydroxybutyrate (PHB) is produced by several bacteria including Ralstonia 
eutrophus, a gram negative, non-spore forming bacterium which thrives in 
millimolar concentrations of heavy metals. Capable of growing chemo-
lithotropically by using molecular hydrogen as an energy source and CO2 as a 
carbon source, R. eutrophus can also store carbon and energy as PHB which is 
subsequently used as a metabolite. 
 
Although chemically different to polypropylene, the physical properties of PHB 
are similar, being stiff and brittle but having high crystallinity and a melting point 
of 180ûC. Although currently prohibitively expensive compared to other 
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biodegradable polymers, extensive research is being conducted in both academic 
and industrial institutions to biotechnologically manufacture PHB (and other 
PHAs) for commercial and medical applications.  
 
In 1992, a team at the DoE Plant Research Laboratory, Michigan State University 
successfully introduced the three PHB forming genes into cress, thereby creating a 
harvestable method for producing biodegradable plastics from a renewable 
resource; without affecting the plants growth, 14% of the dry weight of the leaves 
were PHB although did not exhibit quite the same stereoregularity as naturally 
occurring PHB (Poirier et al, 1995; Coghlan, 1992).   
 
Monsanto, which now markets PHB (co-polymerised with hydroxyvalerate, 
another PHA) as Biopol have purchased all patents for making the polymer from 
ICI/Zeneca, although current adverse public opinion and media attention to GM 
crops have delayed news of Monsantos plans for future marketing of PHAs. 
 
In 2005, the US Environmental Protection Agency presented their 2005 Green 
Chemistry Small Business Award to Metabolix, a company involved in developing 
and commercialising a cost-effective method for manufacturing PHAs in general 
(and PHB in particular) using bacterial biotechnology. 
 
 
2.1.1.5. Choice of polymer. 
 
Following these considerations, it was decided that polycaprolactone should be 
employed as the polymer component in the composite for the following reasons: 
 
 Mechanical stability over a long time period  (more than 6 months). 
 Mass produced in standardised bulk volumes.    
 Inexpensive (£46.80/100g, Sigma Aldrich, February 2009). 
 Soluble in a range of solvents (including low-toxicity acetone). 
 Low melting point (~60°). 
 Existing use as a biomaterial.   
 Existing use as a drug delivery vehicle.  
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As a means of validating this choice, comparisons between PCL, PLGA and PHB 
pSi composites were made experimentally in this investigation. 
 
 
2.1.2. Degradation of the composite in acellular fluids. 
 
The dissolution of pSi in polymer composites into a surrounding volume is by 
hydrolysis of S-H bonds to generate free Si(OH)4 which disperses into solution 
(Canham, 2000) or polycondenses onto the surfaces of the pSi, composite or 
reaction vessel walls. The degradation of PCL and pSi and the rate of silicic acid 
polymerisation are therefore respectively governed by hydrolytic and 
condensation reaction rates and so the chemical nature and conditions of the 
dissolution medium are important in determining silicic acid release rates and 
potential bioactivity. 
 
Simulated body fluid (SBF) was developed by Kokubo et al in 1990 and is widely 
used to simulate the in vivo conditions to which a biomaterial is exposed by closely 
replicating the ionic composition of human blood plasma (see table 2.5). This 
approach is biologically relevant and allows for calcium deposition from the 
solution to be monitored, but due to the metastability of the solution, ionic and 
pH changes caused by the presence of hydroxycaproic and silicic acids, and 
precipitated calcium and phosphates can alter the balance of the solution in an 
unpredicatable and complex way (Rhee & Lee, 2007).  
 
Phosphate buffered saline (PBS) is used widely in biochemistry and molecular 
biology to provide a non-reacting buffer solution in which to perform studied 
reactions at a buffered pH (typically pH 7.0). By comparing the degradation of pSi 
and pSi-composites in SBF and PBS, an analysis can be made of the effect of non-
interacting (PBS) versus chemically active solutions (SBF).  
 
More simply, using dH2O as the dissolution solution allows the chemistry of silicic 
acid degradation, condensation and polymerisation to be studied in effective 
isolation, with the formation of silicic acids and silica gel the only product of 
degradation. 
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The effect on porous silicon of the amount of fluid it is allowed to dissolve in has 
not been studied in depth, particularly smaller physiologically relevant volumes 
(<10ml). Whilst it is known that silicic acids polycondense in a concentrated 
solution to form insoluble silica, thereby establishing a dynamic dissolution-
saturation-condensation flux in fluids, it has been reported (pSiMedica internal 
report, unpublished) that highly concentrated solutions inhibit further dissolution 
of the original porous silicon, with a putative 100 Ƭg.ml-1 threshold determining 
the upper concentration of orthosilicic acid which is metastable.  
 
 
2.1.3. Comparison to other bioactive composites. 
 
pSi-PCL composites are currently being studied by only one other group, affiliated 
with pSiMedica (Whitehead et al, 2008) at the Texas Christian University, USA). 
Consequently, comparison to the literature must be via similar materials such as 
Bioglass®-PCL composites. Studies of such composites have been reported by 
two groups, Chouzori and Xanthos (2007) at the New Jersey Institute of 
Technology, USA and Jiang et al (2005) at the University of Nottingham, UK. 
 
Chouzouri & Xanthos report lower than expected bioactivity for composites 
containing up to 30% w/w Bioglass® particles, with an increased rate of polymer 
degradation following addition of Bioglass® particles to the polcaprolactone 
matrix. Other Bioglass®-polylactide composites have been studied, such as 40% 
Bioglass®-polylactide foams (Blaker et al, 2003) which act as a useful reference. 
Other biodegradable composites containing an inorganic phase such as silica, 
silicates and hydroxyapatite (Venugopal et al, 2008) are a useful comparison, but 
these are generally less bioactive than Bioglass® and the ionic dissolution products 
(cheifly silicic acid) do not reach the high concentrations in solution achieved by 
either Bioglass® or porous silicon.  
 
Interestingly, the above mentioned composites have high proportions of the 
inorganic component, from 30% (Bioglass®) to 50% (hydroxyapatite), with 
correspondingly weaker mechanical properties as the strengthening polymer phase 
is reduced and subsequently degraded (Chouzouri et al, 2007; Jiang et al, 2005). 
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2.2. Materials and Methods. 
 
2.2.1. Forming the composite. 
 
Polycaprolactone (MW 65,000; Sigma, UK) was dissolved in acetone at 40°C in a 
1:1 ratio (g/ml) and stirred thoroughly. pSi microparticles (10Ƭm, 70% porous; 
pSiMedica, Malvern, UK) if being used were also added at this stage and stirred 
thoroughly to mix. After removal of the solvent by air drying at room temperature 
for 1-2 hours, the composite was cut into small sections and placed into the body 
of a 5ml polypropylene syringe (Becton Dickinson, UK). The syringe nozzle was 
sealed with adhesive tape and the mould placed upright in an incubator at 65°C to 
allow the sections to fuse together into a cylinder without voids. 
  
 
 
Fig. 2.4. Schematic for forming composite discs for testing. (1) Polycaprolactone 
and pSi microparticles were mixed with acetone, covered (2) and incubated at 
40°C until PCL was fully dissolved and pSi dispersed. (3) The mixture was stirred 
thoroughly and the acetone evolved at room temperature (4) to create a solid 
composite which was cut into sections (5) and placed in a 5ml polypropylene 
syringe body (6,7). After heating to ~70°C to melt together the composite (8) the 
cylinder was cooled and once solid was removed from the syringe body to evolve 
residual acetone (9). The 10mm diameter cylinder was then cut into 250mg discs 
which were used for testing (10).  
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Once melted together the composite cylinder was left at room temperature 
overnight to enable the evaporation of residual solvent. The composite cylinder 
was cut using a single-edged razorblade into discs 10mm in diameter, weighing 
250mg ± 15mg. Throughout the fabrication process, only polyproplylene labware 
was used. 
 
2.2.2. Determining bioactivity. 
 
The following assays and protocols were used in this part of the investigation to 
characterise the composite and so determine bioactive properties and behavior in 
acellular fluids. 
 
2.2.2.1. Simulated body fluid. 
 
Simulated body fluid was prepared as described by Kokubo et al (1990) with the 
compounds listed in table 2.5 added to 1 litre dH2O in the order and in the 
amounts given. All reagents were obtained from Sigma, UK and clean plastic 
labware was used throughout preparation and storage. pH was adjusted to 7.4 
using NaOH and HCl and the solution stored at 4°C for up to one month. 
 
A                  Ion concentration (mmol/dm3) 
SBF          Human plasma 
 
Na+   142.0   142.0 
K+   5.0   5.0 
Mg2+   1.5   1.5 
Ca2+   2.5  2.5 
Cl-   147.8   103.0 
HCO3-   4.2   27.0 
HPO4
2-  1.0   1.0 
SO4
2-   0.5   0.5 
B       SBF Formulation 
Reagent        Mass (g/l) 
 
NaCl   7.995g 
NaHCO3  0.353g 
KCl   0.224g 
K2HPO4.3H2O  0.174g 
MgCl2.6H2O  0.305g 
CaCl2.2H2O  0.368g 
Na2SO4  0.071g 
Table 2.5. A. Comparison of ion concentrations in 1x simulated body fluid and 
typical human blood plasma (Kokubo et al, 1990) and, B. the mass of reagents 
used to formulate the solution. 
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2.2.2.2. Quantifying silicic acid. 
 
Silicic acid release from the composite was measured by placing discs into a 
specified volume (see 2.2.3) of either dH2O, 1x PBS or 1x SBF and fitting a 
screw-cap to ensure the volume was sealed. Samples of the incubating solution 
were taken at fixed intervals, measuring 20  400Ƭl, dependant on the total 
volume of the medium and the incubation time. 
  
Analysis was by a molybdenum (molybdate) blue assay, in which ammonium 
molybdate in solution reacts with silicic acid in the sample to form Ƣ-
silicomolybdic acid (yellow) which is subsequently reduced to form a molybdate 
blue complex with a peak absorbance at 810nm.  
 
Up to 400Ƭl of the incubation solution was removed to a 1.5ml eppendorf tube 
and the volume made to 400Ƭl with dH2O. 100Ƭl of a solution containing 
acidified ammonium molybdate (1g ammonium molybdate (IV) tetrahydrate and 
3ml concentrated (17M) hydrochloric acid in 50ml total volume) was added and 
allowed to stand for 10 minutes. 500Ƭl of a reducing solution (4g oxalic acid 
dihydrate,1.33g 4-(methylamino)phenol sulfate, 0.8g anhydrous sodium sulfite, 
20ml concentrated sulfuric acid, total volume 200ml with dH2O) was then added, 
the solution allowed to develop a blue coloration for 2-4 hours and the 
absorbance read at 810nm using a spectrophotometer zeroed using dH2O. 
 
Calibration of this assay was by a standard curve obtained using known 
concentrations of sodium metasilicate, from which absorbance at 810nm could be 
directly compared to Si in solution. Throughout this work, silicic acid is 
represented as mass units of silicon to avoid confusion between ortho- and 
polysilicic acids in solution. 
 
2.2.2.3. pH. 
 
pH changes in water and buffered solutions incubating porous silicon composites 
were analysed using a calibrated Hannah HI 120 pH meter and measured to three 
decimal places. 
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2.2.2.4. Assessing silica gel formation. 
 
The presence of a hydrated silica gel was initially determined by measuring the 
changes in mass of composite discs incubated solely in dH2O. Discs were weighed 
accurately to 0.1 mg before incubation and at time points throughout the 
experiment by being removed from solution and dried in a slide drying oven at 
37°C for 24 hours prior to weighing.  
 
Silica deposition was then estimated by subtracting the starting mass of the 
composite from the end point mass. The presence of the silica gel was confirmed 
using EDX, see below.  
 
2.2.2.5. Quantifying calcium. 
 
Polycaprolactone / composite discs that had been incubated in SBF were rinsed 
carefully in dH2O and stained for calcium using 1ml staining solution comprising 
1% (w/v) alizarin red S (Sigma, UK) in dH2O. The red-stained calcium was imaged 
using a bifocal dissecting microscope and then the calcium-alizarin complex 
solubilised with 2-5ml 2% (w/v) solution of cetylpyridinium chloride monohydrate 
(Sigma, UK) in dH2O to provide a purple solution with peak absorbance at 
562nm which was measured using a spectrophotometer. 
 
2.2.2.6. SEM, ESEM and EDX. 
 
PCL / composite discs were removed from solution and dried thoroughly in a 
drying oven at 37°C overnight before being mounted onto aluminium stubs for 
scanning electron microscopy. As the discs were acellular, no further fixation or 
dehydration was required. The discs were gold coated for 3-6 minutes in a sputter 
coater and imaged using a Jeol JSM840 scanning electron microscope. 
 
Discs were also imaged using a Phillips XL30 FEG-ESEM in which case no 
processing/coating was required. Samples were imaged using the auxiliary mode 
which allowed for energy dispersive X-ray spectroscopy to be performed on target 
regions of interest and the elemental composition of surface layers to be mapped.  
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2.2.3. Experimental. 
 
The following sections detail the individual experiments that were performed. 
 
2.2.3.1. Composite formation. 
 
pSi-PCL composites were fabricated as detailed in section 2.2.1. A sample of the 
composite was removed at stage 5 (Fig. 2.4) and at stage 10 to compare the 
microtopography of the composites at each stage. The discs were gold coated in a 
sputter coater and imaged using a Jeol JSM 840 scanning electron microscope. 
 
Silicic acid release from the stage 5 (termed freeze-cast) composite and the 
finished stage 10 (termed melt cast) discs was analysed by incubating 250mg ± 
10mg discs of each in 20ml dH2O in screw-capped polystyrene tubes at 37°C for 
10 days, with three repeats for each composite stage. 
 
After 10 days the silicic acid concentration of a 400Ƭl sample of the solution was 
determined using the molybdenum blue assay. 
 
2.2.3.2. Porous silicon  porosity and particle size. 
 
Silicon wafers were porosified at pSiMedica (Malvern, UK) with porosities ranging 
from 49% to 82% and milled by hand for 15 minutes in a pestle and mortar in a 
fume hood. The resulting particles were seived using a series of graded meshes 
into fractions containing particles less than 38Ƭm in size, 39  38 - 150Ƭm and 
more than 150Ƭm in size. The mass of each fraction was recorded. 
 
The 38 - 150Ƭm fraction was used to create 8% w/w composites with 
polycaprolactone, with a standardised 70% porous silicon (11Ƭm particle size) 
used as a control. 1.0g ± 10mg PCL was heated to ~50°C with 1ml acetone in a 
polypropylene beaker until melted/dissolved and 80mg ± 2mg pSi microparticles 
were added. A further 1ml acetone was added to suspend the particles and the 
mixture stirred for 1 minute until homogenous. 
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The composite was cast in a 5ml polyproplyene syringe body at -20°C for 30 
minutes and weighed to ensure full evaporation of the solvent. The 1.08g 
composite was cut into four 250mg ± 10mg discs which were pre-wetted in 
ethanol and placed in wells of a 24-well plate. 2ml freshly prepared simulated body 
fluid was added, the plate sealed and incubated at room temperature for 72 hours. 
 
The silicic acid concentration of the SBF was measured using the molybdenum 
blue assay and calcium phosphate deposition on the disc measured using the 
alizarin red assay. 
 
2.2.3.3. Polymer type  PCL, PHBV and PLGA. 
 
A comparison was made between the behaviour of native polycaprolactone, 
poly(hydroxybutyrate-co-hydroxyvalerate) and poly(D,L lactic-co-glycolic acid) 
and their composites with pSi (using 8% w/w pSi). 
 
PCL (MW 80,000, Sigma, UK) and PLGA (85:15, LA:GA, MW 50-70,000, Sigma, 
UK) were formed into 250mg discs and 250mg composite discs as described 
above. PHBV (8% hydroxyvalerate, MW 272.2, Sigma, UK) was formed into 
composites by melting the polymer in a glass beaker on a hotplate at ~180°C and 
mixing pSi microparticles into the molten polymer. 250mg discs of PHBV and 
PHBV-pSi were the made by melting small sections on top of each other on glass 
slides on a hotplate. 
 
The resulting 250mg ± 10mg discs were accurately weighed and then incubated in 
50ml dH2O at 37°C for 24 weeks in 50ml polypropylene screw-capped tubes. 
400Ƭl of the incubation solution was removed, replaced and tested for silicic acid 
using the molybdenum blue assay every week for 8 weeks and again at 12 weeks.  
 
At 4, 8, 12 and 24 weeks the discs were removed from the solution and allowed to 
air dry overnight at room temperature before being observed and reweighed to 
assess mass loss/gain. At 4 and 8 weeks the pH of the solution was measured 
using a Hannah 120 benchtop pH meter. 
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2.2.3.4. Relationship of composite mass to silicic acid release. 
 
A quantity of 8% pSi-PCL was made and cut into twelve discs with accurately 
weighed masses ranging from 37mg to 157mg. The discs were incubated in 20ml 
dH2O in screw-capped tubes at 37°C for 10 days, at which point the solution was 
tested for silicic acid content using the molybdenum blue assay. 
 
2.2.3.5. Dissolution buffers and solution volume. 
 
To compare the effects of using a metastable solution (SBF) to a pH buffered 
solution, PBS was used as a comparison. SBF was prepared as described in 
(2.1.2x) and PBS was prepared by dissolving one buffer solution tablet (Sigma, 
UK) in 100ml dH2O. The water used in this investigation was millipore processed 
and all solutions were stored at 4°C for no longer than 4 weeks. 
 
250mg ± 10mg 8% pSi-PCL composite discs were placed in 25ml screw-capped 
polystyrene universal tubes (10, 5 & 2.5ml samples) or 5ml polystyrene screw 
capped tubes (1ml samples) with three replicates per condition (n=3). 1x PBS or 
1x SBF were added to each tube, with volumes of 1ml, 2.5ml, 5ml and 10ml. 
 
These were incubated in a shaking water bath (70rpm) at 37°C and each solution 
was removed and replaced every 24 hours. The removed solution was tested for 
silicic acid using the molybdenum blue assay. 
 
2.2.3.6. Comparison of pSi-PCL to 45S5 Bioglass®-PCL. 
 
45S5 Bioglass® particles were provided by Dr Julie Gough (University of 
Manchester) and used as a direct comparison for equal amounts of pSi in PCL 
composites. Bioglass®-PCL composites were produced in an identical manner to 
pSiPCL composites containing 8% Bioglass® particles or 8% pSi (20mg per 
250mg PCL) and cut into 250mg ± 10mg discs.  
 
Bioglass®-PCL and pSi-PCL composite discs were placed in 20ml polystyrene 
screw-capped tubes, 20ml dH2O added and incubated at 37°C for 42 days. 400Ƭl 
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of the incubation volume was removed and replaced every 14 days with the 
removed solution tested for silicic acid using the molybdenum blue assay. 
 
2.2.3.7. Long-term incubation. 
 
250mg discs were created using PCL and 1  30mg pSi (70% porous, 11Ƭm 
particles) using the method described above. The discs were incubated in 500ml 
dH2O at 37°C for 360 days with samples of the solution taken at 30, 210, 290 and 
360 day intervals and measured for silicic acid content. The solution was changed 
completely at 4 and 8 months at which time the pH was measured and the discs 
dried overnight at room temperature and re-weighed. 
 
2.2.3.8. Morphology and composition of apatite formation. 
 
250mg discs containing 0, 1mg, 10mg or 20mg of pSi were incubated in SBF for 
28 days and the calcium phosphate layer analysed by ESEM and EDX. Seperately, 
20mg pSi-PCL and PCL-only discs were co-incubated in 20ml dH2O in order to 
test how readily a silica gel layer forms on surrounding surfaces. 
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2.3. Results. 
 
2.3.1. Forming the composite. 
 
Polycaprolactone is highly viscous at temperatures below 100°C, but is soluble at 
room temperature in a range of organic solvents, including acetone, 
dichloromethane and chloroform. Of these it was determined that acetone was 
preferable for dissolving the polymer due to its low toxicity and high volatility, 
enabling the solvent to be quickly extracted from the composite at temperatures 
below the 60°C melting point of the polymer.  
 
This method proved successful in forming composites by allowing a fully 
homogenous composite to be produced, but the mechanical properties of the 
material were poor and the composites often deformed after drying due to the 
micropores formed by evolving a large volume of acetone from the matrix (fig. 
2.6.A). To overcome this a two-stage process was developed, with the first phase 
being dissolution of the polymer and mixing with pSi microparticles. At this stage 
the acetone in the composite was frozen at -80°C to allow the microporous 
morphology of the composite at this stage to be imaged using SEM (fig. 2.6.A).  
 
 
 A        B 
 
 
 
 
 
 
Fig. 2.6. Comparison of two methods of casting composites, each showing a 
10mg composite. A. Composite produced by freezing an acetone-containing 
cylinder at -80°C to cast an open-textured microporous polymer. B. Composite 
produced by allowing the acetone to evolve at 70°C during the two-stage process 
outlined in fig. 2.4 and following drying the construct at room temprature 
overnight.  
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The second phase of fabrication was to cut the composite into fragments 
followed by melt-casting into shape at 60°C. This method was found to produce a 
dense composite with high resistance to deformation (identified subjectively by 
manual handling of the material) with an approximately four-fold lower silicic acid 
release rate (for comparable composites, fig. 2.7) and is outlined in methods, 
section 2.2.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.7. Silicic acid release from freeze-cast (microporous) or melt-cast (dense) 
composite discs containing 20 mg pSi incubated in 20ml H2O for 10 days at 37°C. 
Bars show standard error of the mean, n=3. 
 
 
2.3.2. pSi particle size. 
 
Porosified silicon wafers were produced at pSiMedica (using the electrochemical 
etching process described above) in a range of porosities from 49.0% to 66.4% 
porous and ground in a pestle and mortar in a ventilated fume hood for 10-15 
minutes. The resulting particles were seived using graduated mesh filters to obtain 
particle size fractions of  38Ƭm, 38 - 150Ƭm and  150Ƭm. The mass of each 
fraction is shown in fig. 2.8.  
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Size range of hand-milled pSi particles
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Fig. 2.8. Mass of particle size fractions resulting from hand-milling of porosified 
9 silicon wafers. The percentage of the total mass comprising the intermediate 
(38 - 150Ƭm) fraction was between 76.2% (for 57% porous silicon) and 99.1% 
(for 49% porous silicon). 
 
 
The 38  150 Ƭm particles were used for this investigation to evaluate specific pSi 
porosities, but were considered both too large and the size range too broad for 
optimal applications (fig. 2.9.A). At pSiMedica a standardised size range of 11Ƭm 
(fig. 2.9.B) is used for most applications which has a very small distribution in 
particle sizes and small enough to allow uniform dispersal of the particles 
throughout the polymer phase (see fig 6.7). 
 
 A         B  
 
 
 
 
 
 
Fig. 2.9. SEM images of A. 49% pSi particles (38-150Ƭm) and B. 70% (11Ƭm) 
particles. 
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Silicic acid release from pSi of varying porosities in 8% 
composites with PCL
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Fig. 2.10. Silicic acid release from 8% w/w (20mg pSi per 250mg disc) 
composites containing pSi microparticles of varying porosity. 70% porous silicon 
was obtained from pSiMedica and had a smaller average particle size (11Ƭm) than 
the other porosities, which were hand-milled and seived. pSi release was evaluated 
over 72 hours in 2ml SBF at room temperature. Error bars are standard error of 
the mean, n = 4.  
 
 
In addition, it was observed that pSi porosity does not have a linear relationship 
with silicic acid release rate when the particles are not of comparable sizes (fig. 
2.10), with a linear regression coefficient (R2) of 0.4996 ([silicic acid]/pSi porosity 
(%). Smaller particles of 70% pSi generated more silicic acid over 3 days in SBF 
than 82% porous silicon particles of a larger size, indicating that particle size 
(available surface area) has a greater effect on degradation rate/silicic acid release 
than porosity of the particles when the pores may be blocked/filled with polymer. 
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2.3.3. PLGA, PHBV and PCL. 
 
The silicic acid release profiles and degradation rates of the three polmer-
composites were somewhat different. Fig. 2.11 shows the release of silicic acid 
from the composites over the initial 8 weeks of the experiment, and illustrates 
three different profiles for silicic acid release: sigmidal (PCL), exponential (PLGA) 
and linear, but erratic (PHBV). 
 
Despite the differences in the trend lines, the concentrations of the two aliphatic 
polyesters PCL and PLGA were similar at each time point, whereas PHBV 
released consistently less silicic acid into solution. Analysis of the masses of each 
composite in comparison to the basic polymer (fig. 2.12) illustrates the differences 
in degradation rate which partially describe the difference in silicic acid release. 
 
All basic polymers showed a loss in mass over 24 weeks: PCL lost ~0.4% of the 
original mass after 24 weeks, PHBV lost ~1.0% and PLGA lost 80-100% of 
original mass by this time. During the initial period of the experiment (up to 8 
weeks), PLGA increased in mass  this was discovered to be due to a hydrated 
layer inside the material which remained following drying at 40°C for 24 hours.  
 
PCL-pSi and PHBV-pSi composites showed an increase in mass despite the 
combined losses from polymer and pSi degradation, which is thought to be 
through the deposition of hydrated silica gel on the surface of the material, adding 
to its overall mass. The mass increase due to silica formation was greatest for 
PHBV-pSi despite the lower solution concentrations of silicic acid for these 
samples, indicating that condensation of silicic acid to silica occurred within the 
material prior to release of silicic acids into solution.  
 
PLGA-pSi was discovered to degrade extremely rapidly, with two out of the three 
sample discs degrading completely within 8 weeks and all discs totally degraded 
within 12 weeks. Mass loss was also consistent for these samples with no hydrated 
layer inside the material, possibly due to the porous nature of the composite at the 
10Ƭm particles of pSi were dissolved into solution. 
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Silicic acid release from polymer-pSi composites containing 
20mg pSi
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Fig. 2.11. Silicic acid release profiles of 8% w/w pSi-composites showing 
polycaprolactone (red), poly(lactic-co-glycolic acid) (blue), and poly-3-
hydroxybutyrate (green) composite summed silicic acid release over 8 weeks into 
50ml dH2O. PLGA data only shown to 6 weeks as two out of three discs had 
totally degraded by 8 weeks. Bars show standard error of the mean, n=3; R2 for 
trendlines > 0.99. 
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Fig. 2.12. Changes in mass of pure-polymer and 8% w/w pSi-composites with 
polycaprolactone, poly(lactic-co-glycolic acid), and poly-3-hydroxybutyrate 
expressed as a percentage of original mass. PLGA percentage mass loss is shown 
on the 2nd Y-axis. 
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The pH of the solutions was similar for both basic polymer and composites, with 
composites acidifying solutions by an additional pH 0.53  0.63 at 8 weeks over 
the acidification caused by polymer hydrolysis which generates carboxylic acids 
(fig. 2.13). The change in pH of solutions between 4 and 8 weeks shows that the 
degrading polymers continued to acidify the solution, whereas the additional 
chemical interactions of the composites resulted in an increase in pH from 4 to 8 
weeks (fig. 2.14). 
 
 
Fig. 2.13. pH of dissolution volume (dH2O) after A. 4 weeks incubation. B. 8 
weeks incubation. (Bars show standard error of the mean, n=3). 
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Fig. 2.14. Subtracting the pH of the solutions at 4 weeks from the pH at 8 weeks 
shows that the acidification caused by polymer degradation was offset by silica 
formation in the composite samples, resulting in a lowering of acidity over time 
for PCL and PHB composites. The enhanced degradation of PLGA-pSi resulted 
in further acidification of the solutions and importantly the pH generated by all 
composites was lower than basic polymer (see fig. 2.13). Bars show standard error 
of the mean, n=3. 
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2.3.4. Composite mass. 
 
Fig. 15 shows the silicic acid release from 8% melt-cast composites (20mg per 
250mg PCL) with masses ranging from 37  157 mg and incubated in dH2O for 
10 days, and shows that silicic acid release is proportional to composite mass. 
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Fig. 2.15. Silicic acid release from 8% w/w pSi-PCL composites of varying size 
(37mg - 157mg) incubated in dH2O for 10 days. Lines of best fit for linear 
regression (green) and second order regression (red) are shown with 
accompanying coefficients, R2 (Bars show standard error of the mean, n=3).  
 
 
The linear and second order lines of best fit show a slight effect of composite 
thickness on dissolution rate, indicating that pSi is able to elute from deep within 
the construct. This suggests that the polymer phase of the composite is largely 
amorphous (non-crystalline), allowing for water ingress and silicic acid elution 
throughout the bulk of the composite without being obstructed by the matrix. 
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2.3.5. Solution and volume. 
 
Dissolution of pSi-PCL in small (1  10ml) volumes of PBS followed a linear 
regression (R2 = 0.9875) over these volumes, indicating that PBS does not interact 
with the dissolution of pSi in solution. Interestingly, pSi dissolution in SBF was 
non-linear and instead followed a second order regression (R2 = 0.9875), implying 
that SBF interacts with pSi and silicic acid in solutions, particularly when the silicic 
acid concentration is abouve ~ 500Ƭg.ml-1.  
 
Fig. 2.16. Total silicic acid released into solution by 8% composite discs in 1  10 
ml volumes of SBF or PBS after 28 days. Bars show standard error of the mean, 
n=3. 
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2.3.6. Comparison of pSi to Bioglass® in PCL composites. 
 
Composites made from PCL with 8% (w/w) either 45S5 Bioglass® particles or 
70% pSi both released silicic acids into solution. Over 42 days the release of silicic 
acids was linear for both composites (Bioglass®, R2 = 0.8592; pSi, R2 = 0.8556). 
pSi-PCL was shown to release significantly more silicic acid than Bioglass®-PCL (p 
 0.001 at each time point, detemined by Students T-test), with pSi releasing an 
average of 2.5 times more silicic acid than Bioglass® in comparable composites 
(fig. 2.17). 
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Fig. 2.17. Silicic acid release into 20ml dH2O from 8% w/w pSi-PCL and 8% 
45S5 Bioglass®-PCL. (Bars show standard error of the mean, n=3). Linear 
regression for silicic acid release (per day) from each composite is shows silicic 
acid release (y in Ƭg Si) to be 0.9186x for Bioglass®-PCL and 2.2964x for pSi-PCL, 
where x is time (days). 
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2.3.7. Long term study. 
 
Silicic acid was released from all composites in quantities that were detectable 
within 24 hours (for 15-30 mg discs) but not until day 28 for discs containing 
lower amounts of pSi (1-5 mg), (fig. 2.18). In this static, non-agitated system, 
silicic acid levels did not exceed 500 ng.ml-1, equaivalent to a total mass of Si in 
500ml of 0.25mg. For a 30mg pSi-composite disc this is equivalent to 0.83% of 
the total pSi present and is similar for all discs tested (fig. 2.19).  
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Fig. 2.18. Silicic acid release for pSi-composite discs incubated in dH2O for 360 
days at 37°C. Error bars ommitted for clarity, see fig 2.20. 
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For all composite discs, silicic acid was released continuously through the 
experiment, although the rate becomes lower over time for composites with less 
pSi, silicic acid release from 30mg discs was almost linear over 360 days (R2 = 
0.997, compared to 10mg discs with linear R2 = 0.933). From this data, the 
amount of silicic acid released per mg pSi in a 250mg disc when the system is not 
subject to fluid flow (see section 5.1.2., page 173) can be determined as 0.299 ± 
0.004 ng.day-1. 
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Fig. 2.19. Percentage of Si originally added (as pSi) present in solution as silicic 
acid after 360 days. Error bars are standar error of the mean, n=3. 
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Fig. 2.20. Silicic acid concentrations at 360 days for each ratio pSi-PCLcomposite. 
Trend line (linear) shows silicic acid release per disc, R2 = 0.8646 when plotted on 
scatter graph. Error bars are standard error of the mean silicic acid concentration 
at day 360, n=3. 
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Polycaprolactone discs without pSi lost 6-8% initial mass within 90 days which did 
not change for the remainder of the experiment and was attributed to the loss of 
residual solvents and small molecular weight polymers which were able to disperse 
from the matrix. 1mg discs lost <1% mass whereas discs containing more pSi 
increased in mass, peaking at a 4% mass gain for 20mg discs. 25mg and 30mg 
discs did not increase in mass to the same extent and some replicates showed a 
net loss in mass. The loss in mass from 280-360 days was observed in all 
composite discs regardless of initial weight gains corresponding to the increase in 
mass loss from polymer decomposition at this time. 
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Fig. 2.21. Mass changes of pSi-PCL over 360 days showing the decrease in mass 
of PCL and the relative increase in mass of pSi-composites due to the build up of 
a hydrated silica gel layer on the surface of composites and oxidisation of pSi in 
the matrix. Error bars are standard error of the mean, n=3. 
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Mean mass change and silicic acid concentration 
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Fig. 2.22. Mass change against mean silicic acid concentration in solution at 90 
days. Error bars for mass change are standard error of the mean at day 90, n=3. 
Error bars ommited from silicic acid line for clarity (see fig. 2.17.) 
 
 
Solution pH after 120 days was lower for all composites than PCL-only and was 
inveresly proportional to pSi content of the composite, with a coefficient of linear 
regression (R2) of 0.939 (fig. 2.23). 
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pH after 120 days in solution
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Fig. 2.23. pH of initial solution after 120 days incubation. Error bars are standard 
error of the mean, n=3. 
 
 
Fig. 2.24. Discs removed from solution and dried after 360 days (One third of 
each disc has been removed for analysis), showing reduction in composite disc 
diameter compared to PCL. Image was taken using a Brother DCP -560CN 
scanner. Bar shows 10mm, initial diameter at Day 0 for all discs was 11.5mm. 
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2.3.8. Morphology and composition of silica and apatite formation. 
 
Scanning electron microscopy of composites incubated in H2O shows the 
formation of a silica gel layer with a pronounced surface togography on composite 
discs. As the PCL and composite discs in fig. 2.25. were co-incubated, the silica 
gel formed on the surface of the PCL-only disc results from condensation of 
silicic acids from solution, demonstrating that pSi can condition peripheral 
surfaces with a silica gel layer. 
 
  
  
Fig. 2.25. ESEM images of A. PCL and B. 20mg (8%) pSi-PCL composites co-
incubated in the same volume (50ml) dH2O for 14 days, and EDX spectra (C. 
PCL. D. pSi-PCL) showing the deposition of silica occurs across all surfaces 
exposed to the degradation products of pSi. 
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Fig. 2.26. Magnified ESEM image of Fig. 2.25.B showing the surface 
morphology of the silica gel layer is highly contoured surrounding pSi particles. 
 
 
Incubation of 0.4% (fig. 2.27), 4% (fig. 2.28) and 8% (fig. 2.29)composite discs 
in SBF for 4 weeks results in the formation of a calcium phosphate layer in 
addition to the silica gel layer. This calcium phosphate layer has the morphology 
of biological apatite seen in Bioglass® studies. Analysis of the surface using X-ray 
dispersive spectroscopy shows that the calcium/phosphate ratio is closer to 
biological apatite (1.5) than phase-pure hydroxyapatite (1.67). 
 
In some regions, the cracked surface is perpendicular to the disc, allowing a cross-
section of the layer to be imaged. This shows a sandwich of silica, with an inner 
and outer cortex surrounding an inner region which appears less dense (fig. 
2.27.B & C) 
 
Further analysis of calcium phosphate layers on increasing concentrations of pSi 
show that the calcium deposits become increasingly large and more continuous. 
In addition, EDX reveals that the calcium/phosphate ratio of the mineral is 
proportional to silicon content (fig. 2.30). That is, increasing pSi in the matrix or 
[silicic acid] in solution results in increased substitutions in the apatite crystal for 
phosphate, or possibly reduced substitution for calcium. 
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Fig. 2.27. ESEM images of 1mg (0.4%) composite discs incubated in SBF for 4 
weeks, showing the build up of a calcium- and phosphate-containing surface layer. 
(D) This layer is shown to have a Ca/P ration of 1.487. In this spectrum, silicon 
represents only 0.7% of the atoms present in the target region, (A). B. and C. 
show a section through this layer which appears to contain an interior architecture 
of lower density. The Ca/P ratio in this spectrum is 1.487. 
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Fig. 2.28. ESEM images of 10mg  (4%) composite discs incubated in SBF for 4 
weeks, showing the build up of a calcium- and phosphate-containing surface layer 
(A). This surface layer is contiguous but was fractured during the drying process 
to reveal separated plates approximately 2Ƭm in thickness (B). Distinctive 
biological apatite formations are observed on this surface layer (C) with an overall 
Ca/P ratio of 1.498 (from A). 
 
 
 
 
 
 
 
 76 
Chapter Two 
  
   
Fig. 2.29. ESEM images of 20mg (8%) composite discs incubated in SBF for 4 
weeks, showing the build up of a calcium- and phosphate-containing surface layer 
with a distinctive apatite-like morphology. 
 
 
 
Fig. 2.30. A. Calcium/phosphorus ratios of the surface layers deposited on the 
composite surfaces after 4 weeks in SBF. Increasing the pSi content of the 
composite correlates to a decrease in phosphate content of the mineral layer. B. 
This effect is linear over the composite range tested (0.4  8% w/w), R2 = 0.9986. 
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2.4. Discussion. 
 
This section of the work describes the initial trials that were performed in order to 
assess the effect of adding porous silicon to biodegradable polymers in terms of 
biodegradation rates, silicic acid release and the enhancement of calcium 
phosphate deposition from acellular simulated body fluids. 
 
The method developed for forming the pSi-polycaprolactone composite involved 
first combining pSi microparticles with a solution of polycaprolactone in acetone 
to create a homogenous, microporous composite. The mechanical properties of 
this composite appeared to be enhanced (by subjective analysis: the mechanical 
properties were not measured directly) by then melting the composite at >60°C to 
eliminate most of the micropores and residual solvent. The final composites for 
testing were cast in the body of a polypropylene syringe, which allowed a cylinder 
of uniform, consistent diameter to be produced, which could be easily cut into 
discs with regular size and weight, standardised to 250mg ± 10mg. 
 
In this investigation, the pSi content of the composite is presented in two ways, 
either as a mass value indicating the amount (in mg) of pSi in a disc (which were 
almost always 250mg in total) or as a percentage composition. Thus 10 % 
composites contained 25mg pSi for every 250mg PCL. It is important to note that 
due to the large surface area and volume to mass ratio, composites containing 10 
% by mass of porous silicon contained a much larger proportion by volume. The 
typical density of monocrystalline silicon is 2.33 g.cm-3, but for 70% porous silicon 
this density is only 0.7 g.cm-3. Therefore the volume percentage of this composite 
would theoretically be closer to 33%. 
 
In practice, the method used for creating the composite using a solution of the 
polymer in acetone would allow some of the internal pore spaces of the pSi to 
become filled with polymer, particularly after recasting using heat as the molten 
polymer was compressed into the pores. Some groups have exploited this effect 
by sing pSi pores as a template for producing male casts of pSi pore architectures 
for various applications (Kim et al, 2007).  
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At the beginning of the investigation several porosities of pSi were evaluated, 
from 49% porous to 82% porous. These were produced by pSiMedica Ltd at the 
company laboratories in Great Malvern, Worcestershire, and milled by hand on 
the premises using a pestle and mortar. This generated pSi particles of varying 
sizes, with the main fraction (~80%) of particles being in the 38  150Ƭm size 
range. These particles were used for initial trials, but it was decided that greater 
uniformity and a smaller size range was required and so in later experiments a 
standardised 70% porous silicon was obtained from pSiMedica with 11Ƭm 
particles in a narrow size range. In this part of the investigation, all experiments 
(unless stated otherwise) utilised the 70% standard pSi to allow direct 
comparison between experimental conditions to be made. Alternative porosities 
were utilised for in vitro testing of osteoblasts as will be discussed in chapter three. 
 
The proposed bioactive properties of porous silicon result from the materials 
release of orthosilicic acid, which was detected and quantified throughout this 
investigation using the molybdenum (molybdate) blue assay. In this assay, 
ammonium molybdate in solution reacts with silicic acid in the sample to form Ƣ-
silicomolybdic acid (yellow) which is subsequently reduced to form a molybdate 
blue complex with a peak absorbance at 810nm. The assay was highly adjustable 
as up to 40% (400Ƭl) of the reaction volume comprised the tested solution, 
allowing for very dilute samples to be successfully assayed, with a lower limit of 
detection at 1 ng.ml-1 of the test solution. The assay worked equally well using 
PBS and SBF as incubation/buffer solutions as with water and was linear over the 
concentration ranges tested, with typical coefficients of linear regression for 
calibration (using sodium metasilicate standards) being R2 > 0.99. 
 
Silicomolybdic acid is formed rapidly from the interaction of the molybdate with 
orthosilicic acids, and increasingly slowly for larger weight di- and poly-silicic 
acids. Colloidal silica and solid silica gels do not form silicomolybdic acids at all, 
but do exist in dynamic equilibrium with soluble silicate species in solution 
(Alexander et al, 1954). The time allowed for the formation of silicomolybdic acid 
in this assay was fixed at 10 minutes, which allows all of the orthosilicic acid in the 
solution to react, but minimises the amount of polysilicic acids detected by the 
assay. This was done to allow a measure of control and standardisation over the 
 79 
Chapter Two 
complex and dynamic chemistry of silicic acid polycondensation occurring in the 
system. 
 
Microporosity caused by acetone evolution had a large effect on the rate of 
orthosilicic acid release, increasing the rate of silicic acid release into solution 
almost five-fold. This indicates a surface area/volume effect, allowing small 
weight silicic acids to diffuse out of the matrix rapidly. All of the experiments in 
this part of the investigation were performed on two-dimensional discs without 
significant or designed interior architecture apart from some micropores as 
illustrated. 
 
In this investigation, porous silicon composites were made from the addition of 
pSi microparticles to biodegradable polymers. The choice of biodegradable 
polymer was made early in the project based on the considerations outlined in the 
introduction to this chapter, but a selection of relevant biodegradable polymers 
were also included in the trial to determine the effect of the polymer phase on 
composite behaviour in terms of degradation, silicic acid release and calcium 
phosphate nucleation. 
 
It was observed that silicic acid release was not equal for polycaprolactone, 
poly(D,L lactide-co-glycolide) or poly(hydroxybutyrate-co-valerate) and the release 
kinetics also differed. Composites based on PCL show a sigmoidal pattern of 
silicic acid release with an increase in release rate after one week which stabilises 
and gradually decreases over time. It can be surmised that these changes result 
from changes in surface chemistry of the composite over this time, with water 
ingress through the matrix and wettabilty increasing due to reduction of water 
contact angles through the hydrolysis of hydrophobic S-H motifs to more 
hydrophilic Si-O (Tolstoy et al, 2003). The deposition of a silica gel layer on the 
surface of the composite then inhibits both further water ingress and elution of 
orthosilicic acid from the material. This silica gel layer was observed and recorded 
in electron micrographs. Additionally, it should be noted that the continuing 
degradation of pSi in solutions of orthosilicic acid under the silica layer increases 
the rate of silicic acid polymerisation as the reaction is concentration dependent, 
leading to a reduction in the concentration of dispersible, detectable species. 
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Degradation of pSi in PLGA and PHBV occurs via the same mechanism, but 
release profiles of silicic acid were different. Rather than sigmoidal, PLGA 
released silicic acid in an exponential way, with the degradation rate of porous 
silicon in the matrix increasing at a steady second order rate over the 8 week 
period but generating similar concentrations of silicic acid at each time point as 
PCL composites. PHBV degradation was slower than both PCL and PLGA and 
more erratic, following a linear profile over 8 weeks but with a coefficient of linear 
regression (R2) of only 0.68. 
 
The differences in the behaviour of these three biodegradable composites derive 
from three parameters: polymer degradation rate, relative hydrophilicity / 
hydrophobicity and percentage crystallinity of the native polymer. 
 
The hydrolytic degradation of polycaprolactone occurs slowly, taking up to two 
years for substantial mass loss, whereas PLGA degradation occurs much more 
quickly, within 3 months. PHBV degrades over 200-300 days under physiological 
conditions (Muhamad et al, 2006). In this investigation it was noted that the 
addition of porous silicon to the polymer matrix increased the rate of polymer 
degradation (determined from total mass loss) in PLGA significantly, causing two 
out of the three samples to completely decompose after 8 weeks, with complete 
degradation occurring for all samples within 12 weeks.    
 
Hydrophobicity and crystallinity of the native polymers/co-polymers affect the 
behaviour of all aqueous solutions in contact with the material. Water contact 
angle is used as a measure for hydrophobicity, and is 82° for PCL (Tan & Teoh, 
2006), 78° for PLGA (Wan et al, 2004) and 72.5° ± 5.6  for PHBV (Wang et al, 
2006), interesting illustrating that the more hydrophobic polymers show greater 
solubility/degradation of pSi from the composite. Crystallinity for native polymers 
is cited as being ~50% for PCL (Goldberg, 1995), 51.1% for PHBV (Muhamad et 
al, 2006) and considerably lower for PLGA co-polymers. Polymer crystallinity 
therefore does not appear to have a bearing on the degradation rate of pSi in the 
matrix in this case, although it is noted that the percentage crystallinity of 
composites may be different to that of native polymer. 
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Acidification caused by the presence of polymer degradation products is a 
concern in orthopaedics that has been a major factor limiting their use, 
particularly in ischemic conditions that surround many orthopaedic wounds and 
implant sites. Acidosis inhibits bone formation and stimulates osteoclastic 
resorbtion of bone (Frick and Bushinsky, 2003), and so limiting the acidification 
of orthopaedic wounds is important in designing degradable implants. As a 
material designed to elute orthosilicic acid, this was a concern from the beginning 
of the investigation.  
 
Whilst composites of PCL, PHBV and PLGA with pSi lowered the pH of 
incubating solutions, the composites were shown to stabilise the solutions over 
time, with volumes incubating composites increasing in pH after 8 weeks rather 
than decreasing. This is through the formation of silica which eliminates silicic 
acid from solution as described in simplified formula: 
 
Si(OH)4 + Si(OH)4 Ⱥ 2SiO2 + 4H2O 
 
In addition to porosity and concentration of pSi microparticles in the polymer, 
other factors which effect silicic acid release were the size of the composite and 
the volume of medium in which the material was incubated. Composites 
containing the same percentage of pSi (8%) but with varying sizes released silicic 
acid in an almost linear way, indicating that the material is fully permeable to water 
and demonstrating that, at least for small-sized composites, the mass of the 
composite is directly proportional to the amount of silicic acid eluted. The slightly 
better fit of a second order trend line to the graph demonstrates that release of 
silicic acid from larger composites may be slightly inhibited by the mass of the 
material. 
 
The volume of the surrounding solution into which the porous silicon degrades 
was shown to have a linear relationship to the amount of silicic acid detected in 
PBS. Larger volumes supported higher concentrations of orthosilicic acid, either 
by stimulating enhanced degradation of pSi or inhibiting condensation of 
polysilicic acid. Interestingly, the [Si(OH)4]/volume was non-linear when SBF was 
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used as the dissolution solution, with significantly higher concentrations of silicic 
acids detected in 10ml SBF than either 10ml PBS or 2 x 5ml SBF.  
 
The proposed bioactivity of porous silicon results from its degradation in 
aqueous solutions to yield soluble silicates and form a hydrated silica gel on the 
materials surface. This mechanism has been extrapolated from studies of 
Bioglass® bioactivity, in which the glass dissolves in solution to liberate its ionic 
constituents, chiefly comprising silicon (Reffit et al, 2003; Keeting et al, 1992). The 
class A bioactivity of this type of biomaterial therefore can be reasonably related 
to the generation of silicic acids, therefore, and so a comparison of the silicic acid 
release rate of both pSi-PCL composites and 45S5 Bioglass®-PCL composites was 
performed in order to evaluate pSi activity in relation to a well-documented and 
well-known example. 
 
8% w/w composites of pSi or Bioglass® in PCL were made and incubated in H2O 
for a period of 6 weeks. Over this time, release of silicic acids from both 
composites was linear, but pSi generated 2.5 times more silicic acid than Bioglass®. 
As a measure of potential bioactivity therefore, this suggests that pSi-PCL will 
outperform Bioglass®-based composites in subsequent in vitro tests, based on 
silicic acid acting as the main bioactive component of both materials.  
 
The polymer chosen for the composite in this investigation, polycaprolactone, 
degrades slowly, with substantial mass loss occurring only after 6-24 months. 
Therefore it was decided that a long-term degradation study covering one year 
should be performed to evaluate the behaviour of the composites over this time 
scale. Silicic acid release in this system was proportional to the pSi-content of the 
composite, and linear over the first 200 days, after which the silicic acid release 
plateaued in lower compositions (up to 25mg, 10% w/w) but 30mg (12% w/w) 
continued to release silicic acids into solution at the same constant rate of ~1.4 
ng.ml-1.day-1.  
 
Despite the continued release of silicic acids over 360 days, at the end of this time, 
the mass of silicon in solution was less than 1% of the mass of pSi originally 
added into the system. Free pSi degrades rapidly in solution (pSi data), so the low 
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rate of degradation suggested by this data in incongruous with the predicted 
results. However, silicic acids polymerise rapidly in solution, with the rate 
proportional to the concentration, which becomes high peripheral to the surface 
of the composite and within the matrix, particularly in the static system used here 
with little solution flow around the material. 
 
This polymerisation results in the formation of large molecular weight silicic acids 
and solid silica, which condense on the surfaces of the composite and the walls of 
the incubation vessel. In this investigation, the silica formation on the composites 
was measured by comparing the original mass of the discs to the mass of the discs 
at set intervals during the experiment. The weight gain due to the presence of 
silica was easy to determine in this simple system, as the baseline mass loss due to 
polymer degradation could be determined from the PCL-only control, any mass 
increase therefore was due to silica deposition. 
 
Gain in mass due to silica deposition is pronounced in this system. One mole of 
Si (or pSi) masses 28.09 g whereas one mole of silica (SiO2) is 60.08 g, therefore 
the full dissolution and conversion of 20mg pSi would generate 42.78g SiO2, a 
percentage increase in mass of the composite of 9.11%. In the investigation, the 
maximum mass gain achieved by a composite disc was ~5%, indicating 
condensation of silica occurs on other surfaces in the reaction vessel and that 
larger, undetectable polysilicic acids are present in solution.       
 
Electron microscopy of composite discs incubated in just water shows a 
pronounced surface layer which was attributed to a hydrated silica layer, possibly 
containing polymer fragments resulting from the combined dissolution of both 
polymer and silicon in the material. A cross section through this layer shows it to 
have a pronounced internal architecture, with perpendicular striations between 
solid outer layers.  
 
Calcium phosphate was detected in composites incubated in acellular simulated 
body fluid and shown to be proportional to the amount of silicic acid released by 
the material. This calcium phosphate was shown using SEM to have the 
characteristic morphology of biological apatite, with a Ca:P ratio of ~1.5, 
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supporting this conclusion. Interestingly, the Ca:P ratio was proportional to the 
pSi/[silicic acid] in the system, with increasing pSi in the disc resulting in a lower 
proportion of phosphate in the crystal. Due to the higher amount of silicates in 
the system here, it is proposed that the apatite in these cases is silicate substituted 
(for some phosphate and carbonate).  
 
In summary, these initial investigations demonstrate that porous silicon 
microparticles can be added to biodegradable polymers to create a silicic acid acid-
eluting material which forms a silica/calcium phosphate layer autonomously in 
acellular simulated body fluid. Silicic acid release rates can be finely controlled by 
varying the percentage porosity and amount of microparticles added, and pSi-PCL 
composites outperform comparable 45S5 Bioglass®-PCL composites in terms of 
silicic acid release. 
 
Further and more detailed physical characterisation of the composites is discussed 
in chapters 5 and 6 and in the appendix. 
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Osteoblast Response to Porous Silicon  
Polycaprolactone Composites in Vitro 
Chapter Three 
3.1. Introduction. 
 
In vitro cultures of osteoblast-like cells are a useful means of analysing cell biology 
and interactions with biomaterials in effective isolation from other cells. Using 
such cultures allows the molecular biology of large populations of similar cells to 
be quantified, enabling statistical significance to be determined and enhancing the 
reproducibility of experimental data. In addition, current trends in tissue 
engineering have been towards the development of in vitro cellularised scaffolds  
three-dimensional porous materials which can be seeded with the autologous cells 
and cultured in the laboratory prior to implantation (Wang et al, 2009). 
 
 
3.1.1. Osteoblasts in vitro. 
 
Osteoblasts derive from a pluripotent mesenchymal lineage, sharing common 
progenitor cells with fibroblasts, chondrocytes, myoblasts and adipocytes (Aubin 
et al, 1995) as illustrated in fig. 3.1.  
 
 
Fig. 3.1. Osteoblast ontology proposed by Aubin et al, 1995. Osteoblasts derive 
from a pluripotent mesenchymal lineage. 
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Differentiation of progenitor cells into osteoblasts is triggered by several 
physiological factors, including the relative vascularisation of the tissue (Cormack, 
1984) and numerous autocrine and paracrine cell signals such as bone 
morphogenetic proteins (BMPs) - chiefly acting through the hedgehog signaling 
cascade - and the transcription factor, core-binding factor -1 (Yamaguchi et al, 
2000; Soltanoff et al, 2009). Upon receiving signals for differentiation, the pre-
osteoblasts mature, gradually losing the ability to divide and increasing the 
expression of mature osteoblastic markers such as type I collagen and alkaline 
phosphatase (Leung et al, 1993). 
 
Methods for isolating and culturing osteoblasts have been developed, beginning 
with Peck et al (1964) and utilising cells from a variety of sources. Commonly used 
sources of primary osteoblast-like cells for research purposes are neonatal mouse 
or rat calvaria and human femoral head trabecular bone (fig. 3.2), which is 
removed from patients undergoing total hip arthroplasty and is therefore relatively 
easy to obtain.  
 
 
Fig. 3.2. Mouse calvarial MC3T3-E1 cells (A) and primary human osteoblasts (B) 
cultured in vitro on sintered hydroxyapatite showing distinctive morphology: cells 
appear superficially similar to fibroblasts with a ruffled plasmalemma and 
numerous filipodia. From Trentz et al (2003). 
 
 
Alternatively, cell lines exist which are derived from osteosarcomas, including rat 
osteosarcoma (ROS) and human MG-63 cells and these exhibit a constant 
phenotype, although being immortalised and adapted to in vitro conditions these 
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cells may not be fully representative of normal osteoblast behaviour (Majeska, 
1996). It is thought that primary cultures are more representative of the natural 
behaviour of osteoblasts in vivo, and therefore are more useful to studies of 
response to biomaterials in vitro. Cell lines established from normal cells, such as 
MC3T3-E1 from mouse calvaria, show that these primary cultures of normal cells 
can be passaged for long periods and stored in liquid nitrogen, retaining their 
expression of markers of osteoblastic differentiation and activity (Sudo et al, 1983). 
 
Proliferation in vitro continues until a confluent cell layer is formed (fig. 3.3). At 
this point the collagenous matrix matures, containing non-collagenous bone-
specific proteins, becoming crosslinked and calcified (Hasegawa et al, 2008). 
Osteoblasts become encased in nodules  cell multilayers in which the 
microenvironment is controlled by the osteoblasts and which form the nucleation 
points for mineralisation. Cells entrapped in the calcifying matrix can be said to 
behave from this point as osteocytes, with a proportion of the cells undergoing 
apoptosis (Nijerwerde et al, 1996). 
 
 
Fig. 3.3. Osteoblasts cultured in vitro on titanium surfaces for 7 days form a 
confluent cell layer. From Ramires et al (2002). 
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In vitro, osteoblasts express a number of molecular markers, some of which are 
unique to the osteoblast. These markers are expressed at different times during 
maturation of the osteoblast, from the proliferation of osteoprogenitors and pre-
osteoblasts to mature secretory cells which regulate a maturing and finally 
mineralising extracellular matrix (Aubin et al, 1995).  
 
These stages are accompanied by changes in the relative expression of both 
collagen and other non-collagenous matrix proteins (fig. 3.4). As described by 
Aubin et al (1995), collagen formation is high following differentiation and 
decreases over time, as does alkaline phosphatase activity once mineralisation is 
well progressed. Expression of osteopontin precedes the expression of bone 
sialoprotein and osteocalcin, which is first detected with the onset of 
mineralisation (Liu et al, 1994). Therefore, primary human osteoblasts in vitro are 
well characterised both by their molecular biology and by their morphology.  
 
 
 
Fig. 3.4. Schematic representation of Southern blots from maturing osteoblasts in 
vitro showing the stages at which RNAs for various extracellular matrix 
components are expressed. Shading shows:  Low expression.  High 
expression. Probes were for ribosomal protein control (L32), Collagen-I (Coll-I), 
Alkaline phosphatase (ALP), Osteopontin (OPN), Bone sialoprotein (BSP), 
Osteocalcin (OCN), Fibroblast growth factor receptor 1 (FRF-R1), Platelet-
derived growth factor receptor ơ (PDGF-Ra) Parathyroid hormone receptor 
(PTH-R), Parathyroid-related protein (PTH-rP). Redrawn from Aubin et al 
(1995).
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3.1.2. Practical in vitro culture of osteoblasts. 
 
Eukaryotic cell culture was pioneered in the late 19th Century by both Sydney 
Ringer and Willhelm Roux who developed salt solutions which allowed tissue 
explants to survive and function for several days. The methodology of tissue and 
cell culture was further developed during the 20th Century, particularly during the 
1940s and 1950s to support research in virology and the production of vaccines 
(Norrby, 2008). 
 
In modern times, effectively all mammalian cell types can be supported in vitro, but 
the conditions for the culture of specific cells varies in terms of their individual 
requirement for salts and molecules which ensure the normal behaviour of the 
cell, maintain a phenotype or stimulate physiological activity, proliferation or 
maturation. 
 
Osteoblasts in vitro require several additions to the basic salts solution, including 
foetal calf serum (containing macromolecular proteins, albumins to aid protein 
solubility, hormones and cell-attachment factors) and ascorbic acid (for collagen 
crosslinking; Majeska, 1996). In addition, supplements such as the steroid 
hormone dexamethasone and sodium Ƣ-glycerophosphate help maintain an 
osteoblastic phenotype and provide a source of inorganic phosphate for matrix 
mineralisation respectively (Yamanouchi et al, 1997; Luriya et al, 2004).  
 
In this investigation, osteoblasts were isolated from human femoral head 
trabecular bone and characterised by Di Silvio (1995), Gough & Downes (2001) 
and Anderson et al (2001). These cells exhibit a typical osteoblast morphology, 
express relevant molecular markers such as alkaline phosphatase and osteocalcin 
and form multilayered nodules which mineralise within 4 weeks without the 
addition of either dexamethasone or sodium Ƣ-glycerophosphate.  
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3.1.3. The effect of silicon on osteoblasts. 
 
Silicon was determined to be an essential element for normal development by 
Carlisle (1972) and by Schwartz and Milne (1972), with the effects of silicon-
deficient diets being abnormal bone formation. Similarly, Carlisle also 
demonstrated that chicks fed a silicon-supplemented diet (28 Ƭg.ml-1 silicon as 
sodium metasilicate) had enhanced bone growth. 
 
Several decades later, the role of silicon in bone metabolism has been further 
elucidated. Electron microprobe analysis has revealed that silicon is concentrated 
in the growth areas of developing bone, such as the epiphyseal growth plates  
(Carlisle, 1980; Landis et al, 1986): the sites of greatest osteoblastic activity. Within 
the osteoblast, silicon is present in similar amounts to magnesium and 
phosphorus (Carlisle, 1976) and may be localised to mitochondria and other 
intracellular organelles (Carlisle, 1975), particularly during the early stages of 
mineralisation. 
 
In the extracellular matrix (mineralising osteoid) silicon has been shown to be  
essential to the normal development of the glycosaminoglycan network, helping 
to stabilise the complex polysaccharide structures and forming crosslinks via 
silanolate bonds which regulate the structure and function of these molecules 
(Schwartz, 1973). 
 
Carlisle demonstrated that silicon-supplemented embryonic chick bones showed a 
100% increase in collagen content over silicon-deficient bones after 12 days in 
culture (Carlisle, 1974), whilst more recently Reffitt et al (2003) demonstrated that 
type I collagen synthesis increased in osteoblastic cells cultured in the presence of 
orthosilicic acid concentrations of 10 and 20 ƬM (280 ng.ml-1  560 ng.ml-1 
silicon). Similarly, Arumugram et al (2004) demonstrated that type I collagen 
mRNA increases significantly in osteoblasts supplemented with orthosilicic acid 
concentrations from 5 to 50 ƬM (140 ng.ml-1  2.8 Ƭg.ml-1 silicon). 
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3.1.4. The effect of silicic acid-eluting biomaterials on osteoblasts in vitro. 
 
Bioglass® and silicate biomaterials such as silicon-substituted hydroxyapatite have 
been studied for several decades under in vitro conditions, and the effects on 
osteoblasts of both biomaterial surface substrates (Anderson et al, 2001; Gough et 
al, 2003) and their degradation products (Xynos et al, 2001) have been extensively 
analysed.  
 
Osteoblasts cultured on 45S5 Bioglass® produce collagen-I which quickly 
becomes mineralised, leading to maturation of osteoblasts into matrix-encased 
osteocytes after 6-12 days of in vitro culture (Loty et al, 1999). The expression of 
insulin-like growth factor (IGF) axis system proteins, responsible for regulating 
certain key growth factors, are shown to increase by 300 to 500% over controls 
after only a few hours of exposure to the chemical extracts of 45S5 Bioglass® 
(Valerio et al, 2003)  implying that osteoblasts are rapidly able to sense changes in 
the calcium and or silicon content of their environment. 
 
Osteoblasts cultured in vitro on Bioglass® also show a distinct morphology 
compared to cells grown on control substrates such as thermanox or tissue culture 
plastic. As shown by Gough et al (2003), osteoblasts cultured on 45S5 Bioglass® 
for two days maintained a more compact shape, with numerous filipodia, dorsal 
ridges and microvilli, characteristic of actively secreting cells exhibiting an 
osteoblastic phenotype. In contrast, cells grown on bioinert substrates for the 
same period formed flattened confluent sheets  features normally attributed to 
non-differentiated cell types. 
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3.1.5. Aims. 
 
The aims of this section of the work were to evaluate the effect of silicon on 
osteoblasts, particularly the effect of porous silicon  polycaprolactone 
composites as a bioactive substrate to support cell growth. In addition, by 
evaluating the response of osteoblasts to the degradation products of pSi and pSi-
PCL and to a range of orthosilicic acid concentrations in media comparable to the 
concentrations eluted by the materials, the relative effects of soluble silicon 
species and biomaterial surfaces on cell behaviour can be determined.  
 
Several markers of osteoblastic activity were quantified at set intervals, including 
DNA as a measure of cell proliferation, collagen as an indicator of relative 
osteoblastic activity, alkaline phosphatase activity as a time marker of the onset of 
mineralisation and glycosaminoglycans as a measure of extracellular matrix 
composition and stability. The morphology of cells cultured on both PCL and 
pSi-PCL was also observed using conventional light microscopy and scanning 
electron microscopy. 
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3.2. Materials and Methods. 
 
3.2.1. Osteoblast in vitro culture. 
 
Osteoblasts isolated from human femoral head trabecular bone (removed during 
total hip arthroplasty) were cultured to passage 30 - 35 in DMEM supplemented 
with 10% FCS, 2mM L-glutamine, 1% non-essential amino acids, 0.2mM HEPES, 
150 Ƭg.ml-1 ascorbic acid, 2% penicillin/streptomycin and with 10mM sodium ฀-
glycerophosphate and 10-7M dexamethasone (all Sigma, UK). Cells were seeded at 
a density of ~105 cells.ml-1 directly onto the PCL or composite disc surface or well 
surface in either 12- or 24-well plates (Nunc).  
 
Media was replaced as dictated by the experimental set up (see below) and the 
osteoblasts incubated at 37°C in 5% CO2. At set time points during the 
experiment plates were analysed for osteoblastic activity. 
 
 
3.2.2. Analysis. 
 
At the required time point, the media was removed from the well which was then 
rinsed carefully in three changes of PBS. The cells and extracellular matrix were 
prepared into a homogenous lysate by rapidly freeze-thawing the plate with 1 ml 
H2O per well for three cycles between -80°C and 20°C. DNA, collagen, 
glycosaminoglycan and calcium content of the lysate were quantified and alkaline 
phosphatase activity was measured at each time point. A measure of 
glycosaminoglycan and protein crosslinking was provided by quantifying 
pyridinoline in the cell lysate. 
 
Statistical significance was determined by Students T-Test compared to control 
populations  PCL for comparing substrates and Si-unsupplemented media for 
comparing Si-supplemented and conditioned media. Both conventional light 
microscopy using histological staining and scanning electron microscopy were 
used. 
 
 
95 
Chapter Three 
3.2.2.1. Silicic acid content of media. 
 
The silicic acid content of media incubated with pSi-PCL or Bioglass®-PCL was 
determined by analysing a 50Ƭl sample of the incubating culture media. This was 
added to 350Ƭl dH2O and 100Ƭl of a solution containing acidified ammonium 
molybdate (1g ammonium molybdate (IV) tetrahydrate and 3ml concentrated 
(17M) hydrochloric acid in 50ml total volume) was added and allowed to stand for 
10 minutes. 500Ƭl of a reducing solution (4g oxalic acid dihydrate, 1.33g 4-
(methylamino)phenol sulfate, 0.8g anhydrous sodium sulfite, 20ml concentrated 
sulfuric acid, total volume 200ml with dH2O) was then added, the solution 
allowed to develop a blue coloration for 2-4 hours and the absorbance read at 
810nm using a spectrophotometer zeroed using dH2O. 
 
Calibration of this assay was by a standard curve obtained using known 
concentrations of sodium metasilicate prepared in fresh DMEM, from which 
absorbance at 810nm could be directly compared to Si in solution. Silicic acid is 
represented as mass units of silicon to avoid confusion between ortho- and 
polysilicic acids in solution. 
 
3.2.2.2. DNA. 
 
DNA was quantified by the intercalation of the fluorophore bisbenzimide 
(Hoechst 33258) between adenine-thymine residues and the analysis was 
performed from a commercially available kit (Sigma, UK). 200Ƭl of the sample 
was added to wells of a 96-well transparent plate and 100Ƭg.ml-1 bisbenzimide in 
the supplied fluorescent assay buffer (1x in dH2O) was added. The cell lysate 
samples were allowed to incubate for 20 minutes and the fluorescence measured 
at an excitation wavelength of 360nm and an emision wavelength of 460nm. A 
stock solution of 100Ƭg.ml-1 calf thymus DNA was supplied with the kit and 
diluted to provide a standard curve for calibrating the assay between 30Ƭg.ml -1and 
100Ƭg.ml-1 DNA. 
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3.2.2.3. Collagen. 
 
Collagen was quantified using the collagen stain sirius red (Direct red 80, Sigma 
UK), an anionic dye with sulphonic acid side chain groups which interact with the 
side chain groups of the basic amino acids present in collagen. Specific affinity of 
the dye for collagen under the assay conditions is due to the elongated dye 
molecules becoming aligned parallel to the long, rigid structure of native collagens 
that have intact triple helix organisation. 200Ƭl of the cell lysate was added to a 
1.7ml microcentrifuge tube and 1ml 1% w/v sirius red S in dH20 added.  
 
The solution was incubated at room temperature for 20 minutes and centrifuged 
at 10,000 rpm for 15 minutes to form a pellet. The supernatant was decanted and 
the tube walls carefully dried using cotton buds. The pellet was resuspended in 
1ml 0.5M NaOH and the dye dissociated, the absorbance of the solution at 
540nm was measured in a spectrophotometer. The assay was calibrated against a 
standard curve of 12.5Ƭg.ml-1 - 100Ƭg.ml-1 rat tail collagen (type I collagen from 
rat tail, Sigma, UK). 
 
3.2.2.4. Alkaline phosphatase activity. 
 
Alkaline phosphatase activity was determined by the ability of the cell lysate to 
cleave the substrate 4-methylumbelliferyl phosphate (4-MUP) into the fluorescent 
product 4-methylumbelliferone. 4-MUP liquid substrate system (Sigma, UK) 
contains 0.6mM 4-MUP in a pH 10.0 buffer solution. 200Ƭl of this was added to 
wells of a 96-well plate containing 50Ƭl cell lysate and the fluorscence measured 
with excitation at 360nm and emission at 440nm within 5 minutes of the reagent 
solution being added. The results were presented as units of activity derived 
directly from the fluorescence. 
 
3.2.2.5. Glycosaminoglycans. 
 
Glycosaminoglycans (GAGs) were quantified using Alcian Blue 8GX (Sigma, 
UK), a cationic dye which forms strong but reversible electrostatic bonds with 
anionic groups on the polysaccharide. 50Ƭl cell lysate was placed into a 1.3ml 
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microcentrifuge tube and acidified by the addition of 100Ƭl 8M guanidine 
hydrocholoride. After 15 minutes, 500Ƭl 0.3% sulphuric acid (with 0.75% triton x-
100, in dH2O) was added to the tube followed by 500Ƭl 200Ƭg.ml-1 Alcian blue 
8GX and the mixture incubated at room temperature for 15 minutes. The tube 
was centrifuged at 15,000 rpm for 10 minutes and the supernatant carefully 
decanted and discarded. Residual supernatatant was carefully removed with a 
cotton tip and the pellet resuspended in buffer (4M guanidine hydrochloride, 33% 
1-propanol, 0.25% triton x-100). The absorbance of the solution at 620nm was 
measured and compared to known concentrations of chondroitin-4-sulphate 
(from bovine trachea, Sigma, UK) from 50 - 200Ƭg.ml-1.    
 
3.2.2.6. Calcium. 
 
Calcium is chelated by alizarin red S in aqueous solution, forming a complex 
which can be subsequently dissociated. A 1% w/v solution of alizarin red S in 
dH2O was prepared and adjusted to pH 10.0 using ammonium hydroxide, 1ml of 
this solution was added to the empty well or disc and allowed to incubate for 10 
minutes. The unbound calcium stain was carefully removed in several changes of 
dH2O and allowed to dry before the addition of 1ml 2% w/v cetylpyridinium 
chloride monohydrate. The absorbance of the resulting solution at 562nm was 
measured and expressed directly as units of absorbance. 
 
3.2.2.7. Pyridinoline. 
 
Mature type I collagen is crosslinked by pyridinoline and deoxypyrodinoline which 
are formed by the enzymatic action of lysyl oxidase on the amino acid lysine 
(Delmas, 1995; Seibel et al, 1992). Pyridinoline was quantified using a commercial 
sandwich ELISA fluorescent immunoassay (MetraSys PYD ELISA, 
Technoclone, UK) designed for studying PYD concentration of human serum. 
 
50Ƭl of each cell lysate was pipetted into anti-PYD coated wells of the provided 
ELISA strip alongside serially diluted known concentrations of pyridinoline 
isolated from human urine (0  750 nmol.l-1). 100Ƭl prepared enzyme conjugate 
was added (murine monoclonal anti-pyridinoline antibody conjugated to alkaline 
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phosphatase in non-ionic detergent buffer) and incubated for 3 hours in the dark 
at 4°C. 150Ƭl substrate solution was added (20mg p-Nitrophenol phosphate in 
10ml diethanolamine and magnesium chloride buffer) and incubated for 1 hour at 
room temperature. 100Ƭl stop solution (0.5M NaOH) was added and the 
absorbance (optical density) of the solution measured at 405nm. Sample values 
were compared to a calibration graph of the standard solution. 
 
 
3.2.3. Experimental. 
 
A series of experiments were designed to evaluate the response of osteoblasts to 
porous silicon  polycaprolactone composites containing a range of porosities of 
pSi in a range of quantities per disc. The effect of pSi-PCL degradation products 
on osteoblasts in vitro was determined and compared to the effect of 45S5 
Bioglass®-PCL degradation products. A range of silicic acid concentrations were 
prepared from 100 ng.ml-1 to 100 Ƭg.ml-1 using sodium metasilicate rather than 
porous silicon as a source of bioavailable silicon and used to supplement 
osteoblasts in vitro. 
 
3.2.3.1. Response of osteoblasts to pSi-PCL composites in vitro. 
 
A range of 250mg composite discs were manufactured as described in chapter two 
(fig. 2.4, page 50) containing polycaprolactone and porous silicon with porosities 
of 54%, 66% and 82% which were milled by hand at pSiMedica and seived to 
provide particle sizes of 37 - 150Ƭm, and the standardised 70%, 11Ƭm particles 
that were used in all later experiments. These were made into composites with pSi 
the following ratios:  
 
Experiment     pSi porosity pSi per 250mg composite disc (mg) 
3.3.1.1.  54%   1  5  10  - 25   50 
3.3.1.2.  66%        0.5 5 10 20 - 30 
3.3.1.3.  70%  1 - - 20 - - 
3.3.1.4.  82%   1 5 10 20 - 30 
Table 3.5. Range of compositions tested for each porosity of pSi.  
 
99 
Chapter Three 
Composite discs were sterilised in 70% ethanol for 24 hours at room temperature 
before being dried completely overnight in 24-well plates (Nunc) in a sterile fume 
hood. Osteoblasts at passage 30 - 35 were seeded at a density of ~105 cells.ml-1 
directly onto the tissue culture plastic well, PCL or composite disc surface. 1ml 
DMEM supplemented with 10% FCS, 2mM L-glutamine, 1% non-essential amino 
acids, 0.2mM HEPES, 150 Ƭg.ml-1 ascorbic acid, 2% penicillin/streptomycin and 
with 10mM sodium ฀-glycerophosphate and 10-7M dexamethasone (all Sigma, 
UK) was added which was exchanged every 48 hours.  
 
3.2.3.1.1. Scanning electron microscopy (SEM). 
 
Osteoblasts cultured on PCL and composite discs were dehydrated and coated for 
SEM as follows. Media was removed from cells and the disc washed in PBS 
thoroughly but gently to avoid damaging cell layer. In a fume hood, cells were 
fixed in 3% glutaraldehyde for 1 hour and rinsed with dH2O twice. Osmium 
tetroxide was added and left to incubate for 30 mins and then rinsed off in three x 
1ml dH2O.  
 
A series of ethanol rinses was performed to dehydrate the sample: 2 x 5 mins in 
50% ethanol, 2 x 5 mins in 70% ethanol, 2 x 5 mins in 90% ethanol, 3 x 10 mins 
in 100% ethanol. Finally the discs were incubated for 5 mins each in 2 changes of 
1ml hexamethyldisilizane (HMDS). All HMDS was removed and air dried in fume 
hood completely. The dry discs were gold coated for 3-6 minutes in a sputter 
coater and imaged using a Jeol JSM840 scanning electron microscope. 
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3.2.3.2. Osteoblast response to silicic acid in media. 
 
Silicic acid was added to DMEM using known concentrations of a sodium 
metasilicate (Sigma, UK; Na2SiO4.5H2O) stock solution to generate desired silicic 
acid concetrations as shown in the table below (table 3.6). Sodium metasilicate 
was added to the media as a concentrated solution in 10ml dH2O which was 
sterilised by filtration using a 0.2Ƭm syringe filter.  
 
Control media (0 Ƭg.ml-1) and DMEM for dilution of stocks contained no 
supplemented silicon or sodium metasilicate and were produced at the same times 
as those conditioned and stored under identical conditions (4°C for up to 7 days 
or -20°C for long-term storage). Silicic acid concentrations are presented as ng or 
Ƭg silicon [Si] per ml media. 
 
Osteoblasts at passage 30 - 35 were seeded in DMEM onto the well surfaces of 
24-well plates (Nunc) at a density of ~105 cells per well and once attached (~4 
hours) the media was replaced with 1ml silicon-supplemented media or control 
media (unsupplemented). The media was replaced every 48 hours for up to 28 
days. 
 
Experiment Silicic acid concentrations (per ml)  
   
3.3.1.  100ng 250ng 500ng 750ng 1000ng   
3.3.2.  1Ƭg 2 Ƭg 3 Ƭg 4 Ƭg 5 Ƭg   
3.3.3.  1 Ƭg 5 Ƭg 10 Ƭg 15 Ƭg 20 Ƭg  25 Ƭg 30 Ƭg 35 Ƭg 
3.3.4.   25Ƭg 50Ƭg 100Ƭg     
 
Table 3.6. Silicic acid concentrations used in the investigation achieved by the 
addition of sodium metasilicate to DMEM.  
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3.2.3.3. Osteoblast response to pSi, pSi-PCL and Bioglass®-PCL 
degradation products. 
 
Media was conditioned with the breakdown products of pSi in two ways  by 
incubating pSi microparticles in a stock solution of cell culture medium or by co-
incubating pSi-PCL composite discs in a cell-culture plate, seperated from 
osteoblasts by a semi-permeable (size exclusion) membrane. 
 
3.2.3.3.1. pSi-conditioned media. 
 
1g microparticles of porous silicon were sterilised in 2ml 70% ethanol for 24 
hours and added to 550ml DMEM supplemented with 10% FCS, sodium Ƣ-
glycerophosphate and 10mM dexamethasone. The media was assayed for silicon 
content after 28 days and found to contain 45 Ƭg.ml-1 Si, which was diluted with 
pSi-free media (produced at the same time ad stored at 4°C to produce silicic acid 
concentrations of 1  5 Ƭg.ml-1 Si which were used for culturing osteoblasts. 
 
Osteoblasts at passage 30 were seeded onto the well surface of 24-well cell culture 
plates (Nunc) at a density of ~105 cells per well and 1ml media added. The media 
was replaced every 48 hours for 20 days; one plate was analysed every 5 days for 
DNA and collagen content. 
 
 
3.2.3.3.2. Co-incubation of osteoblasts with pSi-PCL and Bioglass®-PCL 
composites. 
 
Bioactive glass microparticles (batch code PM0126) were obtained from Dr Julie 
Gough (University of Manchester, UK) and composite discs were formed as 
described for pSi-PCL containing: 
 
A. 1mg or 20mg 70% porous pSi per 250mg disc  
B. 20mg Bioglass® or 20mg 70% porous pSi per 250mg disc  
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The composites were sterilised in 70% ethanol for 24 hours and dried overnight 
in a fume hood together with PCL-only discs. The discs were placed in transwell 
inserts (12mm diameter, 3.0Ƭm pore size polycarbonate membrane; Corning, US) 
which were then fitted into 12-well plates. Controls used were empty inserts. 
 
Osteoblasts at passage 30 were seeded onto the well surface at a density of ~105 
cells per well and 3ml media was added to cover the disc in the transwell 
completely. Care was taken to ensure that no cells were introduced to the 
transwell and that all osteoblast growth was on the tissue culture well bottom.  
 
1ml media was removed and replaced daily for 25 days, with time points at 1 day 
and every 5 days at which point the transwell inserts were removed, the plate 
carefully rinsed and freeze/thawed and lysates analysed for DNA, collagen and 
glycosaminoglycan content and alkaline phosphatase activity. 
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3.3. Results. 
 
3.3.1. Response of osteoblasts to pSi-PCL composites. 
 
Composite discs were made containing porous silicon in polycaprolactone and 
formed into discs 250 ± 10mg in weight, approximately 11.5mm in diameter. 
Four porosities of porous silicon were used as outlined in the methods section 
and in Chapter Two, including 54% porous, 66% porous and 82% porous 
microparticles that were milled and seived by hand (38 - 150Ƭm particle size), and 
the 70% particles that were provided in a smaller size fraction (11Ƭm particles). 
 
Composites were manufactured containing 1  50mg pSi per 250mg disc (up to 
20% w/w) and the silicic acid release rates of each material ascertained by 
measuring the silicic acid content of cell culture media. Silicic acid release was 
shown to be proportional to the percentage porosity of the silicon, particle size 
and porous silicon content of the disc (fig. 3.7), with 54% and 66% porous silicon 
releasing similar quantities of silicic acid into the culture medium but leveling off 
from 10mg to 50mg to elute less than 200ng.ml-1 Si per day. 70% porous silicon 
inclusion in the disc showed a more linear relationship with silicic acid 
concentration of incubating media. 82% porous silicon released significantly more 
silicic acid and its degradation caused effervesence of the culture medium, 
producing a foam on the surface of the medium in the culture well.  
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Fig. 3.7. Silicic acid release per day into media. Error bars are standard error of 
the mean, n = 3. 
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3.3.1.1. 54% porous pSi. 
 
Scanning electron microscopy of cultured osteoblasts shows that the cell 
morphology is similar when cultured on PCL or 50mg pSi (20% w/w pSi) at 7 
days (fig. 3.8). Substantial numbers of rounded cells were observed on both PCL 
and composite materials, but it was not determined if these were apoptotic or 
undergoing cell division. 
 
Osteoblast proliferation on 54% porous silicon-containing composite discs was 
similar across the range of compositions and lower than tissue culture plastic 
controls (fig. 3.9.A). Collagen production was also similar, with an increase in 
total collagen on the 50mg composite at day 21 (fig. 3.9.B).  
 
When normalised for cell number (Ƭg collagen / Ƭg DNA) however, the amount 
of collagen produced per osteoblast at day 21 is higher in the high-pSi composites 
and higher than tissue culture plastic controls, but not higher than PCL-only (fig. 
3.9.C). Calcium deposition at day 21 (fig. 3.9.D) was also significantly greater 
than PCL only discs for composites containing  10mg pSi (p < 0.05). 
 
 
 
Fig. 3.8. Osteoblasts cultured on the surfaces of A. PCL or B. 50mg pSi 
composites (54% porous) for 7 days.  
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Fig. 3.9. Osteoblasts cultured on composite discs containing quantities of 54% 
porous silicon. A. DNA content of cell lysate. B. Collagen (total). C. Collagen 
normalised for cell number (collagen/DNA, Ƭg/Ƭg). D. Calcium deposition at 
day 21. Bars show standard error, n=3. Statistical significance was determined by 
Students T-Test compared to PCL as the control population. Significant increase 
p < 0.05 (  ).  
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3.3.1.2. 66% porous pSi.  
 
Addition of 66% porous silicon to PCL did not markedly affect the growth of 
osteoblasts cultured on the surface, although higher pSi concentrations showed 
lower cell numbers at each time point than tissue culture plastic controls. Total 
collagen and collagen per cell (DNA) were also similar across all compositions 
with osteoblasts growing on PCL producing as much collagen as those on 
composites, and more per cell than tissue culture plastic controls (fig. 3.10). 
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Fig. 3.10. Osteoblasts cultured on composite discs containing quantities of 66% 
porous silicon. A. DNA content of cell lysate. B. Collagen (total). C. Collagen 
normalised for cell number (collagen/DNA, Ƭg/Ƭg). Bars show standard error of 
the mean, n=3. No statistical significance was observed as determined by 
Students T-Test compared to PCL as the control population. 
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3.3.1.3. 70% porous pSi.  
 
The osteoblast response to 1mg and 20mg composites containing 70% porous 
silicon at 10 days in vitro culture was evaluated. In previous studies osteoblasts 
were shown to exhibit the greatest difference in behaviour between PCL and 
composite substrates at day 10 in vitro and so a large repeat number (n = 12) was 
used for a thorough statistical analysis of the effect of pSi on osteoblasts 
proliferation and activity.  
 
Osteoblasts at day 10 displayed similar levels of DNA (fig. 3.11) when cultured on 
tissue culture plastic, PCL or 1mg pSi-PCL, but with significantly lower cell 
populations on the 20mg composite (p = 0.0027) than PCL-only. Alkaline 
phosphatase activity was significantly higher for osteoblasts cultured with 20mg 
pSi than either PCL alone or 1mg pSi at day 10 (fig. 3.12). Collagen production 
was higher for the 20mg composite than PCL (p = 0.0070). Osteoblast production 
of glycosaminoglycans (total and per Ƭg DNA) as determined by alcian blue was 
significantly higher on 20mg pSi-containing composites (p < 0.001). 
 
Osteoblasts cultured on thin discs of PCL or 20mg pSi-PCL showed different cell 
morphologies at 5 days in vitro culture (fig. 3.13). Osteoblasts on PCL-only are 
rounded and closely packed, whereas those on pSi-PCL appear to have more 
pronounced filipodia and cellular processes which are associated with collagen. 
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Fig. 3.11. Proliferation of osteoblasts cultured for 10 days on the surface of tissue 
culture plastic, PCL, 1mg pSi-PCL and 20mg pSi-PCL. Statistical significance was 
determined by Students T-Test compared to PCL as the control population. 
Significant decrease p< 0.01 ( ). 
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Fig. 3.12. Osteoblasts cultured for 10 days on the surface of tissue culture plastic, 
PCL, 1mg pSi-PCL and 20mg pSi-PCL. A. Alkaline phosphatase activity. B. 
Collagen (total) and collagen per Ƭg DNA. C. Glycosaminoglycan content in total 
and GAGs per Ƭg DNA. Bars are standard error of the mean, n=12. Statistical 
significance was determined by Students T-Test compared to PCL as the control 
population. Significant increase p < 0.05 ( ); p < 0.01 ( ); p < 0.001 ( ). 
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 3.3.1.4. 82% porous pSi. 
 
82% porous silicon proved toxic to cells in vitro. Upon immersion in tissue culture 
medium, composites containing more than 5mg pSi effervesced, forming a foam 
which filled the well. No osteoblasts were observed surviving in the wells or on 
the discs after 24 hours.  
 
 
3.3.2. Osteoblast response to silicic acid in media. 
 
Osteoblasts were cultured in vitro on the well surfaces of 24-well cell culture plates. 
Media was DMEM containing 10% FCS and supplemented with sodium Ƣ-
glycerophosphate and 10mM dexamethasone to maintain osteoblastic phenotype, 
and supplemented with sodium metasilicate to generate desired concentrations of 
soluble silicon species. Silicic acid concentration is represented as [Si] to cover the 
presence of mono- (ortho)-silicic acid and polysilicic acids in the solution. 
 
Silicic acid concentrations were tested in four ranges: 
 
3.3.2.1.     100    1000 ng.ml-1  
3.3.2.2.    1  5 Ƭg.ml-1 
3.3.2.3.     5  35 Ƭg.ml-1 
3.3.2.4.     25  100 Ƭg.ml-1 
 
 
3.3.2.1. Osteoblast response to 100  1000 ng.ml-1 Si. 
 
The amount of silicic acid produced by 1-20% composite discs incubated in SBF 
is in the order of 50  500 ng.ml-1.day-1 [Si] which is reflected in the silicic acid 
range established in this experiment by supplementing media with sodium 
metasilicate.  
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Osteoblast proliferation as determined by DNA content of cell lysates was similar 
at each time point at all Si concentrations (fig. 3.13.A). Alkaline phosphatase 
activity per cell was highest at day 7 for all Si concentrations and showed a linear 
decrease over time for all conditions (fig. 3.13.B). Collagen per cell was also 
similar throughout all concentrations tested (fig. 3.13.C). No significant 
difference in any activity marker was observed at any time point, implying that this 
concentration range of silicic acid (when achieved by dissociating sodium 
metasilicate) does not have an effect on osteoblast activity in vitro. 
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Fig 3.13. Osteoblasts cultured in media containing 100  1000 ng.ml-1 Si. A. DNA 
content of cell lysate. B. Alkaline phosphatase activity per Ƭg DNA. C. Collagen 
produced per Ƭg DNA. Bars show standard error, n=3. 
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3.3.2.2. Osteoblast response to 1  5 Ƭg.ml-1 Si. 
 
When cultured in media containing Si in the concentration range 1- 5 Ƭg.ml-1, 
osteoblasts proliferated at a similar rate to Si-unsupplemented controls (fig. 
3.14.A), and cell populations were significantly higher at 1 and 4 Ƭg.ml-1 on day 15 
days of the experiment (p < 0.05).  
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Fig. 3.14. Osteoblasts cultured in media containing 1 - 5Ƭg.ml-1 Si, from sodium 
metasilicate. A. DNA content of cell lysate. B. Total collagen per well. C. Collagen 
produced per Ƭg DNA. Bars show standard error of the mean, n=3. Statistical 
significance was determined by Students T-Test compared to 0Ƭg.ml-1 Si as the 
control population. Significant increase p < 0.05 (  ), p < 0.01 ( ); significant 
decrease p < 0.05 ( ). 
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The osteoblast production of collagen was similar for all conditions up to day 20, 
at which point cells cultured with 1 and 4 Ƭg.ml-1 Si produced more collagen in 
total than silicon-free controls (fig. 3.14.B). When collagen production was 
normalised for cell number, collagen per osteoblast at day 20 was significantly 
higher when cultured with 1 and 4 Ƭg.ml-1 Si than in unsupplemented controls 
(fig. 3.14.C). 
 
 
3.3.2.3. Osteoblast response to 1  35 Ƭg.ml-1 Si. 
 
Osteoblast growth rates in higher (> 25 Ƭg.ml-1) concentrations of Si are 
diminished for the first 21 days in vitro culture, with the reduction in cell 
population directly proportional to the amount of Si added  in concentrations 
greater than 20Ƭg.ml-1 Si osteoblast populations are significantly reduced (p < 0.05 
for Si concentrations greater than 25 Ƭg.ml-1 for the first 21 days) although in all 
conditions cell numbers were similar by 28 days (fig. 3.15.A). 
 
Collagen production per Ƭg DNA was higher for osteoblasts cultured with more 
than 20 Ƭg.ml-1 Si than Si-unsupplemented media for the first 14 days, with some 
Si-supplemnted conditions being significantly increased (fig. 3.15.b). Calcium 
deposition was similar under all conditions, but significantly higher at day 7 for 
media containing 30  35 Ƭg.ml-1 Si (p < 0.05; fig. 3.15.C). 
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Fig. 3.15. Osteoblasts cultured in media containing 1  35 Ƭg.ml-1 Si. A. DNA, B. 
Collagen produced per Ƭg DNA. C. Calcium deposition. Bars are standard error 
of the mean, n=3. Statistical significance was determined by Students T-Test 
compared to 0Ƭg.ml-1 Si as the control population. Significant increase p < 0.05 
(  ), p < 0.01 ( ); significant decrease p< 0.05 ( ), p < 0.01 ( ). 
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3.3.2.4. Osteoblast response to 25 - 100 Ƭg.ml-1 Si. 
 
Osteoblasts cultured in media containing 100 Ƭg.ml-1 silicon showed significantly 
reduced growth rates (p < 0.01) compared to silicic acid-free media and media 
containing up to 25 Ƭg.ml-1 Si for the first 15 days (fig. 3.16.A). Media containing 
50 Ƭg.ml-1 Si also inhibited osteoblast proliferation at 10 , 15 and 25 days ( p < 
0.05). 
 
Osteoblast production of collagen was significantly lower with 100 Ƭg.ml-1 Si than 
under control conditions and 25 Ƭg.ml-1 Si at 10 and 20 days (p < 0.01 at day 10 
and day 20), whereas 25 Ƭg.ml-1 Si slightly increased the total collagen produced at 
15 days (fig. 3.16.B). When normalised for cell population (divided by Ƭg DNA, 
fig. 3.16.C), collagen production was higher at day 10 in 50 Ƭg.ml-1 Si and day 15 
for 25 Ƭg.ml-1 Si (p < 0.05) than controls. However, collagen per osteoblast was 
significantly lower at day 20 for cells cultured with 50 Ƭg.ml-1 Si and 100 Ƭg.ml-1 Si 
(p < 0.01). 
 
Osteoblasts cultured in vitro with more than 50 Ƭg.ml-1 Si in culture media showed 
diminished growth and collagen production compared to unsupplemented 
osteoblasts and those cultured in lower silicic acid concentrations.  
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Fig. 3.16. The osteoblasts in vitro response to silicic acid concentrations of 25  
100 Ƭg.ml-1 Si in culture media. A. DNA, B. Collagen, C. Collagen per DNA. Bars 
are standard error of the mean, n=3. Statistical significance was determined by 
Students T-Test compared to 0Ƭg.ml-1 Si as the control population. Significant 
increase p < 0.05 (  ), p < 0.01 ( ); significant decrease p < 0.05 ( ), p < 0.01 
( ). 
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3.3.3. Osteoblast response to pSi degradation products. 
 
Media was conditioned with the breakdown products of pSi in two ways  by 
incubating pSi microparticles in a stock solution of cell culture medium or by co-
incubating pSi-PCL composite discs in a cell-culture plate, seperated from 
osteoblasts by a semi-permeable (size exclusion) membrane. 
 
 
3.3.3.1. pSi-conditioned media. 
 
1g microparticles of porous silicon were used to condition 550ml DMEM 
supplemented with 10% FCS, sodium Ƣ-glycerophosphate and 10mM 
dexamethasone. The media was assayed for silicon content after 28 days and 
found to contain 45 Ƭg.ml-1 Si, which was diluted with pSi-free media to produce 
silicic acid concentrations of 1  5 Ƭg.ml-1 Si which were used for culturing 
osteoblasts. 
 
Osteoblasts proliferated at a similar rate (fig. 3.17). Si-supplemented media 
stimulated cell growth up to day 15, with significantly enhanced proliferation in Si 
concentrations of 4 Ƭg.ml-1 Si (day 5 and 10), 5 Ƭg.ml-1 Si (day 10) and 1 Ƭg.ml-1 Si 
(day 15). At day 20 no difference was observed in cell populations under any 
condition (fig. 3.18.A). 
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Fig. 3.17. Proliferation rate of osteoblasts as determined by increase in DNA 
content of cell lysate per day. Error bars show proportional deviation from linear 
regresssion coefficient, R2 (n = 4). 
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Collagen deposition was significantly higher when osteoblasts were cultured with 
3 - 5 Ƭg.ml-1 Si at day 10, 4 Ƭg.ml-1 Si at day 15 and 4 - 5 Ƭg.ml-1 Si at day 20 (fig. 
3.18.B). When normalised for cell number, collagen per Ƭg DNA was significantly 
greater only at day 20, for osteoblasts cultured with 3  4 Ƭg.ml-1 Si (fig. 3.18.C). 
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Fig. 3.18. Osteoblast response to media conditioned with porous silicon and 
diluted to provide 1  5 Ƭg.ml-1 Si. A. DNA, B. Collagen, C. Collagen per Ƭg 
DNA. Bars show standard error of the mean, n=3. Statistical significance was 
determined by Students T-Test compared to 0 Ƭg.ml-1 Si as the control 
population. Significant increase p < 0.05 (  ), p < 0.01 ( ). 
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3.3.3.2. pSi-PCL discs co-incubated with osteoblasts. 
 
PCL discs containing 0, 10 or 20mg pSi were placed in transwell inserts which 
were suspended in wells of 12 well plates such that the media covered both 
osteoblasts (on the well base) and composite disc (in the suspended insert), 
allowing the degradation products of the immersed disc to condition the media. 
3ml media was contained in the well with 1ml exchanged daily for fresh media 
and assayed for silicic acid content (fig. 3.19).  
 
Silicic acid was shown to elute from the discs at concentrations proportional to 
the pSi content of the disc and at concentrations similar to those observed when 
identical discs were incubated in SBF, PBS or dH2O, demonstrating that the 
soluble degradation products of pSi-PCL passed into the cell culture medium. 
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Fig. 3.19. Maximum silicic acid content of media incubating PCL-composite discs 
containing 10mg or 20 mg (4  8% w/w) pSi. Discs and osteoblasts were cultured 
in 3ml culture medium, 1ml of which was replaced daily for 25 days. Error bars 
show standard error of the mean, n = 3. 
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Osteoblast growth under these conditions was similar for all wells which 
contained PCL in the insert. Controls containing only empty inserts proliferated at 
a constant rate for 25 days, whilst all inserts containing PCL-based materials 
showed similar lower growth rates, although at no time point were these 
statistically significant (fig. 3.20.A). 
 
As a marker of osteoblastic activity, alkaline phosphatase activity (normalised for 
cell number) peaked in control samples at day 10 and at day 15 for all conditions 
containing PCL or composites. Alkaline phosphatase activity was not significantly 
different at any point between PCL-only and composite discs (fig. 3.20.B). 
 
DNA
0
5
10
15
20
25
30
1 5 10 15 20 25Time (days)
DN
A 
(ug
)
Control PCL 10mg pSi 20mg pSi
 
Alkaline phosphatase / DNA
0
50
100
150
200
250
1 5 10 15 20 25
Time (days)
AL
P 
a
ct
iv
ity
 
(un
its
)
Control PCL 10mg pSi 20mg pSi
Fig. 3.20. Osteoblast proliferation on well bases cultured in the presence of PCL 
and pSi-PCL composite discs (A), and alkaline phosphatase activity as a marker of 
osteoblastic activity (B). Bars are standard error of the mean, n=3. Statistical 
significance was determined by Students T-Test compared to PCL as the control 
population but no treatment was shown to be significantly different to PCL alone.  
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Fig. 3.21. Osteoblast formation of extracellular matrix components on well bases 
cultured in the presence of PCL and pSi-PCL composite discs. A. Collagen per Ƭg 
DNA. B. Total glycosaminoglycans. C. Glyosaminoglycans per Ƭg DNA. Bars 
show standard error of the mean, n=3. Statistical significance was determined by 
Students T-Test compared to PCL as the control population. Significant increase 
p < 0.05 (  ), p < 0.01 ( ). 
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Osteoblast deposition of collagen was higher for all conditions including PCL or 
composite than controls containing empty inserts throughout the investigation 
(fig. 3.21.A). Comparing PCL-only to 10mg or 20mg composite discs, collagen 
(per cell) was higher for 10mg at day 1 (p < 0.01) and 20mg at day 15 (p < 0.01). 
 
Glycosaminoglycan content of the cell lysate and ECM was higher when 
osteoblasts were cultured with 20mg pSi-PCL discs (fig. 3.21.B), significantly so 
at day 20 and 25 (p < 0.01) and at day 10 for osteoblasts cultured with 10mg pSi-
PCL discs. When normalised for cell number (fig. 3.21.C), glycosaminoglycans 
were significantly higher than PCL at day 20 for 10mg pSi (p < 0.05) and 20mg (p 
< 0.01). 
 
Pyridinoline concentration of the lysate was used as a measure of GAG / protein 
cross-linking and showed an apparent increase in crosslinking for both 20mg pSi 
and 10mg pSi over PCL-only (fig. 3.22). This effect was significantly greater for 
20mg pSi (p < 0.01) than for 10mg pSi (p < 0.05). 
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Fig. 3.22. Crosslinking of extracellular matrix components determined by assay 
for free pyridinoline in the cell lysate. Error bars show standard error of the mean, 
n = 3. 
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3.3.3.3. pSi-PCL and 45S5 Bioglass®-PCL discs co-incubated with 
osteoblasts. 
 
The above experiment was repeated with 8% w/w 45S5 Bioglass®-PCL composite 
and compared to 8% w/w pSi-PCL composites. Osteoblast proliferation was 
similar under all conditions although PCL-free controls proliferated at a faster rate 
to reach higher cell populations at day 20 than either PCL- or composite-
containing wells (fig. 3.23.A). Alkaline phosphatase activity per cell was slighly 
higher for Bioglass® and pSi-containing wells than PCL- containing wells up to 15 
days (but not significantly so), and decreased at a similar rate to controls (fig. 
3.23.B). The reasons for the decrease are unclear as this experiment was not 
repeated, but may result from the maturation of osteoblasts into osteocytes in the 
nodules in vitro. 
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Fig. 3.23. Osteoblasts cultured on tissue culture plastic with composite discs 
containing quantities of 70% porous silicon or 45S5 Bioglass® suspended in the 
media in permeable transwell inserts. A. DNA content of cell lysate. B. Alkaline 
phosphatase activity per Ƭg DNA. Bars show standard error of the mean, n=3.  
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Total collagen and collagen per cell was higher for both PCL-only and Bioglass®- 
or pSi-PCL conditioned media at day 10. No difference was observed in the 
osteoblast response to either Bioglass®-PCL or pSi-PCL in terms of collagen 
deposition, although at day 25 pSi-PCL produced significantly more collagen than 
Bioglass®-PCL (fig. 3.24). 
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Fig. 3.24. Osteoblast formation of collagen on well bases cultured in the presence 
of PCL, Bioglass®-PCL and pSi-PCL composite discs. A. Total collagen per well. 
B. Collagen per Ƭg DNA. Bars show standard error of the mean, n=3. Statistical 
significance was determined by Students T-Test compared to PCL as the control 
population. Significant increase p < 0.05 (  ). 
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3.4.Discussion. 
 
In this part of the investigation, the response of human osteoblasts to silicon was 
evaluated by exposing the cells in vitro to porous silicon in a polycaprolactone 
matrix, the degradation products of both pSi and the composite and to a range of 
silicic acid concentrations in the growth media.  
 
This approach was undertaken to attempt an understanding of the mechanisms 
which may underlie the potential bioactivity of porous silicon and further 
elucidate silicons known role in bone metabolism in vivo. In the previous chapter 
it has been shown that the addition of porous silicon to polycaprolactone results 
in a material that elutes stable daily concentrations of soluble silicic acids over 
several weeks in simulated acellular body fluids. Further, these composites 
spontaneously form a silica gel layer on their surface in any aqueous environment 
and in SBF this gel layer increases the precipitation of calcium from the solution, 
forming crystals on the material surface with bone apatite like molar ratios and 
morphology. 
 
As has been discussed (Chapter 1), the physiological requirement for silicon and 
the bone-bonding effects of Bioglass® are attributed to both stabilisation of the 
collagen and glycosaminoglycan components of the extracellular matrix and 
silicate substitution in the calcium phosphate crystalline structure in matrix 
mineralisation. In this investigation it was possible to test the effects of heavily 
silica-modified surfaces (pSi-PCL discs) and bioavailable silicon acid separately to 
some extent by providing composite substrates with silica gel layers and silicon-
substituted calcium phosphate for osteoblast growth and separately culturing 
osteoblasts with the soluble silicon species available in media. The question of the 
relative importance of substrate chemistry and bioavailable silicon could therefore 
be addressed. 
 
The first stage in this investigation was to determine the response of osteoblasts 
to a range of porous silicon  polycaprolactone compositions and to observe the 
effect of pSi-porosity/degradation rate on cells in vitro. The results of this analysis 
show that 54% and 66% porous silicon microparticles do not appear to 
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significantly enhance the proliferation or osteoblastic phenotype; whereas 82% 
microparticles degrade so rapidly the resulting accumulation of degradation 
products and effervescent hydrogen evolution is effectively toxic to cells. 
 
70% porous silicon particles in a smaller particle size range (11Ƭm rather than 38 
 150Ƭm) proved to be more compatible with osteoblasts, stimulating the 
progression of the osteoblast from de-differentiated and dividing preosteoblast-
like cells to mature secretory cells. Osteoblasts cultured on the surface of 8% w/w 
pSi-PCL composite discs produced significantly more collagen at 10 days in vitro 
than osteoblasts cultured on either PCL or tissue culture plastic. In addition, these 
cells were associated with a more than two-fold increase in glycosaminoglycan 
content of the extracellular matrix, which may be due to increased production of 
GAGs by the osteoblasts or by stabilisation of the ECM by soluble silicate 
species. 
 
To examine the effect of these soluble degradation products on osteoblasts, 
porous silicon microparticles were added to cell culture medium to generate a 
solution containing known concentrations of silicic acid. When applied to 
osteoblasts, concentrations of silicic acids from 1  5 Ƭg.ml-1 appeared to increase 
the proliferation rate of cells and also their metabolic activity in terms of collagen 
production. Previous research has shown that silicic acid-releasing zeolite A has 
similar effect on osteoblasts, increasing the rate of proliferation in densely seeded 
cells by the autocrine TGF-Ƣ route (Keeting et al, 1992). Glycosaminoglycan 
content in the ECM was higher for osteoblasts grown with 20mg pSi-PCL 
indicating that pSi was having a positive effect on osteoblastic phenotype 
 
Interestingly, osteoblasts cultured in media containing PCL-only discs suspended 
in inserts show almost identical, low rates of proliferation to discs containing pSi. 
Similarly, markers of osteoblastic activity such as alkaline phosphatase activity and 
collagen production are also comparable between PCL and pSi-PCL. 
 
The reduction in osteoblast proliferation when exposed to the degradation 
products of PCL-only could derive from three sources: i) the breakdown products 
themselves  carboxylic acids and CO2, ii) residual acetone being released from 
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within the polymer upon immersion in culture medium, iii) release of ethanol 
from the matrix which was used for sterilisation of the discs. 
 
As the discs were prepared several days prior to use, it was expected that residual 
solvents would have evolved from the matrix before they were used. Also, both 
acetone and ethanol are highly volatile, and at least 12 hours was left between 
sterilisation and the immersion in media, with the interim period being inside a 
sterile fume hood with laminar air flow. In chapter two, it was observed that 
polycaprolactone discs lost up to 8% of their starting weight within 90 days which 
was attributed to small molecular weight polymer fragments eluting from the 
matrix.  
 
It is concluded therefore that these polymer fragments have a significant effect on 
the growth of osteoblasts in vitro, both reducing their proliferation and slightly 
enhancing the osteoblastic phenotype. Ignatius and Claes (1996) demonstrated 
that the oligomeric breakdown products of polylactide biomaterials can prove 
toxic to cells by reducing mitochondrial activity and cell proliferation. In this 
investigation a slight increase in osteoblastic phenotype was observed (collagen 
production) for cells cultured with the breakdown products of PCL. 
 
In summary, porous silicon can affect the growth of osteoblast-like cells in vitro. 
When cultured either on or in the presence of porous silicon, osteoblasts show 
reduced proliferation indicating cell maturation and an increase in the production 
of extracellular matrix components and calcium. The morphology of osteoblasts 
cultured on PCL containing pSi microparticles differs from those cultured on 
PCL only, being more osteoblastic, with numerous and extended filipodia which 
are strongly associated with collagen.  
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Chapter Four 
4.1. Introduction. 
 
Fractures of the skeleton account for the majority of orthopaedic operations - 
with an estimated 6.8 million fractures coming to medical attention annually in the 
United States, the average person in a developed country can be expected to 
suffer two broken bones during their lifetime (American Academy of Orthopaedic 
Surgeons). The most common fractures are of the extremities in men under the 
age of 45, with the second most common being extremity fractures in women 
over the age of 45, due to loss of bone density post-menopause, particularly 
fractures of the wrist and hip (Singer et al, 1998). Additionally, ~600,000 articular 
joint prostheses (mainly hip and knee) are implanted annually in the US (Lentino, 
2004).  
 
In many cases, the breaking of a bone or replacement of a joint is accompanied by 
other pathologies, such as osteoporosis, severe trauma (such as car accidents), 
osteosarcoma or post-operative infection, many of which require medication. 
Bone fixation following either accidental breakage or surgical intervention also has 
associated pain, which is regulated intravenously in extreme cases and by oral 
medication in others (Duellman et al, 2009). 
 
The total global market for orthopaedic drugs, implants and fixation devices stood 
at $44 billion in 2004 and is projected to reach $74.1 billion by 2009 (BCC 
Research, 2004 report). Of this, approximately three quarters constitutes drug 
sales, although sales of implants are increasing at a higher annual rate of 12.5% 
(against 10.5% for drugs). Additionally, the market for drug-releasing polymers 
currently stands at $28 billion per annum, with biomaterials encompassing a 
significant share (e.g. $5 billion P.A. for drug-releasing vascular stents).  
 
Pharmaceuticals which are potentially relevant to bone implants and fixation 
devices can be fitted into three categories: 
 
฀ Bone stabilizers (bone growth promoters & resorbtion inhibitors). 
฀ Analgesics and anti-inflammatories. 
฀ Antimicrobials. 
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4.1.1. Bone stabilisers. 
 
Bone is a dynamic tissue which is remodelled continually through life. 
Osteoclastic bone resorbtion and osteoblastic bone matrix deposition are 
dynamically linked via a number of signalling pathways and are partially under 
central endocrine control (Karsenty, 2000). Disruption of these pathways leads 
most commonly to osteoporosis and results in a gradual weakening and loss of 
bone mass. As most hip and knee replacements are performed on patients over 
the age of 60, osteoporosis is a factor which must often be considered when 
implanting an articular prosthesis and care taken to avoid damaging the weakened 
bone matrix.  
 
Bone turnover may be stabilised through inhibiting osteoclast activity or by 
stimulating pre-osteoblasts and osteoprogenitor cells to develop or enhance an 
osteoblastic phenotype. Osteoclast inhibition by bisphosphonates is the main 
route by which menopausal osteoporosis is managed, and the response to orally-
delivered doses is well characterised and presents few side effects (Iwamoto, 
2008). Additional bisphosphonate stabilisation following surgery may enhance the 
rate and extent of local bone healing and serve to reduce the need for or delay 
subsequent revisions, although intravenous use has been associated with jaw 
osteonecrosis (Ruggiero et al, 2004). 
 
Bisphosphonates function by shortening osteoclast lifetimes (via apoptosis) and 
localise to bone mineral, thereby being endocytosed by the osteoclast during 
remodelling. Bisphosphonates already bound to bone therefore may continue to 
act in reducing bone loss for long periods after the oral dosing has stopped. The 
most commonly prescribed bisphosphonates are sodium alendronate (Fosamax, 
Merck) 10mg a day or 70mg once a week, risedronate (Actonel, Procter & 
Gamble) 5mg a day or 35mg once a week and ibandronate (Boniva) once a 
month. 
 
Loading of bisphosphonates into drug-delivery vehicles has been attempted by 
several research groups with in vitro success (Shi et al, 2009; Faucheux et al, 2008), 
but is so far unreported in vivo or in clinical trials. Methods of conjugating proteins 
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to bisphosphonates have also been developed that provide a means to localise 
specific proteins to the bone mineral surface (Wright et al, 2009; Gittens et al, 
2004). It is also apparent that preventing or reducing osteolysis and resorbtion of 
bone surrounding an implant may help to stabilise and improve the fixation of 
prostheses (Huolman & Ashammakhi, 2007). Stabilisation may alternatively be 
provided by treatment with promoters of osteoblast activity, such as bone 
morphogenic proteins or dexamethasone (see below).  
 
 
4.1.2. Analgesics and anti-inflammatories. 
 
Reducing post-operative pain and inflammation is essential to a patients quality of 
care and may accelerate the rate of recovery and time in hospital. Most pain relief 
following surgery is given systemically by patient-controlled intravenous morphine 
drip, or by a multi-modal route which combinines several analgesics and anti-
inflammatory drugs in order to improve efficacy and reduce side effects 
(Duellman et al, 2009). Topical pain relief is commonly by ibuprofen- or 
diclofenac-containing gels (Banning, 2008). Caterina et al (2001) have also 
suggested a use for topical doses of capsaicin post-operatively. 
 
Release of analgesics and anti-inflammatory drugs from implanted materials has 
been studied in comparatively little detail considering the proven advantages of 
both topical pain relief and combined, multi-route methods for pain management. 
Analgesic-releasing bone cements have been patented (e.g. US patent numbers 
6713527 and 6355705, both by Queens University, Ontario, Canada) but clinical 
data is limited to one successful trial described in the patents using 5% lidocaine 
in poly(methyl methacrylate) bone cement in a total knee arthroplasty revision on 
a 68-year old female patient. Analgesic effects were described to increase to 
optimum levels over six hours and lasted for more than two days. 
 
Release of this type of drug is therefore relatively untried when compared to 
antibiotic-releasing bone cements and materials (see below), but presents a 
potentially vast market for post-operative pain management.  
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4.1.3. Antibiotics. 
 
In 1957, Elek and Conen demonstrated that the presence of a foreign body (such 
as an orthopaedic implant) significantly reduces the number of bacteria required 
to produce an infection. Approximately 1% of primary and 3% of secondary 
(revised) orthopaedic prostheses in the US become infected (Stocks et al, 2000), 
and most treatments require removal of the implant with associated morbidity and 
peripheral tissue destruction. The majority of these infections are bacterial in 
origin, but a small proportion (<1%) are produced by Candida (fungal) biofilms 
(Kojic et al, 2004). 
 
In clinical practice, antibiotic-eluting polymers have been used for several years. 
Gentamicin- and other aminoglycoside- loaded bone cement was first used 
clinically in the late 1960s by Buchholz and Engelbrecht (see Wahlig et al, 1984), 
less than a decade after poly(methyl methacrylate) (PMMA) itself was first applied 
in prosthesis fixation. The loading ratios and release kinetics of aminoglycoside-
bone cements have been well characterised over the last four decades and the 
mechanical properties of adding such substances evaluated.  
 
Commercial products such as Depuy 1 Gentamicin Bone Cement (Depuy 
Orthopaedics) and Simplex (releasing tobramycin, Stryker Orthopaedics) 
contain 1g of the aminogycoside antibiotic mixed into the 40g powder component 
of the cement (approximately 1.5% final concentration, w/w). Clinicians may 
choose to add gentamicin separately to the PMMA bone cement and often favour 
a high-loading of gentamicin, commonly >9% w/w loading and up to 20% for 
treatment of active infections in revisions (Lautenschlager et al, 1976).  
 
PMMA bone cement is not biodegradable, osteoinductive or permeable to water 
and consequently only a small percentage of the antibiotic is released into the 
wound site in a burst release following would closure. The primary clinical 
concerns with antibiotic-releasing cements are the potential for development of an 
immune response to high-doses and the possibility of gentamicin-resistant 
bacterial infections developing. A more detailed analysis of poly(methy 
methacrylate) bone cements in drug delivery is provided in the appendix. 
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4.1.4. Porous silicon for drug delivery. 
 
Porous silicon exhibits numerous properties that make it desirable as a drug 
delivery vehicle: it can be manufactured with a range of pore architectures (width 
and depth) and the surface chemistry can be adjusted by various well-
characterised technologies to aid both storage and release of specific molecules.  
 
As pSi is biodegradable, its use as a delivery vehicle can provide a carrier for 
hydrophobic molecules which do not readily disperse using conventional means. 
pSi microparticles in suspension can distribute through a target area, organ or 
tissue, a property which has been exploited by pSiMedica in a radiotherapy 
treatment known as brachytherapy. In this technique, 32P is loaded into porous 
silicon and injected percutaneously into a tumour, providing very high doses of 
localised radiation. This method is currently being explored as a method for 
treating tumours which are not treatable by conventional means, such as 
pancreatic and liver cancer (Zhang et al, 2005). 
  
Conventional drug delivery has also been explored by several research groups 
with the release kinetics of various molecules including cis-platin (Coffer et al, 
2003), dexamethasone (Anglin et al, 2004), ibuprofen (Charnay et al, 2004), and 
doxorubicin (Vaccari et al, 2006) being studied for drug delivery applications. A 
comprehensive review of pSi (and silica derivatives of the pSi matrix) for drug 
delivery applications is given in Salonen et al (2008).  
 
Several methods to securely encapsulate molecules in a porous silicon matrix have 
been described, including covalently bonding drugs to the host silicon, although 
this may interfere with the structure and function of the API upon release       
(fig. 4.1). Alternatively, drugs may be attached to silicon via a cleavable linker, 
such as polyethylene glycol (Schwartz et al, 2005).  
 
pSi loaded with pharmaceuticals may be subsequently oxidised which considerably 
decreases the internal diameter of the pores and so effectively locks the drug into 
place, releasing only as the silicon matrix degrades as described (for the release of 
iron oxide nanoparticles) in Dorvee et al (2008).  
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Fig. 4.1. Methods for incorporating pharmaceuticals into the pore spaces of pSi.  
1. Covalently bonding the drug to silicon via a polyethylene glycol linker, 2. 
Oxidising the pSi after/during drug loading decreases pore diameter, trapping 
molecules in the oxide layer, 3. Allowing the electrostatic forces between silicon 
hydride/oxide domains and charged/polar molecules to adsorb the molecules to 
the surface. 
 
 
In this investigation, drug loading into pSi was achieved by filling the pore spaces 
with the sample substance, but even this simple method for containing drugs 
involves electrochemical interactions with pSi. As the surface of native pSi 
(presenting hydrides, Si-H) is initially highly hydrophobic it presents a net positive 
charge to the surrounding medium to which negatively charged molecules are 
drawn; conversely, oxidised regions of the pSi matrix present an overall negative 
charge and adsorb positively charged molecules (Anglin et al, 2008). In reality, pSi 
stored in atmospheric conditions and prepared in a standard laboratory possesses 
both Si-H and Si-O domains and so can attract ampiphilic molecules as readily as 
either negatively or positively charged species.  
 
For advanced drug-delivery applications, electrostatic binding to the surface can 
be more finely controlled during pSi fabrication, helping to adsorb relevant 
molecules to the pore surface and effecting more rapid release (Arwin et al, 2000). 
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4.1.5. Polycaprolactone for drug delivery. 
 
Polycaprolactone and polylactide blends or co-polymers are becoming 
increasingly popular as potential drug delivery vehicles in their own right, with a 
common application being the formation of a drug-polymer emulsion in a solvent 
which is subsequently formed into microspheres that can either be implanted into 
a target organ or wound site or injected (Sinha & Trehan, 2008). 
 
Microsphere technology is well studied and patents cover numerous applications, 
but are currently commercially restricted due to several technical difficulties which 
range from the denaturing of proteins during formulation and encapsulation, 
processing or during prolonged release to overcoming burst release profiles, 
incomplete release and low encapsulation efficiency - factors which often have to 
be resolved simultaneously if the device is to be effective (Wu & Jin, 2008).  
 
Targets for microsphere-encapsulated drugs have so far been in the sustained 
release of antibiotics such as gentamicin (Sinha et al, 2004), protein drugs (Wu & 
Jin, 2008), contraceptives (Dhanaraju et al, 2006) and various other molecules 
(reviewed in Varde & Pack, 2004). The aims of sustained drug release are to 
bypass issues in self-medication such as patient compliance, to increase the 
efficacy of drugs in tissues that are poorly vascularised or damaged, such as 
orthopaedic wound sites following prosthesis implantation and to provide a 
dispersible sustained dosage of drugs for cancer treatment. 
 
The emulsion technology for producing microspheres lends itself equally to the 
formation of polymer-based tissue engineering scaffolds, and several groups have 
successfully produced tissue engineering scaffolds which elute therapeutic agents, 
particularly antibiotics such as gentamicin and amikacin (Prabu et al, 2006), and 
bone morphogenic proteins (BMP-2 and BMP-7; Kempen et al, 2008).  
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4.1.6. Loading and release of substances in pSi-PCL composites. 
 
Substantial data exists at pSiMedica Ltd. for a range of pharmaceuticals which 
have been loaded into pSi microparticles and the release profiles they display. 
Prior to this investigation, however, the more complex release profiles of 
substances from pSi microparticles in a polymer composite had not been 
evaluated. pSiMedica data suggests that the degradation of pSi host matrices in 
aqueous media enhances the rate at which poorly soluble or hydrophobic 
molecules and proteins substances are carried into solution. 
 
Loading of a substance into pSi is straightforward: a concentrated solution of the 
substance is made which is then added to pSi particles in suspension (in an 
organic solvent) and the solvents extracted by evaporation. The high surface area : 
volume ratio of pSi coupled with the capillarity of the pores ensures that the 
internal pore walls of the particles are lined with the substance. The particles are 
then mixed with the polymer in solution and the composite achieved.  
 
The process of loading substances into pSi and releasing them from an actively 
degrading material involves exposing the active substance to several factors which 
may potentially degrade or inactivate pharmaceuticals: 
 
1. Loading: 
1. Dissolution in organic solvents 
2. High temperatures as pSi oxidises 
 
2. Storage: 
3. Reducing conditions inside pSi nanopores 
4. Polymer impurities, including: 
ɸ Tin (<200ppm)  ɸ Toluene (~100ppm) 
3. Release: 
5. Localised high silicic acid concentrations 
6. Associated composite degradation products include:  
ɸ 5-hexanoic acid  ɸ CO2   ɸmolecular hydrogen (H2) 
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The activity of APIs following release from polylactide-only vehicles had been 
assessed (e.g. Park et al, 1995) and reviewed (OHagan et al, 1998) by several 
researchers to evaluate some of the concerns which relate to biodegradable drug 
carriers. Exposure of aqueous solutions of protein-pharmaceuticals to organic 
solvents results in the formation of an emulsion, minimising the effects of 
denaturing solvents except at the interface of the two solvents. Denaturation by 
this means can be minimised by using dried, powdered pharmaceuticals in 
suspension or by minimising the time spent in contact with the organic solvent 
(OHagan et al, 1998).  
 
Exposure to acidic and reducing environments has only a minimal effect on 
protein structure, and it has been shown that even acid-sensitive proteins (cholera 
toxin B, OHagan et al, 1995) are released intact in both in vitro and in vivo trials 
from polylactide microspheres, although some hydrolysis does occur. Acidic 
conditions within larger materials have not been fully evaluated, but it would seem 
that the combination of fluid flow surrounding the material/microspheres 
coupled with the higher solubility of APIs in relation to the degradability of the 
polylactides allows the protein to escape the matrix with the native tertiary and 
quaternary structure intact.   
 
No drug interactions with low level Tin or toluene contamination or degradation 
on exposure to molecular hydrogen or CO2 are reported in the literature. 
 
 
4.1.7. Substances tested. 
 
For this investigation a number of substances were tested to simulate the wide 
range of APIs used, or potentially usable in orthopaedic pharmacy. It was the aim 
of this investigation to represent each class of API with a tested example, ranging 
from small hydrophilic compounds to large, dimerised proteins with limited 
solubility (such as alkaline phosphatase), as listed in fig. 4.2.  
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Release kinetics studies  To provide preliminary data on the release kinetics of 
molecules released from the material: 
 
฀ Fluorescein    small, water-soluble molecule 
฀ Bovine serum albumin  medium-sized water-soluble protein 
฀ Alkaline phosphatase    large, membrane-derived glycoprotein 
 
Antimicrobial activity  To test the efficiency of the material in releasing active 
concentrations of antimicrobial compounds: 
  
฀ Gentamicin     broad spectrum antibacterial 
฀ Nystatin     antifungal, used against Candida infections 
 
Effects on human osteoblasts in vitro  To test the ability of the material to 
elicit biological responses to eluted substances: 
 
฀ Dexamethasone  promotes alkaline phosphatase expression  
฀ BMP 7    promotes pre-osteoblast differentiation and 
calcification 
 
Fig. 4.2. List of substances tested indicating the general class of pharmaceutical 
each substance was chosen to represent. 
 
 
 
4.1.7.1. Fluorescein. 
 
Fluorescein is a small, water soluble molecule (C20H12O5, 332 g.mol
-1) which was 
used in this investigation to represent a broad range of pharmaceuticals such as 
steroid hormones which share similar basic properties including molar mass, 
hydrophilicity and molecular structure. A comparison of fluorescein mass and 
molecular structure to several pharmaceuticals relevant to orthopaedics is given in 
fig.4.3. 
 
Fluorescein was used in this investigation because of the relative ease and 
accuracy of determining concentrations in solution, allowing rapid and consistent 
analysis of solutions incubating fluorescein-containing polymer-composites. It was 
expected that similar molecules such as gentamicin and dexamethasone would 
elute in similar ways to fluorescein, a hypothesis which was subsequently tested. 
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Fig. 4.3. Structures and molecular weights (g.mol-1) for fluorescein and several 
similarly sized water-soluble pharmaceuticals: A. Fluorescein, B. Dexamethasone, 
C. Diazepam, D. Gentamicin, E. Streptomycin, F. Kanamicin (D-F are 
aminoglycoside antibiotics), G. Tiludronic acid, a bisphosphonate, H. PenicillinG, 
I. Ibuprofen. Images and data are from Sigma-Aldrich technical webpages. 
  
 
4.1.7.2. Bovine serum albumin.  
 
Bovine serum albumin (BSA) is a 66 kDa protein which constitutes approximately 
50% of the total protein in bovine serum. Serum albumins are responsible for 
maintaining osmotic pressure throughout body tissues and for binding to and 
aiding the solubility of numerous hydrophobic hormones and fatty acids in the 
blood (Bhattacharya et al, 2000).  
 
In this investigation, BSA was chosen as an example of a medium-sized, water 
soluble protein which was easy to determine and quantify in solution using well-
described colorimetric assay techniques such as the Bradford assay (Bradford, 
1976). 
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4.1.7.3. Alkaline phosphatase. 
 
Alkaline phosphatase from bovine intestinal mucosa is a dimeric, membrane-
derived glycoprotein with a mass of ~160 kDa, representing a broad range of 
membrane-bound and partially hydrophobic proteins which can be used 
therapeutically. Active alkaline phosphatase dephosphorylates various molecules 
and in this investigation the enzyme was used to test the effect of loading and 
release of proteins on their activity in eluted solutions.  
 
During the course of loading substances into pSi or PCL and casting the material 
into discs, molecules may experience high temperatures, exposure to organic 
solvents and various residual salts and experience a wide range of pH. The effect 
of this on enzymatic activity is crucial to evaluating pSis suitability as a vehicle for 
pharmaceuticals. 
 
 
4.1.7.4. Gentamicin. 
 
 
Fig. 4.4. Gentamicin sulphate. 
 
 
Gentamicin (fig. 4.4) is an aminoglycoside antibiotic with a broad spectrum of 
antibacterial action, particularly against Gram-negative species, and is the most 
commonly used antibiotic following orthopaedic surgery (Dr Roger Bayston, 
personal communication). Gentamicin is also heat stable up to and exceeding 
autoclave conditions (Bourne, 2004), therefore presenting less of a problem in 
maintaining activity during loading into pSi / PCL. 
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4.1.7.5. Nystatin. 
 
Fig. 4.5. Nystatin. 
 
 
Nystatin (fig. 4.5) is a polyene antimycotic with a broad spectrum of antifungal 
activity, being effective against most cutaneous, mucosal and oesophageal Candida 
(yeast) infections. Polyenes associate with ergosterol in the fungal cell membrane, 
forming a channel which allows K+ leakage resulting in cell death (Ghannoum & 
Rice, 1999).  
 
As such, polyenes are fungi-specific and show only limited toxicity when delivered 
intravenously - polyenes are not absorbed across mucous membranes or the skin. 
Nystatin is not water soluble but forms an active suspension in solution and is 
thus also used as an example for this class of pharmaceuticals.  
 
Fungal diseases of bone are rare, forming less than 1% implant infections (Kojic et 
al, 2004), but when presented are usually treated with a combination of 
debridement and topical treatment with a polyene antimycotic such as nystatin or 
amphotericin B (Kojic et al, 2004). Articular prostheses can become infected with 
Candida biofilms which are considerably more resistant to systemic treatment and 
require surgical intervention. 
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4.1.7.6. Dexamethasone. 
 
Fig. 4.6. Dexamethasone. 
 
 
Dexamethasone (fig. 4.6) is a glucocorticoid steroid hormone with anti-
inflammatory properties considerably greater than hydrocortisone (Jain & 
Srivastava, 1979). Dexamethasone also promotes the osteoblastic phenotype of 
human osteoblast-like cells and mesenchymal cells in vitro, stimulating alkaline 
phosphatase expression in responsive cell types (Yamanouchi et al, 1997; Yang et 
al, 2003).  
 
 
4.1.7.7. Bone morphogenic protein 7. 
 
Bone morphogenic proteins (BMPs) are a group of cytokines and growth factors 
which mainly belong to the TGFƢ family and have an ability to stimulate bone 
formation both in vitro and in vivo (Cheng et al, 2003). Bone morphogenic proteins 
have several clinical uses in treating non-union, with BMP2 and BMP7 having 
FDA approval in the US for human clinical applications and used in the UK for 
treating non-union and for spinal fusion.  
 
Treatment programmes are expensive, however - typically in excess of £7,000 for 
treating tibial non-union in pilot studies (Dahabreh et al, 2008). BMP7 is a serum 
protein which binds to transmembrane proteins, signalling through the SMAD1 
and SMAD5 signal cascade and inducing the transcription of several osteogenic 
genes including osteonectin, osteopontin and osteocalcin (Itoh et al, 2001). 
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4.1.8. Aims. 
 
The aims of this part of the investigation were to evaluate porous silicon-
polycaprolactone composites for sustained delivery of a range of molecules which 
have existing or potential orthopaedic applications. The objectives therefore were 
to: 
  
1. Devise an appropriate method for loading substances into pSi 
microparticles, polycaprolactone and pSi-PCL composites. 
 
2. Determine and compare the release kinetics of a preliminary range of 
small to large, hydrophilic and hydrophobic molecules. 
 
3. Analyse the viability of biologically active molecules (such as enzymes) 
following release. 
 
4. Investigate the antimicrobial effect of composites eluting gentamicin (anti-
bacterial) and nystatin (anti-fungal). 
 
5. Study the effect of composites releasing dexamethasone and BMP7 on 
osteoblast growth and activity in vitro. 
 
Throughout this investigation, the release of substances from the composite 
was compared to the release from polymer-only vehicles prepared under 
identical or near-identical conditions and tested concurrently.  
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4.2. Materials and Methods. 
 
4.2.1 Loading of substances into pSi and polycaprolactone. 
 
Substance loading into porous silicon, polycaprolactone and the composite was 
achieved in the following way. A solubility study was performed on each 
substance in a series of organic solvents with a range of relative polarities and 
boiling points (fig. 4.7). A visual analysis was made to determine the level of 
solubility of 60mg of the substance in 150Ƭl solvent in a glass vial (solution 
clarity). 
 
A Solvent  Boiling point(°C) Dielectric constant(ƥr) 
    
Water    100   80 
Dimethylsulfoxide  189   47.2 
N,N-dimethylformamide 153   38.3 
Acetonitrile   81   36.6 
Methanol   68   33 
Ethanol   78   24.3 
Acetone   56   20.7 
2-propanol   82.3   20.18  
Methylene chloride   40   9.08 
Tetrahydrofuran   66   7.52 
Ethyl acetate    78   6.02  
 Chloroform   61.2   4.8 
 
B 
   
 
 
 
 
 
 
 
Fig. 4.7. A. Solvents listed in order of dielectric constant (ƥr), a measure of 
polarity. ( source Sigma-Aldrich technical webpages). B. Scatter graph showing 
the relationship between polarity and hydrogen bonding for several common 
solvents (adapted from pSiMedica internal report by Dr. Christian Barnett). 
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In practice only three solvents were used: water, acetone and ethanol as all 
substances tested were soluble in either one or in combination, and which have a 
low boiling point to allow rapid extraction of the solvent. Substances which are 
only soluble in water were first fully dissolved in water and subsequently mixed 
with an equal volume of ethanol or acetone to aid loading into pSi. A table listing 
the solvents used for each substance is given below (table 4.8). High 
concentrations of the substance (solvent volume < 3ml) were used to minimise 
the loading time and subsequent solvent extraction. 
 
Substance    Primary solvent Secondary solvent 
Fluorescein    Water   Ethanol 
Bovine serum albumin (BSA)  Water   Acetone 
Alkaline phosphatase (AP)  Ethanol  Ethanol 
Gentamicin    Water   Ethanol 
Nystatin    Ethanol  Ethanol 
Dexamethasone   Ethanol  Ethanol 
Bone Morphogenic Protein 7   Water   Acetone 
 
Table 4.8. Solvents used to dissolve substances used in this investigation. 
Secondary solvents were added to aid wetability (reduce contact angle) of porous 
silicon in the solution and enhance the uptake of the substance into pores. 
 
 
Once dissolved in the solvent the solution was added to a measured amount of 
porous silicon (70% porous, 11Ƭm particle size; pSiMedica) and agitated to fully 
disperse the silicon through the solution. The substance-loaded pSi was incubated 
at 4°C for 2 hours and then air dried in a mortar before being ground to 
redisperse the pSi microparticles and reweighed. If no pSi was to be used (i.e. 
direct release from PCL) the pSi loading stage was bypassed and the solution 
dried, ground in a pestle and mortar and added directly to PCL as follows.  
 
The microparticles or ground substance were added to a 50:50 (w/v) solution of 
polycaprolactone in acetone at room temperature and dispersed through the 
polymer, which was immediately loaded into a 5ml syringe body and cast as a 
cylinder. The cylinder was allowed to dry overnight before being cut into 250mg 
discs for experimental use. 
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In this work the nomenclature used for the drug-loaded composites is: 
 
(mg pSi) (polymer or composite) (mg drug loaded)  
 
As an example, a standard 250mg composite disc containing 20mg porous silicon 
which has been loaded with 5mg fluorescein would be represented as 20 pSi 5. 
Similarly a 250mg polycaprolactone-only disc containing 5mg fluorescein would 
be represented as PCL 5. 
 
 
4.2.2. Substances tested. 
 
4.2.2.1. Fluorescein. 
 
Fluorescein (Sigma, UK - C20H12O5 332 g.mol
-1,) was loaded into polycaprolactone 
and into 20mg (8%) pSi composites in three different quantities: 1mg, 5mg and 
10mg as shown in fig. 4.9. In addition, 20mg pSi microparticles were loaded with 
fluorescein and contained in a short piece of dialysis tubing by knotting the ends 
of the tubing. 
 
Sample  Polymer  pSi  Fluorescein 
  
PCL    PCL        -   
PCL+pSi  PCL    20mg pSi 
PMMA   PMMA        -   1, 5 & 10mg  
PMMA+pSi  PMMA    20mg pSi 
pSi       -   20mg pSi 
 
Fig. 4.9. Polymer : pSi : Fluorescein ratios used in the investigation. 
 
 
The 250mg discs and pSi-tubing were placed in the wells of a 24 well cell culture 
plate, with three discs per sample condition (n = 3). The discs were weighed down 
with a 5mm diameter rubber rings, 1ml PBS added and the plate lid secured. The 
PBS was removed every 24 hours, analysed and replaced - the well/disc was 
rinsed with PBS between solution changes.  
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The fluorescence at excitation 494nm and emission 521nm of 300Ƭl of the 
released fluorescein solution was measured and quantified against known 
concentrations of 0.1 to 10 ng.ml-1 fluorescein. Cumulative release was plotted 
against time for each loading concentration of fluorescein tested.  
 
4.2.2.2. Bovine serum albumin & alkaline phosphatase. 
 
Bovine serum albumin (BSA fraction V, MW ~66 kDa, Sigma, UK) and alkaline 
phosphatase (AP Type VII-L from bovine intestinal mucosa, homodimer MW 
~160 kDa; Sigma, UK) were loaded into porous silicon as described above in the 
ratios shown in table 4.10. 
 
Sample pSi (mg)  BSA/AP (mg) Polycaprolactone  
PCL 5   0   5    
PCL 10   0   10    
20 pSi 5  10   5   250mg 
20 pSi 10  20   10    
 
Table 4.10. Polymer : pSi : Protein ratios used in the investigation. 
 
 
The discs were placed in the wells of a 24 well cell culture plate, with 4 discs per 
sample condition (n = 4). The discs were weighed down with a 5mm diameter 
rubber ring, 1ml PBS added and the plate lid secured. The PBS was removed 
every 48 hours for 8 days and analysed as described below; the well/disc was 
rinsed with PBS and 1ml PBS re-added to the well. 
 
4.2.2.2.1. Protein release. 
 
Protein release was determined by a Bradford assay (Bradford, 1976). To 400 Ƭl of 
the incubation media was added 100 Ƭl pre-prepared Bradford reagent 
(Coomassie blue solution, Sigma, UK) and the absorbance measured at 595 nm. A 
calibration curve was established using known concentrations of BSA or alkaline 
phosphatase from 10 ng to 100 Ƭg. The assay was optimised such that the 
calibration curve was linear for the concentrations determined in the experiment. 
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4.2.2.2.2. Alkaline phosphatase activity.  
 
Alkaline phosphatase activity was determined using 50 Ƭl of the incubation media 
and 250 Ƭl 4-methylumberiferyl phosphate substrate system (Sigma, UK). Alkaline 
phosphatase in the sample enzymatically cleaves phosphate from the 4-MUP, 
producing the 4-methylumbeliferone which can be quantified by its fluorescence 
(excitation 360nm, emission 460nm) and represented as relative units. To ensure 
the quantification was comparable for each time point, samples were immediately 
frozen at -20°C until the end of the experiment and assayed under identical 
conditions (5 minutes incubation time with substrate at room temperature). 
 
 
4.2.2.3. Gentamicin. 
 
Gentamicin was loaded into polycaprolactone / pSi in the ratios shown in table 
4.11. 250 mg discs were placed in wells of a 24-well plate (Nunc), n = 4. 1ml PBS 
was added and the covered plate incubated at 37°C for 21 days. Gentamicin in the 
solutions was quantified using an o-phthalaldehyde reagent which becomes 
fluorescent when conjugated to primary amines (Gubernator et al, 2006). 
 
50Ƭl of the incubating solution was pipetted into wells of a 96 well plate and 200Ƭl 
pre-prepared cold o-phthalaldehyde reagent (1 mg.ml-1 o-phthaldialdehyde with 2-
mercaptoethanol, potassium hydroxide, methanol, boric acid and Brij 35  pH 
10.0, Sigma, UK) was added and the solution allowed to incubate at room 
temperatre for 10 minutes. The fluorescence of the solution was measured at ƫ 
340nm (excitation) and ƫ 465nm (emisson) and compared to known 
concentrations of gentamicin sulphate in PBS (1  250 Ƭg.ml-1). 
 
Sample  pSi (mg) Gentamicin(mg) Polycaprolactone 
PCL 5   0  5    
PCL 10   0  10            250 mg 
20 pSi 5  20  5             
20 pSi 10  20  10    
 
Table 4.11. Polymer : pSi : Gentamicin ratios used in the investigation (n = 4). 
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4.2.2.4. Nystatin. 
 
Nystatin was loaded into PCL and pSi-PCL in the ratios shown in table 4.12. An 
experimental set up was established to qualitatively (and semi-quantitatively) 
determine the amount of nystatin released from a static system. The polymer / 
composite disc was placed in the centre of a 10cm diameter polystyrene petri dish 
and 3ml 1% agarose (electrophoresis grade, Sigma, UK) added which contained a 
suspension of yeast cells (saccharomyces cerivisiae) such that only the upper surface of 
the disc was exposed (fig. 4.13). Once the gel was set, 2ml dH2O was added to the 
surface of the agarose/disc to act as a medium for nystatin release and the discs 
incubated at 37°C for up to 5 days.  
 
Sample pSi (mg)  Nystatin (mg) Polycaprolactone  
PCL 5   0   5    
PCL 10   0   10    
10 pSi 5  10   5          250 mg 
20 pSi    10   5    
20 pSi 10  20   10    
 
Table 4.12. Polymer : pSi : Nystatin ratios used in the investigation. 
 
 
At 1 and 5 day time points the plates were analysed for the proportion of dead 
yeast cells by staining dead cells only with a 1% w/v aqueous solution of 
methylene blue (Kucsera et al, 2000). 1ml of the stain was applied and incubated at 
room temperature for 5 minutes before being thoroughly rinsed in several 
changes of PBS.  
 
Controls used were agar discs containing no yeast cells to determine background 
staining and a plate containing heat-killed yeast cells with no nystatin which was 
irradiated by microwave radiation for 60 seconds to determine maximum staining 
for dead cells.  
 
Analysis was by imaging the under surface of the plates using a Brother DCP-
560CN scanner and quantification by transferring three circumferencial sections 
of the stained agarose/yeast to 1ml cuvettes by stamping the cuvette into the gel 
 149 
Chapter Four 
to ensure identical volumes were tested. The absorbance of the agarose at 660nm 
was measured for each sample in triplicate and expressed as a percentage of the 
difference between background staining (0%) and maximum staining of irradiated 
cells (100%)  
 
 
 
Fig. 4.13. Experimental set up for study of nystatin release. 
 
 
 
4.2.2.5. Dexamethasone. 
 
Results from early experiments to determine fluorescein release rate (4.3.2.1.) 
allowed the release profiles of other small, water soluble compounds to be 
predicted [fluorescein C20H12O5 332g.mol
-1 dexamethasone C22H29FO5 392g.mol
-1]. 
Therefore, the initial loading concentrations of the substance into the material 
could be calculated to generate the required concentrations (see 4.3.2.1). 
 
Dexamethasone was loaded into polycaprolactone-only or a 20mg pSi (8%) 
composite in three concentrations based on the loading/release ratio of the 
similar molecule fluorescein. Yamanouchi et al (1997) suggests the optimum 
dexamethasone concentration for stimulating osteoblast activity in vitro is ~10-7 M 
(39.2 ng.ml-1). This was set as the intermediate (Med) release concentration 
maximum per day (± one standard deviation, ~50%) and achieved by loading 
20mg pSi or PCL directly with 9.26 Ƭg dexamethasone in ethanol (diluted from a 
50 mg.ml-1 stock solution).  
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Maximum daily concentrations of one order of magnitude lower and higher (10-8 
and 10-6 M) than this optimum were achieved by loading pSi or PCL with 926 ng 
and 92.6 Ƭg respectively and designated Low or High Dex(amethasone). 
 
Negative controls were unmodified tissue culture plastic wells, PCL discs and 8% 
psi-composite discs. Positive controls were replicates of these discs with 10-7M 
dexamethasone added to the culture medium, corresponding to the projected 
maximum daily release from PCL/pSi Med discs and equal to the concentration 
recommended for use in osteoblast supplementation in vitro. 
 
Human osteoblasts extracted from femoral head trabecular bone were cultured in 
DMEM with 10% FCS, 2mM L-glutamine and 25mM HEPES. Osteoblasts at 
passage 30 were seeded at ~100,000 cells per well into a 48-well plates onto 
250mg composite discs or into empty wells. 1ml media was added per well which 
was replaced every 24 hours for 15 days.  
 
One plate was analysed every 5 days by rinsing each well carefully in PBS followed 
by freeze-thawing the plate with 1ml H2O per well for three cycles between -80°C 
and 20°C. DNA and collagen were quantified and alkaline phosphatase activity 
was measured as described in section 3.2.: at day 15 the amount of calcium per 
well/disc was also measured. 
 
 
4.2.2.6. Bone morphogenic protein 7 (BMP7). 
 
Human BMP7 (Monomer MW 15.7 kDa, Sigma UK) was loaded into pSi-PCL 
composites only in the ratios given in table 4.14. The discs were compressed 
between clean glass slides and removed once solid to produce a thin disc or film 
(~12mm x ~1mm) on which cells were seeded. Human osteoblasts at passage 30 
were seeded at ~100,000 cells per well into a 12-well cell culture plate (Nunc) 
directly onto the well surface or onto the polymer/composite. 3ml culture media 
(DMEM with 10% FCS, 2mM L-glutamine, 25mM HEPES) was added which 
was exchanged every 5 days.  
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Sample BMP7 (Ƭg) pSi (mg) PCL (mg) 
Control 0  0  0 
PCL  0  0  0 
pSi  0  2  25 
BMP7  2.5  2  25 
 
Table 4.14. Loading concentrations of BMP7, pSi and PCL used in the 
investigation. 
 
 
Three plates were set up which were analysed at 5 and 10 days for DNA and 
collagen content and alkaline phosphatase activity as described in section 3.2.2. 
Calcium deposition was not measured due to the small repeat number (n=4). At 
the end of each time point the PCL, composite and BMP7-composite discs were 
removed from the wells and analysed seperately to determine the response of 
osteoblasts to growth directly on the eluting material (discs) and peripheral 
surfaces (wells). 
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4.3. Results. 
 
4.3.1. Loading of substances into pSi and polycaprolactone. 
 
The substance loading technique was optimised for this investigation to minimise 
the time substances were exposed to heat and solvent, therefore high 
concentrations of the substance in solvent were used (less than 3ml total solvent). 
Recovery of the pSi-substance was >98% by weight once the solvent was 
extracted with some loss experienced in transferring the pSi in slurry form to the 
mortar for drying and then again between the mortar and weighing boat/PCL 
solution. When water was used as the primary solvent some oxidisation 
(effervescence of the slurry) and heating was observed which was minimised by 
performing the loading stage at 4°C.  
 
 
4.3.2. Substance release. 
 
4.3.2.1. Fluorescein. 
 
1, 5 or 10mg fluorescein was loaded into 250mg polycaprolactone and 250mg 8% 
pSi-PCL composite discs. In addition, 20mg pSi microparticles (encapsulated in 
dialysis tubing) were loaded with the same amounts of fluorescein.  
 
Fig. 4.15. shows the release rates observed for each loading concentration from 
the materials tested. At a loading of 1mg per material, the pSi microparticles in 
dialysis tubing are shown to release fluorescein rapidly (11.1 ± 1.84 Ƭg.day-1), 
corresponding with the high surface to area ratio of these particles.  
 
PCL and PCL-pSi composite showed similar release rates (PCL: 5.78 ± 2.28 
Ƭg.day-1; pSi-PCL: 4.20 ± 2.20 Ƭg.day-1). At this loading concentration the pSi 
microparticles became depleted of fluorescein after 9 days  it was noted that 
considerable fluorescein was lost in the washing steps between each media 
change. Both PCL and pSi-PCL eluted fluorescein at a consistent rate over 24 
days.  
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Fig. 4.15. Fluorescein release from polycaprolactone (PCL), 20mg (8%) pSi-PCL 
composites and tubing-contained pSi microparticles loaded with A. 1mg 
fluorescein; B. 5mg fluorescein; and C. 10mg fluorescein. Error bars are one 
standard deviation of the mean for daily release over 24 days. 
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At 5mg and 10mg loading, release was equivalent for pSi microparticles, PCL and 
the composite. For pSi microparticles the relationship between fluorescein loading 
and release was linear for the concentrations tested (fig. 4.16), whereas the PCL 
and PCL-composite relationship is second order, showing that the material 
inhibits the elution of fluorescein to some extent. 
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Fig. 4.16. Cumulative fluorescein released over 24 days at each concentration, 
showing a first order rate for pSi microparticles and second order rates for PCL 
and composite. Error bars are standard error of the mean. 
 
 
 
Material     Release rate      Standard Deviation 
  Ƭg.day-1 ƬM.day-1 (%)†  
PCL   5.78  18.0  0.58  ± 39.5 % 
PCL-pSi  4.20  13.0  0.42  ± 52.4 % 
pSi   11.10  34.5  1.11  ± 16.5 % 
 
Table 4.17. Fluorescein release per day for discs of PCL and PCL-pSi composite 
and pSi containing 1mg fluorescein. Release per day was similar for PCL and 
composite but fluctuated (standard deviation shown for data points across 24 
days). pSi microparticles in dialysis tubing released significantly more fluorescein 
initially but became depleted (data shown for first 6 days of experiment during 
linear release). † refers to fluorescein released per day/fluorescein loaded x 100. 
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4.3.2.2. Bovine serum albumin and Alkaline phosphatase. 
 
BSA was released from all polymer/composites but preferentially from PCL-only 
discs (fig. 4.18.A). Doubling the loading concentration (from 5mg to 10mg) 
increased the amount of BSA released into solution by an equal amount (107 ± 17 
Ƭg.day-1 to 223 ± 7 Ƭg.day-1). Release of alkaline phosphatase into solution was 
lower than release of BSA but greatly increased when released from psi-
composites (fig. 4.18.B and fig. 4.20) 
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B.   Alkaline phosphatase release from polymer / composite
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Fig. 4.18. Release profiles of BSA (A) and alkaline phosphatase (B). Error bars 
are standard error of the mean, n = 3. 
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Alkaline phosphatase activity per Ƭg protein was highest across all samples at day 
2 and decreased thereafter. Phosphatase activity was equally decreased across all 
samples at other time points (fig. 4.19) and appeared to further decrease over time 
in both PCL and pSi independently of loading vehicle. 
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Fig. 4.19. The phosphatase activity per Ƭg of alkaline phosphatase released from 
the polymer or composite at each time point. Error bars are standard error of the 
mean, n = 3. 
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Fig. 4.20. Relative release rates of BSA and alkaline phosphatase from each 
material showing the enhanced released of alkaline phosphatase when loaded into 
pSi. Bars show standard error of the mean, n = 3. 
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4.3.2.3. Gentamicin. 
 
Gentamicin was released from PCL and from pSi in PCL into PBS. Gentamicin 
release from pSi was significantly higher than from PCL when 5mg was loaded (p 
= 0.037) and when 10mg was loaded (p = 0.005). In addition, release from pSi was 
proportional to loading concentration, but release from PCL was not significantly 
different at either 5 or 10mg loading (p = 0.074). 
 
Release of gentamicin (MW 447 g.mol-1) from PCL and pSi-PCL was similar to 
the release of similar small, water soluble molecules such as fluorescein (MW 332 
g.mol-1)  (4 - 5 Ƭg.day-1), supporting the hypothesis that such molecules have 
similar release kinetics. 
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Fig. 4.21. Gentamicin release per day over 21 days from discs containing 5 or 
10mg gentamicin in PCL or in pSi-PCL. Bars are standard error of the mean, n=4. 
Statistical significance was determined by Students T-Test compared to PCL as 
the control population. Significant increase p < 0.05 ( ); p < 0.01 ( ). 
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4.3.2.4. Nystatin 
Yeast cells were killed by nystatin released from all polymer and composite discs 
in a broad region throughout the agar plate (fig. 4.22). No gradient was observed 
from the central disc, indicating that the nystatin was released from the exposed 
upper surface into the aqueous surface layer and did not diffuse through the agar. 
Fig. 4.23 indicates high release rates of nystatin from polymer-only discs and 
10mg-loaded 8% composites with much reduced release from composites 
containing 5mg nystatin.  
 
Fig. 4.22. Methylene blue staining of dead yeast cells at day 5. No gradient was 
observed in the area of effect and the region peripheral to the disc did not uptake 
more dye. A. PCL 5;  B. PCL 10;  C. 10 pSi 5; D. 20 pSi 5; E. 20 pSi 
10.  
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Saccharomyces cerevisiae
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Fig. 4.23. Percentage of S. cerevisiae cells killed by nystatin as determined by 
methylene blue uptake. Bars show standard error of the mean, n = 3. 
 
 
 
4.3.2.5. Dexamethasone. 
 
Dexamethasone was loaded into the PCL and pSi-PCL composite in 
concentrations designed to release a daily maximum of 10-6M, 10-7M and 10-8M ± 
50% into solution. Controls show the response of osteoblasts cultured on tissue 
culture plastic (T), PCL and an 8% pSi-composite (pSi) without exposure to 
dexamethasone (labelled -) and also with 10-7M dexamethasone in the culture 
medium (labelled +).  
 
Cultured with or without dexamethasone, osteoblasts grown on tissue culture 
plastic show higher cell populations but lower levels of collagen per cell and lower 
levels of alkaline phosphatase expression, indicating limited osteoblastic 
phenotype (fig. 4.24.A). Cells cultured on both PCL and composite produce 
more collagen and alkaline phosphatase at each time point than osteoblasts on 
tissue culture plastic (fig. 4.24.B and fig. 4.24.C).  
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Fig. 4.24. Effect of dexamethasone release on human osteoblasts. A. DNA. B. 
Collagen normalised for osteoblast population (Ƭg collagen / Ƭg DNA). C. 
Alkaline phosphatase activity normalised for cell population (ALP / Ƭg DNA). D. 
Calcium deposition on the disc surface. Bars show standard error of the mean, n 
= 3. 
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Osteoblasts cultured on dexamethasone-loaded PCL and composites showed 
imilarly, the osteoblast response to PCL or pSi-PCL eluting dexamethasone was 
.3.2.6. Bone morphogenic protein 7. 
o examine the effect of the material surface on osteoblast activity from the 
steoblast populations were significantly lower on the surface of PCL, composite 
steoblasts cultured on PCL, composite and composite-BMP surfaces exhibited 
alkaline phosphatase activity comparable to media-supplemented cells, and 
similarly high levels of collagen. No statistically significant difference was 
observed in collagen deposition or alkaline phosphatase activity at any time point 
for any of the material substrates (thermanox, PCL or pSi-PCL) with or without 
dexamethasone-supplemented media. 
 
S
not significantly different to that of PCL or pSi-PCL with dexamethasone-
supplemented media. No significant difference in calcium deposition at 15 days 
was observed in any condition. 
 
 
4
 
T
behavior of osteoblasts on surrounding tissue culture plastic, the PCL, pSi-PCL 
and BMP-loaded pSi-PCL discs were removed from the wells and analysed 
seperately using the same techniques. 
 
O
and composite materials loaded with BMP7 (fig. 4.25.A) than on tissue culture 
plastic surrounding the material. Osteoblast populations on adjacent tissue culture 
plastic and control wells showed no significant difference across the conditions at 
each time point. Although control well populations appear higher, they were 
equivalent when compared to the sum of well plus composite.  
 
O
significantly more alkaline phosphatase activity than tissue culture plastic (p < 
0.01). Alkaline phosphatase activity was greater on composite and BMP7 than on 
PCL surfaces at day 5 (p < 0.05) but not at day 10. The addition of BMP to the 
composite did not significantly increase alkaline phosphatase activity.  
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Total collagen per well was similar across all samples and slightly higher in pSi-
containing composites. Collagen per cell was significantly higher on composite 
materials than on surrounding tissue culture plastic (p < 0.01). The addition of 
BMP7 to pSi-PCL significantly increased the osteoblast production of collagen at 
ten days over tissue culture plastic (p < 0.01) and PCL (p <0.05) but not 
significantly more than pSi-PCL (p = 0.119). 
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4.4. Discussion. 
 
The aim of this investigation was to assess porous silicon as a carrier for active 
pharmaceuticals in a polycaprolactone matrix for use in orthopaedic tissue 
engineering. In parts 4.2.1 and 4.3.1 a method is described for loading substances 
into pSi using a two-solvent technique whereby the drug in solution is mixed with 
a secondary solvent phase containing microparticles of porous silicon.  
 
In this investigation it was important to determine that the substances were 
actually loaded into pore spaces of pSi and not simply precipitated out of solution 
with the microparticles before being cast into the polycaprolactone matrix. The 
large surface area to volume ratio of porous silicon (~500 m2.g-1) coupled to its 
capillarity and electrostaically charged positive (silicon hydride) and negative 
(silicon oxide) surface regions suggest that substances would be drawn into the 
pore spaces and precipitate on internal (pore) surfaces. 
 
Evidence for this is provided by the sustained release over 7 or more days of 
fluorescein from pSi microparticles which were contained in dialysis tubing. In 
this system, fluorescein continued to be released from the particles over a period 
of several days, even when the particles were thoroughly rinsed with water 
between solution changes. The pSi therefore prevented the fluorescein from being 
immediately washed out of the matrix during these rinses and allowed the 
fluorescein to elute from the material steadily over time in solution. Further 
evidence for this was subsequently provided by CLSM imaging of fluorescein-
loaded pSi particles. 
 
pSi-PCL composites have similar release profiles to drugs loaded into 
polycaprolactone-only for most of the substances tested in this investigation. 
Therefore the results of this research can be directly compared to the wealth of 
published data on polycaprolactone drug delivery devices, microspheres, screws 
and sutures (Wu & Jin, 2008; Varde & Pack, 2004). 
 
The release of small, water-soluble molecules such as fluorescein and gentamicin 
were found to be similar, 6 -12 Ƭg.day-1 for 10mg substance loaded into pSi-PCL, 
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allowing the amount of substance released to be broadly predicted from loading 
concentration. The release of proteins such as BSA and alkaline phosphatase from 
pSi-PCL was more dependent on protein mass and structure, with BSA (MW 66 
kDa) being released into solution in concentrations an order of magnitude greater 
than the very hydrophobic dimer alkaline phosphatase (MW 160 kDa).  
 
Sustained release of all tested molecules from pSi-PCL composites indicates that 
release is both stable and predictable over experimental timescales. Release of 
fluorescein was dependant on initial loading concentration, and was linear over 
time for loading concentrations of up to 50% w/w fluorescein into pSi (10mg 
fluorescein per 20mg pSi). The ability to achieve high loading densities of drugs 
into pSi without altering its physical properties is an advantage of porous silicon 
for drug delivery applications.  
 
The loading of drugs directly into a polymer can change the mechanical properties 
of the material - as described for PMMA bone cement by Lautenschlager et al 
(1976) - but the mechanical properties of pSi-PCL composites are not affected by 
the type or amount of drug loaded into pSi. Therefore, any combination or 
quantity of pharmaceuticals can be loaded into pSi (up to 50% of the pSi) whilst 
the mechanical properties remain the same, an important consideration for 
determining load-bearing, consistency and compliance with safety regulations set 
by the FDA and BSA standards commission. 
 
A further advantage of using pSi carriers for pharmaceuticals is that they can be 
prepared and stored in advance and added to polymers to form composites which 
elute a combination of substances, such as antibiotics, steroid hormones, pain-
killers and growth factors. The combination of drugs and dosages are therefore 
effectively bespoke and can be tailored by pharmacists or physicians to suit the 
patient. Surgeons familiar with preparing their own antibiotic bone cements 
currently use similar techniques as the antibiotic powders are mixed with the 
PMMA powder and formed into a dough. It is conceivable that mouldable or 
injectable polymers containing pSi-encapsulated drugs could be used by surgeons 
in a similar way. 
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Regarding the potential for pSi breakdown products to denature pharmaceuticals, 
the effects of reactive silicon species such as high concentrations of silicic acids, 
hydrated SiO2 and silane on the stability of pharmaceuticals are not covered in the 
literature specifically, although silane is known to be a strong reducing agent. A 
major limitation of polylactide vehicles for drug delivery has been the acidic 
degradation products which are particularly damaging for protein drugs (Wu & 
Jin, 2008). This remains a concern for pSi-based polymer composites as the 
additional acidification caused by pSi dissolution into orthosilicic acid decreases 
the pH of incubating solutions.  
 
The biocompatibility of pSi with organic molecules has been ascertained by 
several research groups (e.g. Bayliss et al, 2000). The effects of silicic acids on 
biological macromolecules have been studied, and as discussed elsewhere in this 
work, Bayliss et al (2000) showed that glycoproteins in the extracellular matrix may 
be crosslinked by siloxane bonds in the presence of silicic acids. 
 
The effects of this on the enzymatic activity of a well-described glycoprotein 
(alkaline phosphatase, ALP) are studied in 4.3.2.2. Activity per unit of eluted ALP 
was measured and found to decrease at a similar rate under all conditions, 
regardless of silicon content. It can therefore be concluded that crosslinking of 
the glycosaminoglycan chains by silicon species, if it occurs, does not adversely 
affect the activity of this glycoprotein in terms of enzymatic dephosphorylation 
ability. In in vitro conditions however, the precise tertiary and quaternary structural 
conformation of the protein may be more essential to its function in ligand 
binding (e.g. Jefferis et al, 1995). 
 
Bone morphogenic proteins are an important family of molecules for advanced 
orthopaedic applications and can be topically delivered to complicated wound 
sites, such as non-union and following substantial bone loss (Dahabreh et al, 
2008). In this investigation, BMP7 was still active upon release from pSi-PCL 
composites and able to stimulate osteoblastic activity in vitro. Based on these 
results it can be concluded that in preliminary trials, protein drugs were not 
denatured by the breakdown products of porous silicon, including heavily 
glycosylated proteins (ALP) and proteins which are functional only as 
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homodimers (BMP7). The polyene antifungal nystatin was also anti-microbrially 
effective following release.  
 
Interestingly, release of BSA from pSi-PCL appeared to be substantially lower in 
comparison to release from PCL alone. The Bradford assay used to detect protein 
in this investigation is also able to detect proteins which are denatured, 
demonstrating that BSA was either not released from pSi-PCL or was bound to 
the material following release. A further examination of this effect is given in 
chapter five (page 172), in which protein interactions with the material surface are 
investigated.  
 
To conclude, porous silicon can be added to polycaprolactone to moderate the 
delivery of various drugs, and in combination with the proposed bioactivity of pSi 
may present a means for increasing the bioavailability and activity of several drugs 
for orthopaedic scaffolds. Based on the results from the present study however, 
the release kinetics from both PCL and pSi-PCL are similar. Advanced techniques 
for drug delivery such as staged release of various pharmaceuticals or easily 
tailored combination therapies may be developed which can make use of the 
advanced properties of pSi.   
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Chapter Five 
5.1. Introduction. 
 
Characterisation of successful biomaterials progresses along well-developed 
routes, from initial studies of behavior in acellular simulated body fluids, to in vitro 
culture of relevant cell types and finally in vivo studies using experimental animal 
models.  
 
Whilst animal models are useful for many applications and an essential 
prerequisite for clinical use and regulation, using animals for initial trials of 
biomaterials is costly, raises ethical issues and also limits the number of samples 
which can be tested. In addition, the reproducibility of the data is questionable, 
and so to overcome this, several groups have reported progress in developing 
simulated in vivo techniques. An example of this are the 4th generation composite 
femurs manufactured by Pacific Research Laboratories (Vashon, USA), which are 
similar in shape, mechanical characteristics, and material density to those of 
human femurs and are used for mechanical testing of hip arthroplasties (Zdero et 
al, 2008).  
 
Such techniques are designed to mimic as closely as possible relevant factors in 
biomaterial testing and has considerable success in describing properties of 
biomaterials that previously would have been difficult to reproduce under 
controlled or in vivo conditions. 
 
This section of the work encompasses the further acellular characterisation that 
was performed on the composite and includes:  
 
 The dissolution of pSi-PCL in simulated static and perfusion bone models.  
 The permeability of the composite to orthosilicic acid and small molecules. 
 Evaluating protein adsorption onto pSi-PCL from simulated plasmas. 
  
This work was performed in order to allow comparisons between features of pSi-
PCL and other composite biomaterials in the literature. 
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5.1.1. Protein adsorption. 
 
Part of the theory behind Bioglass® bioactivity is that the silica and hydroxyapatite 
layers accrued on the surface of the materials provides an adsorption bed for 
biological molecules. In a wound site, certain molecules such as IGF-I (Nakasaki 
et al, 2008), BMP-2, BMP-4, and PDGF-bb (Fiedler et al, 2002) are both localised 
and secreted, acting as chemotactic cues for osteoblast migration, differentiation 
and adhesion. 
 
It has been proposed by several researchers (Kaufmann et al, 2000; Rosengren et 
al, 2003) that binding such molecules to a material surface enhances bioactivity by 
concentrating them on an implant surface and improving wound healing at the 
site. The activity of adsorbed proteins is crucial to their function in a wound site, 
and it has been shown (Lobell and Hench, 1998) that the activity of enzymes such 
as horseradish peroxidase continues following adsorption onto Bioglass®-silica-
hydroxyapatite layers. 
 
Misra et al (2008) showed that micro- and nanoparticles of 45S5 Bioglass® were 
capable of increasing the adsorption of proteins from foetal calf serum (FCS) 
onto poly(3-hydroxybutyrate). The study found that 20% w/w Bioglass® 
nanoparticles were required to significantly increase adsorption, and that this 
needed to be increased to 30% for microparticle-based composites. Soderling et al 
(1996) postulate that the surface energy and protein adsorption of biomaterials 
(specifically bioactive glasses) are directly proportional to their biocompatibility. 
 
The type and function of proteins adsorbed also has a bearing on the effect on 
cell attachment. Whilst many of the proteins expressed in the extracellular 
environment in vitro are likely to be autocrine and paracrine signals from the 
osteoblasts stimulating aspects of activity and growth, other proteins such as 
adsorbed serum albumins may have a negative effect on cell attachment and 
profileration. The effects of protein adsorbtion in vivo in which a larger array of 
macromolecules are abundant may be expected to be considerably more complex. 
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5.1.1. Permeability of polycaprolactone to silicic acid and small molecules. 
 
In this investigation, porous silicon microparticles are combined with 
polycaprolactone to form a biodegradable composite. Polycaprolactone is 
permeable to water, particularly in the non-crystalline amorphous phase (Stevens, 
2001) but the permeability to silicic acid and loaded pharmaceuticals is unknown. 
This is relevant for a number of reasons, chiefly that the thickness and volume / 
surface area for many applications will vary and so the amount of silicic acid and 
loaded pharmaceuticals released should be predictable to enable the correct 
loading dosage to be achieved. 
 
Goodwin et al (1998) report that the delivery of protein drugs from PCL is slow in 
comparison to other aliphatic polyesters. Lu & Lin (2002) attribute this to the 
poor diffusion of hydrophilic molecules through the hydrophobic polymer phase, 
coupled to the presence of non-permeable crystalline regions in the polymer and 
its relatively slow degradation rate. 
 
Consequently, it was necessary to determine the dissolution mode of the pSi in 
the composite. This may be by either surface degradation in which the 
microporous exterior of the material only is permeable to water and dissolved 
molecules, or by bulk degradation if water ingress permeates throughout the 
polymer phase, allowing degradation equally throughout the material. 
 
To investigate this, pSi was loaded with fluorescein and formed into a composite 
as described in Chapter 4. Successive encapsulating layers of PCL were added and 
the release rate of both silicic acid and fluorescein through these layers was 
measured. 
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5.1.2. Composite behaviour in a dynamic perfusion model. 
 
Blood and tissue fluid flow around an orthopaedic implant depends largely on the 
implant type, site and the native physiology of the host tissue and is heavily 
modified by both behavior and pharmacological factors (McCarthy, 2006).  
 
In bone, blood perfusion rates vary enormously due to the varied structure of the 
tissue: from intermedullary spaces and the periosteum in which arterial blood 
pressure determines fluid flow rates, to increasing pressure through narrower 
Haversian and Volkmanns canals. In the canaliculi linking osteocytes the pressure 
is high (and dependent upon variable mechanical loading), but interstitial fluid 
flow rate is relatively low and is regulated largely by the lymphatic drainage system 
in the periosteum (Hillsley & Frangos, 1993).  
 
Therefore it is difficult to ascertain the perfusion rate which a bone implant or 
fixation device would experience in vivo, and also between test subjects, from 
scaling smaller experimental animals (chiefly rabbits) to human patients. From the 
limited literature available, it can be surmised that the flow rates in bone vary from 
300  400 Ƭl.min-1 in rabbit tibial artery (Tu et al, 2000), 2.0ml.min-1.100g-1 in 
rabbit tibial cortical bone (Larson et al, 2008) to 2.29 ml.min-1 in the canine 
femoral periosteum and 6.5 ml.min-1 in the canine ulnar endosteum (Li et al, 1989). 
 
Whiteside et al (1977) also noted that the rate of blood flow in rabbit tibia is 
proportional to osteoblastic activity. Epiphyses with high osteoblastic activity (283 
± 53 Ƭl.min-1.ml-1) had significantly faster blood flow than that in epiphyses with 
minimal activity (97 ± 7 Ƭl.min-1.ml-1).  
 
In this part of the investigation, the response of pSi-PCL composites was 
observed under conditions in which the dissolution volume was continually 
replaced, simulating an in vivo situation such as might be found surrounding a 
fixation screw head or the surface of a healing bone.  
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5.1.3. Bone tissue simulation. 
 
Equal in importance to situations of high rates of fluid flow, the behaviour of an 
eluting biomaterial in a static bone matrix is crucial to its potential success or 
failure as an implant. In clinical situations, many implants are placed directly into 
the bone (screw bodies, bone fillers) where they immediately begin to degrade but 
in which the degradation products are not carried into the bloodstream and 
remain adjacent to the implant where the concentration becomes rapidly increased 
(Liu et al, 2006; Raghoebar et al, 2006).  
 
The rate of clearance of the degradation products is related to the bone 
architecture, and as has been discussed, bone is a complex material with several 
levels of structure on both the macroscopic and microscopic scales. Trabecular 
bone is usually between 50% and 90% porous, with the interstitial spaces filled 
with haemopoetic cells and with a blood supply sufficient to rapidly perfuse the 
implant site with fluid. In this regard section 5.1.2. (ample saturation and generally 
freely-flowing volumes) simulates trabecular and lamellar bone conditions. 
 
Cortical bone, however, is much denser being typically only 5  10% porous. 
Nutrient distribution is effected in cortical bone by a network of inter-connected 
channels, from the longitudinal Haversian canals (20 - 150Ƭm diameter) and 
radiating Volkmann canals (~25Ƭm diameter) to the canaliculi (average diameter 
259nm) that connect individual osteocytes. 
 
Although lamellar and trabecular bone do not form Haversian systems, canaliculi 
are common to all types of mature bone, and represent the smallest and most 
frequent pore size in bone through which a small molecule must pass. Therefore, 
the model chosen to simulate a direct bone-implant interface was to have an 
average pore diameter of approximately 259nm. 
 
To establish a simulated bone model, an agarose hydrogel was used. Agarose is a 
commonly employed hydrogel for molecular biology, used in size-exclusion 
electrophoresis of many molecules including DNA and proteins. This mechanism 
depends on the gelling of agarose producing nanoscale pores within a reasonably 
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narrow range of sizes, and which is furthermore directly related to the 
concentration of the gel (Pernodet et al, 1997).  
 
Following the formula a = Cƣ  [where a is average pore size; C is agarose 
concentration; ƣ is a constant -0.64] it can be derived that an agarose 
concentration of 3.78% will have a mean pore size of 259nm (fig. 5.1).  
 
 
Fig. 5.1. A. Pore size distribution of 3.0% w/v agarose gels. B. Pore size as a 
function of agarose concentration (from Pernodet et al, 1997). 
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5.2. Materials and Methods. 
 
5.2.1. Protein adsorption. 
 
100mg discs of PCL and 8% pSi-PCL were melted on glass slides to produce 
flattened discs 12mm ± 1mm in diameter with a smooth surface. These were 
incubated (n = 4) in 4 ml of either 40 mg.ml-1 bovine serum albumin (Sigma, UK) 
in water or 1 x foetal bovine serum (Sigma, UK) at room temperature for 72 
hours in a sealed 5ml screw-capped polystyrene tube. 
 
After 72 hours the discs were removed, carefully but thoroughly rinsed in dH2O 
and added to 1ml pre-prepared Bradford reagent (Sigma, UK) in a 24-well plate. 
After one hour the absorbance of the reagent at 595nm was read in a 
spectrophotometer. The amount of protein was established by comparison to a 
standard curve of known concentrations of BSA from 7 Ƭg.ml-1 to 120 Ƭg.ml-1, 
prepared in Bradford reagent. 
 
Separately, four 8% pSi-PCL cylinders (500mg ± 50mg) were incubated in 4ml of 
10mg.ml-1 alkaline phosphatase (bovine intestinal mucosa, Sigma, UK) at room 
temperature in screw-capped polystyrene tubes. After 72 hours the cylinders were 
removed, rinsed in dH2O and placed in wells of a 24-well plate. 1ml 4-
methylumbelliferyl phosphate (Sigma, UK) was added and allowed to incubate at 
37°C for 10 minutes. 
 
5 x 200Ƭl of the solution were removed to wells of a 96-well plate and the 
fluorescence measured at an excitation wavelength of 360nm and emission 
wavelength of 460nm. The cylinders were rinsed again in dH2O and the amount 
of protein per cylinder measured as above using the prepared Bradford reagent. 
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5.2.2. pSi encapsulation in PCL layers. 
 
pSi was loaded with 50% fluorescein as described in Chapter 3 and added to 66% 
w/v PCL in acetone to produce an 8% composite. 100mg discs of the composite 
were cut and encapsulated in 1  4 layers of polycaprolactone (fig. 5.2).  
 
Polycaprolactone beads (35-40mg) were melted at 100°C on glass slides using a 
hot-plate and pressed between another glass slide to produce a disc 0.7 mm in 
thickness. pSi-fluorescein/PCL composites were placed on the surface of the PCL 
on the slide and reheated until melted together and a second PCL disc added to 
encapsulate the composite discs  care was taken to ensure no air was trapped. 
The discs were cooled and the process repeated to create discs encapsulated in 1 
to 4 layers of PCL. 
 
Some discs were sectioned to determine the thickness of each layer using a 
dissecting microscope. Intact discs were placed in the wells of a 24-well plate and 
1ml PBS added. The plate was incubated at 37°C for 8 days with the solution 
being changed every 2 days and assayed for silicic acid via molybdenum blue assay 
(section 2.2.2.2.) and fluorescein content by measuring the fluorescence of 200Ƭl 
of the incubation solution at excitation ƫ = 490, emission ƫ = 520. 
 
Fig. 5.2. Method for producing PCL-encapsulated fluorescein composite discs. A. 
50% w/w fluorescein/pSi was prepared in 50:50 ethanol:water and loaded into 
PCL as described in section 2.2.1 (page 50). B. PCL beads (300-350 mg) were 
melted on a hotplate between glass slides and compressed to form 0.7mm thick 
discs. C. Composite discs were encapsulated between two PCL layers at 70°C. 
Encapsulation was repeated to produce discs with one to four surrounding layers.  
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5.2.2. Dynamic perfusion. 
 
25 litres of simulated body fluid were prepared as described previously and stored 
at room temperature in a single reservoir. Six 1g discs were fabricated containing 
PCL or 8% pSi and placed in the base of 10ml syringe bodies which were 
arranged adjacently in a rack.  
 
1mm diameter silicone tubing fed the SBF from the reservoir to the syringe 
bodies via a gravity siphon and the eluent solution was collected in 50ml 
graduated tubes which allowed the flow rate to be calculated (volume/time) and 
silicic acid release to be measured. After 24 hours the discs were removed from 
the tubes, rinsed carefully and assayed for calcium phosphate deposition using the 
Alizarin red S method as described in Chapter 2. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.3. System for testing dynamic perfusion of PCL and pSi-PCL with 
simulated body fluid. 1.0g PCL or 8% pSi-composites were placed in the base of a 
10ml syringe body which was fixed vertically into a rack over a graduated 50ml 
collection vessel. A 25 litre reservoir of SBF was placed slightly above the syringe 
body and connected via a length of 0.1 mm (internal diameter) silicone tubing and 
a flow induced by siphoning the SBF via gravity. Flow rate was adjusted by 
varying the relative height of the syringe rack to be approximately 2.0 ml.min-1.  
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5.2.3. Bone tissue simulation. 
 
3.78g electrophoresis grade agarose was obtained and dissolved in 90ml by heating 
in a microwave oven before being cooled to ~30°C. 10ml penicillin/streptomycin 
solution (Sigma, UK) was then added and poured into 90mm diameter 
polystyrene petri dishes.  
 
Three replicates were produced, with each dish filled to the top with agarose, 
(~5ml agarose). Whilst the agar was still liquid but <40°C, 250mg pSi-PCL discs 
were placed in the centre of the dish. To ensure full immersion, the discs were 
pre-wetted in 50% ethanol : water. When cool, the lids were replaced on the petri 
dishes and sealed with parafilm before being incubated at 37°C.  
 
 
  
Fig. 5.3. Method for analysing silicic acid concentration in agarose gels. A 45° 
radial section is excised from the molybdenum-stained plate and subdivided into 
arcs 5mm in separation. The sections are melted using microwave radiation in 
microcentrifuge tubes and 1ml transferred to cuvettes for spectrometric analysis. 
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The agar was analysed after 7 days using a modified molybdate blue assay. 1 ml 
ammonium molybdate solution (3.5% ammonium molybdate (IV) tetrahydrate 
and 10% concentrated (17M) hydrochloric acid in dH2O) was added to the 
surface of the agar and allowed to perfuse through the agar for 30 minutes at 
room temperature. 5 ml  reducing solution (4g oxalic acid dihydrate,1.33g 4-
(methylamino)phenol sulfate, 0.8g anhydrous sodium sulfite, 20ml concentrated 
sulfuric acid, total volume 200ml with dH2O) was then added and left at room 
temperature for 2 hours.  
 
After this time, the plate was imaged from underneath using a Brother DCP-
560CN scanner. Secondly, a section of the agar was removed and subdivided into 
sections which were solubilised by heating and separated by centrifugation to yield 
a coloured supernatant that could be analysed spectrometrically at 810nm as with 
the standard molybdenum blue assay (fig. 5.3). 
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5.3. Results. 
 
5.3.1. Protein adsorption. 
 
Both polycaprolactone and 8% pSi-PCL adsorbed protein from BSA solutions 
and FCS which was not removed by washing in dH2O. In both cases however, the 
amount adsorbed onto composites was significantly higher than PCL (p < 0.05) as 
shown in fig. 5.4. Adsorption of protein from either source was not significantly 
different per material (PCL, p = 0.11; pSi-PCL, p = 0.28), demonstrating that all 
proteins are adsorbed similarly, and allowing for further comparisons to published 
studies. 
 
Adsorption of alkaline phosphatase onto pSi-PCL was lower than expected, 
although the SA/V of the cylinders was lower than for the discs used in BSA and 
FCS studies.  
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Fig. 5.4. Protein adsorption onto PCL and 8% pSi-PCL from solutions of BSA 
(40 Ƭg.ml-1) and 1 x FCS after 72 hours. Protein adsorption is significantly higher 
on composites in both BSA (p = 0.033) and FCS (p = 0.030). Comparison was by 
Students T-test (bars show standard error of the mean, n = 3). 
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Fig. 5.5. Alkaline phosphatase activity per Ƭg adsorbed protein. The relationship 
is linear (coefficient of determination, R2 = 0.809) over the concentration range 
tested. Y-axis error bars are standard error of the mean (n = 5), X-axis error bars 
are standard error of the mean based on BSA concentration determination, 12% 
of value. 
 
 
Alkaline phosphatase activity correlated with the mass of protein adsorbed onto 
the surface (R2 = 0.809), indicating that the process of adsorption onto the silica 
gel does not denature the protein significantly (fig. 5.5).  
 
 
5.3.1. Encapsulation. 
 
Microscopy of the encapsulated discs showed no visible demarcation between 
layers and that the PCL layers were continuous with the central composite. 
 
Silicic acid release for the unencapsulated disc was 125  180ng.ml-1 per day, as 
predicted from previous studies. When encapsulated in PCL layers, silicic acid 
release is lower but does not decrease as further layers are added (fig. 5.6). 
Fluorescein release is proportional to the thickness of the PCL encapsulation layer 
with levels becoming undetectable when encapsulated in four layers of PCL (fig. 
5.7). 
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Fig. 5.6. Silicic acid release from pSi-PCL composites encapsulated in 1  4 layers 
of PCL (each layer 0.7 mm thick). Error bars are standard error of the mean, n=3 
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Fig. 5.7. Fluorescein release from pSi-PCL composites encapsulated in 1  4 
layers of PCL (each layer xmm thick). Error bars are standard error of the mean, 
n=3 
 
 
 
3.3. Dynamic perfusion. 
 
The flow rate was measured throughout the 24 period and found to be 2.0 ± 0.1 
ml.min-1. Over 24 hours therefore, 2880 ± 288 ml SBF flowed across each disc 
with a volume of approximately 3ml covering the disc continuously.  Silicic acid 
concentrations in the eluent were higher than expected based on data from 
previous static studies with no fluid flow  at 4 hours silicic acid concentrations 
were 223 ± 0.8 ng.ml-1  and slightly lower at 20 hours, 215 ± 0.6ng.ml-1 
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After 24 hours and following drying, the masses of the discs had also changed 
more than expected  PCL discs had lost 0.56 ± 0.09mg (0.05% initial weight) 
and pSi-composites lost 1.2 ± 0.17mg (0.15%). The amount of silicon lost as 
silicic acid over 24 hours can be estimated from the silicic acid concentrations of 
the eluent at 4 and 20 hours, being 0.64 and 0.62 mg respectively. The average 
mass loss due to pSi dissolution (mean composite mass loss  mean PCL mass 
loss) was 0.63mg  approximately the same as can be accounted for by the silicic 
acid in solution. 
 
Calcium deposition was found on both PCL and pSi-composite discs as 
determined by alizarin red staining, with markedly more calcium on discs 
containing pSi (17.5ug) than PCL-only discs (3.5ug).  
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Fig. 5.8. Dissolution characteristics of PCL and 8% pSi-PCL in a continuously 
flowing volume. A. Shows the silicic acid concentration of the eluent collected 
following contact with the composite disc at 4 and 20 hours. B shows that after 
24 hours and following drying, both PCL and composite discs lose mass, with a 
decrease in mass of approx. 0.11% due to silicon dissolution. C shows that the 
mass loss attributable to silicon dissolution is detected as silicic acid in the 
solution. D shows an increase in calcium deposition on composite discs over 
PCL. 
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5.3.3. Bone tissue simulation. 
 
The bone tissue simulation model was partially successful in representing bone 
tissue. Determining the dispersion of silicic acid through the matrix showed that 
in a static environment (no fluid flow), silicic acid dispersed freely through agarose 
gels with an average pore diameter of 259nm as shown in fig 5.9. The 
concentration of silicic acid was found to be linear in regard to radius from the 
centre of the disc (coefficient of regression, R2 = 0.9129) as shown in fig. 5.10.  
 
Fig.5.9. Dispersal of silicic acid through a static agarose gel with 259nm pores, 
stained with molybdenum blue reagent. Dissolution of the disc (A) in the hydrated 
gel is radial from the disc surface along vector, B.  
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Fig. 5.10. Silicic acid concentration in the gel is inversely proportional to distance 
from the surface of the composite disc, measured in mm.  
 185 
Chapter Five 
5.4. Discussion. 
 
Adsorption of proteins onto the surface of Bioglass®-based  biomaterials has been 
postulated as a key method by which they achieve bioactivity (Kaufmann et al, 
2000; Rosengren et al, 2003). 8% pSi-PCL has been shown to significantly increase 
the amount of protein adsorbed from both concentrations of BSA at blood 
plasma concentrations (40 mg.ml-1) and foetal calf serum over polycaprolactone-
only controls. Further, the adsorption of alkaline phosphatase did not denature 
the proteins structure, allowing the complex homodimer to retain phosphatase 
activity when bound to the surface. The adsorption onto PCL-only materials is 
thought to be a result of surface energy or entrapment of the proteins in the 
surface layers of the polymer, and the washing process between incubation and 
testing demonstrated that the proteins were associated with the composite and 
strongly bound. 
 
The behavior of pSi-PCL composites therefore is similar to the established data 
from Bioglass®-based composites, although it is again noted that statistically 
significant enhancement of bioactivity is achieved with a lower percentage 
inclusion of the bioactive phase (pSi vs. Bioglass®).  
 
Encapsulation of the composite in PCL layers shows that both orthosilicic acid 
and small, water-soluble APIs can freely disperse from inside the composite and 
therefore degradation of the composite occurs throughout the material and not 
just at the surface. Release of silicic acid was lowest when encapsulated in one 
layer of PCL, which may be anomalous or possibly due to the way silicic acid 
releases and polymerises in this instance, as will be discussed. Release of 
fluorescein was proportional to the number of encapsulation layers.  
 
As silicic acid is shown to elute freely through PCL, fluorescein was also expected 
to elute in a similar way. The differences between the release profiles for silicic 
acid and fluorescein may be attributed to the relative sizes and solubility of the 
molecules. A measure of solubility in water is the acid dissociation constant (pKa; 
Meissler, 1991), which for fluorescein is 6.4 (www.chemprep.com, 2009) 
orthosilicic acid 9.5 (Canham, 2007) and polysilicic acids >11.4 (Forgács & 
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Cserháti, 1997) which indicates that orthosilicic acid is less soluble than 
fluorescein, and suggests that solubility is not a key factor in the dissolution of 
molecules from within polycaprolactone-based materials. 
 
The molecular weight of fluorescein (332.3 g.mol-1) is considerably higher than 
that of orthosilicic acid (96 g.mol-1), suggesting that molecule size is the limiting 
factor in impeding release from the composite. This is further supported by the 
finding that subsequent layers of PCL do not have a linear effect on the solution 
concentration of orthosilicic acid, as this small acid is freely able to diffuse 
through the layers, whilst larger polysilicic acids are less free to pass through the 
matrix and into solution. 
 
As mentioned in the introduction to this chapter, many of the sites in which a 
bioresorbable device will be implanted exhibit characteristics including high flow 
rates for blood and interstitial fluid. This presents specific challenges to the design 
of the biomaterial, which must be able to tolerate the mechanical stresses of the 
site and potentially enhanced degradation rate and still maintain bioactive 
characteristics. For pSi-PCL composites, degradation rate is not expected to be 
problematic, as data in Chapter 2 demonstrated that pSi dissolution rate is largely 
independent of dissolution volume, and PCL in its native state is sufficiently 
resistant to hydrolytic attack to be stable over several times the projected time for 
which is will be required for mechanical reasons.  
 
The challenge in this situation for pSi relates to the proposed theory of its 
potential for bioactivity, that is in establishing a silica gel / calcium phosphate 
layer on the surface of the material and surrounding tissues (Canham, 1995). In 
static situations, this is affected by the rapid dissolution rate of pSi coupled to the 
low flow rates at the surface of the material. As silicic acids rapidly condense into 
larger silicic acids and eventually precipitate out of solution, a gel is quickly 
formed. However, if the silicic acid solution is rapidly cleared from around the 
material, a silica gel may not form and so the associated bioactivity may be lost.  
 
When compared to previous data obtained from discs incubated in a shaking 
water bath, it can be seen that the amount of silicic acid released from both 
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shaking and flowing systems are similar, 140 ng.ml-1 for shaken solutions and 220 
ng.ml-1  when the solution is flowing. This experiment was designed to test the 
hypothesis using a continuously flowing solution of simulated body fluid and 
shows that even though the amount of silicon lost from the disc is high, calcium 
phosphate rapidly forms on the composite surface. 
 
The amount of silicic acid detected in the eluent was far higher than had been 
expected. Comparable studies in static solutions suggested that a concentration of 
1.4  2.0 Ƭg per day would be generated by the discs tested, whereas a total of 
630Ƭg was recorded. This discrepancy shows that the actual amount of 
degradation undergone by pSi is far higher than previously estimated based on 
static studies, and that the polycondensation back into insoluble polymeric silica is 
similarly high.  
 
Current theories of Bioglass® (and by extension, pSi) bioactivity rely on the 
formation of this silica gel to act as a nucleation bed for calcium deposition (Jones 
et al, 2007). Even though this flow-through experiment converted large quantities 
of silicon into soluble silicic acid and the polycondensation threshold was not 
reached (approx 100 Ƭg.ml-1; Canham 2007), formation of silica gel was implied by 
the increase in mass of the composite discs and the increase in calcium deposition. 
As a significantly greater quantity of calcium was deposited on the composite 
during this experiment, a silicic gel layer is assumed to have developed, acting as a 
nucleation bed for calcium phosphate. 
 
The bone tissue simulation model using an agarose hydrogel was successful in 
demonstrating that diffusion of silicic acids occurs through hydrated porous 
structures. This is an important result, indicating that silicic acids are able to 
diffuse through bone tissue in vivo, even in a cortical setting with limited fluid flow 
and clearance of degradation products. 
 
The methods developed here demonstrate that porous silicon-polycaprolactone 
biomaterials can be successfully evaluated using artificial approaches which 
simulate physiological conditions, and that the adsorbtion of proteins onto the 
surface of these materials are a key aspect of their bioactivity.  
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Chapter Six 
6.1. Introduction. 
 
The physical properties of most biomaterials are crucial to their useful function in 
an in vivo environment, from the essential low-friction surfaces of UHMW 
polyethylene acetabular cups to the supporting strength of a steel orthopaedic 
fixation pin or plate. Composite orthopaedic materials must also support 
biological tissues in a mechanical way even for non-load-bearing applications, and 
for polymer-based materials this can be a challenge due to the far lower strength 
of plastics in comparison to more traditional metal prostheses. 
 
As an added complication, biodegradable materials must be designed to have 
sufficient mechanical strength to function during degradation and over a range of 
normal and excessive load conditions - reflecting the varying height, weight and 
lifestyle of patients - whilst normal tissue function is restored. For bone, this is 
typically considered to be 6-8 weeks (Ham & Harris, 1972) in normal 
circumstances during the formation of a natural callus, but for tissue engineering 
applications and treatment of bone non-union the timescale may exceed this 
nominal range. 
 
Degrading composites therefore must be somewhat over-engineered and capable 
of bearing mechanical loads in excess of those that can be physiologically 
expected, and designed to maintain mechanical function beyond the formation of 
a callus whilst continuing to function as a reactive biomaterial, stimulating bone 
growth. As bone is a strong tissue with excellent mechanical properties, this is a 
complex challenge for material science and has to date limited the use of plastic 
orthopaedic devices to relatively non load-bearing regions such as cranial burr 
plugs, orbital floor supports and jaw fixation. 
 
The application of porous silicon in this investigation also opens the possibilty of 
enabling a novel route for therapeutic electrical stimulation of bone, which has 
been suggested to aid the natural healing of this (Supronowicz et al, 2002) and 
other tissues (Zhao et al, 2006). The electrical and mechanical properties of pSi-
PCL are therefore extremely relevant to this investigation and are reported in this 
section of the thesis. 
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6.1.1. Particle dispersal. 
 
Composite materials derive strength from the combination of tensile strength 
from the polymer phase and hardness/compressive strength from the inclusion of 
microparticles, and so it is important for the materials properties that these two 
phases are correctly or homogenously dispersed (Supova, 2009). Natural 
composites such as bone are structurally highly regulated, and are arranged such 
that the tensile component, collagen, is aligned along stress lines and allow for 
mineral crystals to reinforce the matrix regularly throughout the matrix.  
 
pSi-PCL composites are far less ordered structurally. It is proposed that due to the 
method on fabrication, PCL in the composite is non-crystalline and the 
amorphous phase is composed of polymer chains arranged randomly and without 
crosslinks. The inorganic phase, pSi, is large in comparison to the size of bone 
apatite crystals - 11Ƭm for the pSi used in this investigation in comparison to 
10nm x 0.3Ƭm for bone apatite. 
 
Because of these considerations, it is important that the pSi particles are both 
small in size and within a narrow range of sizes to maximise the distribution of 
pSi in the polymer phase and reduce the number of failure zones  large 
particles/aggregates which reduce the local mechanical properties and can act as 
points at which the material fails mechanically (Yaszemski et al, 2003).  
 
 
6.1.2. Tensile strength 
 
The mechanical properties of several common orthopaedic materials are shown in 
table 6.1 in comparison to bone and cartilage. It is apparent that whilst metals and 
alloys are able to take large mechanical loads even when formed as small pins or 
plates, plastics have much lower tensile strength and are unsuitable for many load-
bearing applications or act as failure points when employed, e.g. PMMA bone 
cement (Allgower & Perren, 1991). 
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Material  Ultimate tensile strength Notes 
          (Mpa) 
 
CoCr Steel  735    28% Cr; 2% Ni; 7% Mo;  
Stainless Steel  600    18% Cr; 14% Ni; 2-4% Mo 
Titanium alloy  900    Ti-6Al-4V 
------------------------------------------------------------------------------------------------------ 
Cortical bone  70  150 
Trabecular bone1  50   
Mandiblea  96.2 ± 40.6   Complete2 
Mandibleb 56 ± 29.6   Trabecular component2 
Cartilage  7  15 
------------------------------------------------------------------------------------------------------ 
Bioglass® (45S5)6 40-60    Bulk 
93.8 ± 8   193Ƭm diamter fibres 
   82 ± 14   280Ƭm diamter fibres 
Monocrystalline Si7 5-9,000 
Hydroxyapatite8 60-80    Sintered at 800°C 
------------------------------------------------------------------------------------------------------ 
PMMA   35 - 50 
Polyethylene  23 - 40 
PLA6   10  70     
PGA6   55 - 58 
Polycaprolactone 5.17  29 3   Block/bulk 
   31.7 ± 4.0 4   Drawn fibre (150Ƭm) 
   16.4 ± 3.9 5   Extruded (500Ƭm) 
PCL/HA (30% HA) 14.2 ± 4.5 5   Extruded (500Ƭm)  
   
Table 6.1. Tensile strength of some common orthopaedic materials, tissues and 
polymers/experimental composites. (from Ratner et al, 2004, and; 1Hollinger et al, 
2005; 2Misch et al, 1999; 3www.ides.com; 4Williamson et al, 2002; 5Kim, 2007; 6De 
Deigo et al, 1999; 7Howatson et al, 1991; 8Ruys et al, 1995). 
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Polymers vary considerably in tensile strength, a property which is dependent on 
the composition of monomers, polymer molecular number/weight and the degree 
of anisotropy in fibre alignment. For bulk polymers, anisotropy is very limited but 
processing techniques can be employed to increase fibre alignment and tensile 
strength, such as fibre extrusion and electrospinning. Thomas et al (2004) showed 
increased tensile strength for polycaprolactone fibres electrospun onto a rotating 
collector to increase fibre anisotropy (table 6.2).  
 
Collector RPM Average ultimate tensile strength (MPa) 
0  2.21  ± 0.23 
300  4.21 ± 0.35 
600   9.58  ± 0.71 
 
Table 6.2. Increasing collecter RPM results in greater fibre anisotropy and causes 
an increase in tensile strength along the orientation of the fibres (from Thomas et 
al, 2004). 
 
 
For the majority of biomedical applications, plastic and composite orthopaedic 
fixation materials are subject to tensile forces, particularly in screws and fixation 
plates. Larger orthopaedic devices such as hip or knee prostheses and long bone 
fixation plates are unsuitable for replacement by current polymer-based materials 
as the cyclic loads and high forces they must endure cannot be tolerated by 
polymers over the 10-20 year life of the implant (Granchi et al, 2006).  
 
Polymer-based composites, therefore, are most usefully applicable as supports for 
tissue regrowth in maxillo-facial applications and as such the mechanical 
properties of the implant are of less concern, although should be sufficient to 
resist deformation under normal and occasional excessive loading forces. Fig. 6.3. 
shows a typical stress-strain curve for a polymer (or polymer-based composite), 
indicating the key aspects of response to strain by extension. The main indicators 
of resitance to deformation are elastic (Youngs) modulus, the elastic limit and 
maximum load. 
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Fig. 6.3. Typical stress/strain curve for a polymer (or polymer-based composite) 
showing yield stress (point at which elastic deformation becomes plastic 
deformation), ultimate stress (the maximum stress the material can withstand), 
ultimate strain (the percentage strain at ultimate stress) and the Youngs modulus 
(the linear component of the stress/strain coefficient below the yield point). 
Failure for polymers is typically by a process referred to as necking, in which the 
cross sectional area of the sample is reduced due to plastic flow of the material 
along the stress line (Considére, 1885).  
 
 
The mechanical properties of currently described polymer-based biomaterials vary 
widely, depending on both the choice of polymer / non-polymer phase and the 
methods of fabrication and testing. Most commonly in the literature, 
biodegradable aliphatic polymers such as PLGA and less frequently PCL and 
PHB (polyhydroxybutyrate) are used as inert, degradable carriers for bioactive 
particles, such as HA microparticles or Bioglass® (Lee et al, 2008; Jukola et al, 
2008; Papatheofanis, 1989). 
 
Lee et al (2008) showed that the addition of 5% and 10% HA in the form of 
100Ƭm particles to PLGA increased the ultimate tensile strength from 1.89 (± 0.4) 
MPa to 3.4 (± 0.3) MPa and 3.9 (± 0.37) MPa respectively, whilst additions of HA 
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beyond this proved detrimental to yield strength, as 15% HA reduced ultimate 
yield strength to 1.77 ± 0.1 MPa.  
 
Similarly, Papatheofanis (1989) showed an increase in the bone-bonding strength 
of isobutyl-2-cyanoacrylate (adhesive) from 8.33 (± 0.41) MPa to 12.03 (± 0.72) 
MPa upon the addition of 10% HA, decreasing to 7.89 (±0.58) MPa when 15% 
HA was added. This strengthening of a polymer fibre with an inorganic phase is 
similar to the enhanced tensile properties of minerilised against non-mineralised 
collagen fibrils (fig. 1.12.B).  
 
Jukola et al (2008) demonstrated that by including Bioglass® fibres (diameter 31-
43Ƭm) to a 30:70 starch/PCL blend, the tensile strength can be increased from 
16-18 MPa (without Bioglass®) to 26-29MPa with 10% w/w Bioglass®.  
 
The mechanical properties of composites therefore can be made to exceed those 
of the components, although careful selection of particle size, shape and polymer 
anisotropy remain important considerations.  
 
 
6.1.3. Electrical conductivity. 
 
The tissues comprising a living organism naturally generate electrical fields as a 
product of chemical activity across membranes and through the transduction of 
mechanical forces. These electrical fields have been shown to play an important 
role in wound healing from the initial disruption of normal cellular interactions 
and leakage of tissue fluid electrolytes to the stimulating electro-mechanical forces 
which influence the extracellular matrix as the tissue returns to function (Zhao, 
2008). 
 
The mechanisms underlying this process are poorly understood but appear to be 
numerous, with several tissues reported to benefit from electrical stimulation 
during healing.  Zhao (2008) indicates that the local electric fields vector towards 
an epithelial wound site, acting on epithelial cells via EGF receptors, integrins, V-
ATPase proton pumps, and PI3 kinase/Pten (the cell compass molecules which 
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determine polarity for chemotaxis) and stimulating migration to the wound site. 
Interestingly, it has recently been shown (Zhao et al, 2006) that electrical fields are 
capable of over-riding other directional cues for cell migration, including 
chemotactic gradients.  
 
The electrical fields in wounds are caused by disruption of the transepithelial 
potential and vary in magnitude according to the site, being determined by the 
activity of the neighbouring cells in maintaining the surrounding potential. A 
corneal wound was observed by Chiang et al (1996) to generate 42 mV.mm-1, 
whereas in guinea pig dermal wounds a steep, lateral voltage gradient falls from 
140 mV.mm-1 at the wound edge to 0 mV.mm-1 just 3 mm laterally to the wound 
edge on the skin surface (Jaffe et al, 1984).  
 
An additional factor is present in bone - as the tissue loads and unloads a pulsatile 
current is established through the tissue. This can be attributed to two sources: 
hydroxyapatite peizoelectricity, and more significantly the flow of electrons along 
hydrated collagen fibrils and through cannaliculi (streaming potentials). This 
mechanism has been proposed to be part of the mechanism by which Wolffs 
Law is effected in bone (Beck et al, 2002), and so has been a target for research 
into advanced treatments for bone repair. The electrical properties of bone have 
been shown to differ according to site and bone type, as demonstrated by the 
variation in skull plate morphology and resistivity in table 6.4. (Tang et al, 2008). 
 
Skull morphology  Resistivity (ƙ.m) 
Standard trilayer   79    ± 17   
Quasi-trilayer     144   ± 30   
Standard compact   265   ± 53   
Quasi-compact    198   ± 32   
Dentate suture    57   ± 17   
Squamous suture   127   ± 41 
  
Table 6.4. Tang et al (2008) show that electrical resistivity of skull fragments 
(flaps removed during surgery) varies according to bone structure. 
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In vitro, osteoblasts have been shown to respond favourably to alternating electric 
currents. Supronowicz et al (2002) showed a 46% increase in osteoblast 
proliferation after 2 days culture with 10 ƬA at 10Hz for 6 hours per day. A 307% 
increase in the concentration of extracellular calcium and upregulation of mRNA 
expression for collagen type-I was observed after 21 days. 
 
Interestingly, similar enhancement effects in wound healing are shown for low-
intensity pulsed ultrasound (LiPUS) such that the two techniques are often 
compared in the literature and used interchangably in clinical practices to treat 
non-unions. With a typical burst width of 200 microseconds, comprising a 1.5-
MHz sinusoidal waveform with a repetition rate of 1 KHz and a spatial average 
temporal intensity of 30 mW.cm-2 applied to bone non-unions for 20 minutes 
daily, LiPUS treatment has a similar profile to the application of alternating 
currents and is proposed to work via the same electromechanical route. 
Papthedourou et al (2009) show that using 1 MHz at a pulse repetition rate of 1 
kHz and with 30 mW.cm-2 for 20 min on rabbit tibial condyl, biglycan and 
collagen I mRNAs are significantly upregulated. 
 
Artificial stimulation of bone to treat non-union by pulsatile electrical fields has 
been studied extensively, and is commonly performed at frequencies of 15 MHz 
(reviewed in Walker et al, 2007) and over long time periods, typically 12-16 hours 
per day for up to 4 months. 
 
A literature review of clinical applications by Mollon et al (2008) shows that 
electrical stimulation has a positive benefit on quickening the onset of callus 
formation on but effects on treatment of non-unions do not show a significant 
benefit. Despite this lack of clinical evidence, numerous devices have been 
developed for employing electrical fields in wound repair, particularly for bone 
healing, with approximately 600 US patents covering this topic (February 2009).   
 
Stimulation of osteogenesis by such devices has generally been performed by 
semi-invasive or transcutaneous methods, such as the direct current bone growth 
stimulator marketed by Zimmer of Warsaw (Indiana, USA) and licensed under US 
patent number 3842841. In this system, several needles are inserted through the 
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skin into a bone fracture, acting as cathodes. An anode pad is externally situated 
adjacent to the fracture and a direct current applied using an external power 
source.  
 
Electrical stimulation of bone directly via conducting biomaterials is a promising 
way of exploiting the potential healing effect. As biomaterials act as support 
scaffolds for bone repair, they can be connected in situ to a current which can be 
applied directly or magnetically induced in a non-invasive way. However, as the 
majority of biodegradable polymeric and composite tissue engineering materials 
are non-conducting, research in this area has been limited. Table 6.5. provides a 
comparison of electrical resistivities for some common materials, showing the 
range of conductivity and that most orthopaedic biomaterials (bioactive glass, 
polymers, etc.) are electrically insulating. 
 
Material    Resistivity (ƙ.m) 
Gold1     2.44 x 10-8 
Iron1     1.00 x 10-7 
Bone (cortical)3   876 
Polyurethane4     1012 
Polyesters4    >1018    
Silicon1     640 
Glass1,2     1010  1014 
SiO2 (fused quartz)1   7.5 x 1017 
Carbon nanotube (single walled)5 10-6 
Pyrrole co-polymers6    104 
 
Table 6.5. Electrical resistivity (ƙ.m) for a range of materials from good 
conductors (eg. Gold), to insulators (eg. Polyesters). From 1Serway, 1998; 
2Griffiths, 1999; 3Faes et al, 1999; 4Warfield & Petree, 1961; 5Frank et al, 1998; 
6Rivers et al (2002). 
 
 
Silicon, however, is a semi-conductor with universal applications throughout 
electronics, and porous silicon has been evaluated by numerous groups 
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researching its unusal electrical properties which diverge from bulk silicon 
(reviewed in Willoughby, 2006). Most carbon-based polymers are electrically 
insulating and so forming a composite from PCL with a porous silicon phase 
forms a material with unknown electrical properties. The potential therapeutic 
benefits of a conducting orthopaedic biomaterial in terms of generating a natural 
response from native bone cells are sufficient that research along these lines is 
worthy of  pursuit. 
 
 
6.1.4. Aims. 
 
The aims of this part of the investigation therefore were to: 
 
 Determine the dispersal pattern of pSi through the polymer phase of the 
composite. 
 
 Measure the tensile strength of a range of composites. 
 
 Determine the electrical resistance of a range of composites and determine 
if the addition of pSi enhances the conductance of the material. 
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6.2. Materials and Methods. 
 
6.2.1. Particle Dispersal. 
 
To determine the dispersal of pSi microparticles within the polymer matrix, pSi 
was loaded with 50% w/w fluorescein (in 50:50 water/ethanol) prior to 
incorporation into the polycaprolactone-based composite as described in chapter 
4 to create final concentrations of 0.2% and 12% w/w pSi in PCL. Fluorescein-
loaded microparticles and fluorescein powder were added to 2.5g PCL in solution 
with acetone (2.5ml acetone, 2.5g PCL) with either 5mg (0.2% w/w) or 150mg 
(12%) pSi in composites. 5mg fluorescein was also added to 2.5g PCL without pSi 
as a control. 
 
The composite was formed into a 50 x 10mm cylinder and sectioned into five 10 
x 10mm discs to enable both the size and dispersal pattern of the particles to be 
observed, and determine that dispersal is equal throughout the cylinder and that 
particles do not settle during casting. The discs were imaged using confocal laser 
scanning microscopy. 
 
Images were processed using Volocity software (Improvision, Coventry, UK) to 
determine particle dispersion over a 5 -100% intensity threshold for background 
fluorescence, filtered using a 3 x 3 (x3) kernel filter (excluding objects smaller than 
3 voxels) and expressed as volume (Ƭm3).  
 
6.2.2. Tensile Strength. 
 
Tensile strength of the composite was tested using either a) an I-shaped melt-cast 
specimen produced from a custom-made mould or b) a cylindrical specimen cast 
in a 1ml polypropylene syringe body (fig. 6.6).  
 
Polycaprolactone-only casts were tested against 10mg (per 250mg PCL; 4%) and 
20mg (8%) pSi-PCL composites (70% pSi, standard grade). Composites were 
produced by mixing pSi particles with melted PCL without solvent to avoid 
weakening the material and evolving solvent gases during casting. The composite 
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was milled and cast in either mould at 120°C by adding small quantities of solid to 
the melted surface to minimise the occurance of air bubbles and voids in the 
finished cast. 
 
 
Fig. 6.6. Two specimen types were developed for testing mechanical properties: 
A. An I-shaped melt-cast specimen produced from a custom-made mould. B. A 
cylindrical specimen cast in a 1 ml polypropylene syringe body. 
 
 
The cast samples were fitted into a 50 KN load cell in an Instron 5569 Tensile 
Testing System to test a 20mm region of the sample. Samples were fitted into 
grips which were moved apart at 2.0 mm.min-1 until fail. Maximum load and 
tensile stress at maximum load were measured. 
 
Elastic modulus was calculated from the stress-strain curve using the formula 
     E =   F . L0 
   A0 . ƅL 
Where E is elastic modulus; F is Force (N); L0 is sample length (m, at T0); A0 is 
cross sectional area (m2, at T0) and ƅL is the change in sample length (m) 
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6.2.3. Electrical resistance. 
 
5ml of a 5% agarose gel were made by adding 250mg agarose (sigma, UK) to 5ml 
dH2O in a 50ml polyproplylene centrifuge tube. pSi was added in percentage 
quantities of 2, 4, 6, and 8% by weight (50mg = 1%) and the the vessels  heated in 
a microwave until the agar had dissolved. Screw caps were replaced to minimise 
evaporative distortion of mass but not screwed tight.  
 
After cooling for 20 minutes, the solution/suspensions were heated again and 
allowed to cool before being drawn into a 1ml polypropylene syringe. The 
syringes were layed horizontally and allowed to set at room temperature. The ends 
of the syringe were removed to leave the graduated section filled with the 
hydrogel, with the hydrogel dimensions being 4.6 mm (diameter) x 60.2 mm 
(length). 
 
Electrodes of a handheld multimeter (Extech DM110) were inserted into each 
end to a uniform 5mm depth (marked on the electrode tip) and the resistance of 
the hydrogel measured over 50 seconds, with readings taken from the multimeter 
every 10 seconds to provide an average value.  
 
Resistivity (Ʊ) was calculated by the formula: 
Ʊ = R x A 
                  l 
Where R is resitance (ƙ), A is cross-sectional area (m2) and l is length (m). 
Polycaprolactone-pSi composites were tested for electrical conductivity in several 
ways, by fabricating thin sections and up to 20% w/w pSi-PCL composites. pSi-
PCL composite cylinders measuring 4.6mm (diameter) x 60mm (length) in this 
[pSi] range were soaked in dH2O for 5 days and the resistance measured across 
the length of the cylinder. 
 
Resistance of polycaprolactone was measured but was found to exceed the range 
of the multimeter. 
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6.3. Results 
 
6.3.1. Particle dispersal. 
 
pSi particles at the surface of 1mg composites were evenly distributed with a 
particle size of 5-20Ƭm, particle aggregates were present but not of a large size 
(fig. 6.7). 20mg composites displayed a similarly well dispersed pattern, aggregates 
were present but appeared uniformly distributed between the top and bottom of 
the fabricated cylinder. 
 
 
Fig. 6.7. Confocal micrographs showing the dispersal pattern of fluorescein in a 
polycaprolactone-pSi composite. A and B show discs created by adding 
fluorescein directly to PCL in acetone (A and B, respectively the top and bottom 
of cylinder). C and D are discs created by adding a low concentration of 
fluorescein-loaded pSi (0.2% w/w) to the matrix (C = top of cylinder, D = bottom 
of cylinder). E and F show discs with high concentrations of pSi (12% w/w; E = 
top of cylinder, F = bottom of cylinder). Scale bar is 300Ƭm. 
 
 
Adding fluorescein directly to PCL in solution in acetone results in a uniform 
distribution of the dye. Importantly for drug delivery applications, fluorescein was 
associated with the microparticles and did not leak out of the particles to the 
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surrounding polymer during manufacture or storage, even when exposed to 
humidity in the air on the cut surfaces. 
 
 
Fig. 6.8. Magnification of fig. 6.5.E showing particle dispersal of 12% 
composites. 
 
 
The volume occupied by pSi was difficult to precisely determine due to the 
conjunction of pSi in the polymer. As the particles were closely packed a 5% filter 
was applied to the analysis to eliminate the lower values of fluorescence and enabe 
the particles to be evaluated. Using this approach, the volume occupied by pSi was 
established (fig. 6.9). 
 
Whilst the distribution of particles appears to be homogenous using microscopy, 
detailed finite element analysis reveals that the concentration of pSi in the top and 
bottom of cylinders differs, with significantly fewer particles at the base of 
cylinders (B columns in fig. 6.9). 
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Fig. 6.9. Volume of pSi in composite, error bars are standard error of the mean. 
 
 
 
6.3.2. Tensile strength. 
 
The custom designed mould A produced materials with poor physical properties, 
having a visible cross-sectional casting meniscus which necessitated sanding to 
remove and numerous small voids throughout the tested region causing 
premature failure at low loads. Consequently all tensile data was obtained from 
cylindrical moulds, B, which had very few voids and were cross-sectionally 
uniform throughout the tested length. 
 
Fig 6.10 shows the stress-strain curve of an 8% composite, annotated to show the 
main features of the curve, including the linear phase and failure mode. All tested 
specimens had similar profiles as illustrated in fig. 6.11. The elastic modulus was 
calculated for the linear portion of the curve in each case. The ultimate tensile 
strength is the maximum strength of the material in MPa, the maximum load is 
the maximum force in N withstood (fig. 6.12). 
 205 
Chapter Six 
 
Fig. 6.10. Typical stress-strain curve of composite (8% pSi) showing the locations 
on the curve of the proportionality limit beyond which stress/strain is non-linear 
and below which Youngs modulus is calculated; the ultimate (or yield) stress, and 
the beginning and mode of failure. 
 
 
Failure of the samples was adjascent to the grips and was by plastic deformation, 
known as necking, as the cylinder stretched into a region with lower cross-
sectional area - fig. 6.14. shows specimens following failure by this route. Samples 
which snapped or failed at a void were not included in the data set (3 out of 15 
samples, total) shown in fig. 6.15.  
 
Maximum load and yield strength for 10mg composites was not significantly 
different to PCL, although the mean values decreased slightly with increasing pSi 
content. The gradient of the linear phase (y/x) of the stress-strain curve was 
greater for composites and this is reflected in the calculated elastic modulus of the 
specimens. The elastic modulus (E) was highest for 8% composites (89.87 ± 5.75 
MPa), followed by 4% composites (79.62 ± 7.94 MPa)  both significantly higher 
than PCL-only (43.36 ± 5.47 MPa), with p = 0.011 (4%) and 0.0011 (8%).   
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Fig. 6.11. Example stress-strain curves for PCL, 4% and 8% pSi-PCL composites. 
Curves are offset to allow comparison. 
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Fig. 6.12. Tensile strength of PCL and PCL-pSi composites (4% and 8% pSi). A 
shows maximum load at fail (ultimate strength). B shows yield strength (stress at 
which material strain changes from elastic to plastic deformation, causing 
permanent deformation). Error bars are standard error of the mean, n=4.  
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Fig. 6.13. Elastic modulus of PCL, 4% and 8% pSi-PCL calculated from the 
gradient of the stress-strain curve below the elastic limit. Error bars are standard 
error of the mean, n = 4.  
 
 
 
Fig. 6.14. Failure mode of tensile testing specimens was by necking, plastic 
deformation as polymer strands are drawn along the stress line. The failure region 
is indicated, ƹ.  
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Fig. 6.15. Sections through the test samples (8% pSi-PCL) show that some air 
bubbles still exist (A) which act as starting points for mechanical failure. Image B 
shows the failure region of a sample which snapped in the load cell (and was 
therefore not counted in the results) showing regions of polymer fibre stretching 
around a large number of voids. 
 
 
 
6.3.3. Electrical resistance. 
 
The electrical resistance of 5% agarose hydrogels was found to be 1.246 ± 0.81 
Mƙ without porous silicon. The addition of 2% w/w pSi to the hydrogel lowered 
the resistance by an order of magnitude to 172 ± 2.9 Kƙ. Increasing the 
concentration of pSi from 2  8% in the hydrogel lowered the resistance of the 
material in a linear way (coefficient of linear regression, R2 = 0.9611, n=5) up to 
8%. 
 
The process used to make the discs, coupled with the reactivity of pSi in warm 
aqueous phases generate bubbles in the hydrogel which had to be dispersed by 
triteration as the gel cooled and prevented the testing of higher concentrations of 
pSi.  
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pSi (%)  Resistivity (Kƙ.m) 
0  34.53 ± 2.25 
2  4.76 ± 0.08 
4  4.19 ± 0.03 
6  2.55 ± 0.40 
8  0.86 ± 0.69 
 
Fig. 6.16. Resistivity of the hydrogel decreases in direct proportion to the 
percentage of pSi in the gel, from 2-8%, coefficient of linear regression (R2) = 
0.9611.  
 
 
Polycaprolactone-pSi composites were tested under various conditions for 
electrical conductivity, including very small/thin sections of 20% pSi-PCL but the 
resistance was higher than could be measured (> 40 Mƙ). Degraded or soaked 
composites with water in the polymer matrix were also tested, but also had 
resistance greater than the testable range.  
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Fig. 6.17. Resistance of pSi-agarose hydrogels was inversely proportional to the 
concentration of pSi, and was linear in the range tested (coefficient of regression, 
R2 = 0.9611). Error bars are standard error of the mean, n = 5.  
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6.4. Discussion. 
 
Determination of particle size and distribution can be a challenge for many 
composite materials, with techniques such as X-ray diffraction being employed 
(Cui et al, 2007), or simply by allowing automated admixing to occur for several 
hours prior to casting, such that homogeneity is inferred (Lee et al, 2008). Usefully, 
pSi microparticles can be loaded with fluorescent dyes to allow them to be 
microscopically visualised, enabling the size range and dispersal of the particles to 
be determined. 
 
It has been shown that the method developed here for forming pSi-PCL 
composites is able to create homogenously dispersed materials with reasonably 
anisotropic distribution of the particles throughout the polymer phase. Further, 
the particles are not aggregated and the size range observed is within the 
parameters of the particles that were used. This result is a fundamental 
justification of the results obtained in this investigation, particularly in the sections 
regarding electrical and mechanical properties which depend on composite 
composition. 
 
Due to the number of techniques for determining biomaterial mechanical 
properties, no standard method is available. This is also reflected in the 
widespread use of the term tensile strength which is commonly cited in the 
literature without clarification. Tensile strength may refer to elastic/yield strength, 
ultimate strength or breaking/fracture strength (all quoted in MPa) all of which 
may be used to determine the materials properties but which refer to specific 
points on the the stress/strain curve.  
 
It is important to understand at this point the application to which biomaterials 
are put, and therefore determine which definition is most descriptive in reflecting 
the biomaterials properties and suitability for internal use. For fixation 
applications, ultimate strength may be considered critical, particularly for 
orthopaedic screws which must secure fixation plates. Alternatively, fracture 
strength (resistance to breakage) may be used, although for ductile materials and 
cold-worked steel fracture toughness is implied by the design. Finally, yield 
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strength  the stress at which the materials elastic limit is reached and plastic 
deformation occurs is a useful way of measuring tissue engineering scaffold 
usefulness, as these materials are chiefly implanted to restore 3-dimensional 
structures to a normal physiological size and shape. 
 
In this investigation, the yield strength is reported. This aspect of the 
polymer/composite was considered to be useful in describing the mechanical 
properties of pSi/PCL as it reflects the point at which each composition 
permanently deforms. The failure mode was found in practice to be through 
polymer dislocation, or necking (Kinloch & Young, 1995) as the failure region 
was drawn into a fibre with smaller diameter; test samples which failed by 
fracturing at a void are not included in the results and amounted to 3 out of 15 
cylinders tested. Voids may have been decreased by use of vacuum in the 
preparation of composites as is now commonly used for the preparation of 
poly(methyl methacrylate) bone cements for prosthesis fixation (Lidgren et al, 
1984). 
 
It is seen from the results that increasing the concentration of pSi to 4%  in the 
composite does not adversely affect the tensile strength, but at 8% a small 
decrease in yield strength is observed. Decrease in tensile properties of the 
material are proportional to the decrease in continuity of the polymer phase, and 
so increasing the particle : polymer ratio decreases the tensile strength 
proportionally. This effect is not observed to be linear, however, due to the 
complex interaction of both phases and the elastic accommodation of stress 
forces - in accordance with the Poisson effect which describes the way in which 
molecules interact under stress (Lakes, 2008).  
 
pSi-PCL composites are significantly more resistant to deformation than PCL as 
shown by the relative gradient of the stress-strain curves in and reflected in the 
higher elastic modulus of composites. This is important in resisting deformation 
to sudden or prolonged loading, particularly in restoring shape in reconstructive 
surgery, a major application for which these composites are being developed.  
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It is therefore determined that the addition of up to 8% pSi to PCL does not 
adversely affect the tensile properties of the composite and increases the 
resistance to deformation. The 8% composites have been shown to elute silicic 
acids, form a surface calcium layer and stimulate osteoblastic activity in cultured 
cells. The abilty for the composite to achieve this is at a considerably lower level 
of particle inclusion than other materials in the literature, such as Bioglass® - 30% 
Chouzori and Xanthos (2007) to 50% Venugopal et al (2008) - allows the 
composite to combine enhanced bioactivity with greater physical strength. 
 
Addition of pSi to 5% agarose gels lowers the materials overall electrical 
resistance by a significant amount but the conductance of the pSi-PCL 
composites are still too low for useful medical applications. 
 
Alternative polymers to PCL may be considered for the composite, however, and 
several groups have achieved success in creating electrically conducting, 
biodegradable polymers for biomedical applications. Rivers et al (2002) fabricated 
a biodegradable copolymer based on pyrrole  thiophene monomers linked by 
hydrolysable ester bonds. Enhancing the bioactivity of such polymers could be 
achieved by the addition of porous silicon to form a composite. When considered 
alongside the additional benefits of drug-delivery and mechanical strengthening, 
pSi-composites with an already conductive polymer are an attractive proposition. 
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Chapter Seven 
The aims of this thesis were to assess the suitability of porous silicon  
polycaprolactone composites for orthopaedic tissue engineering applications. 
Porous silicon was suggested as a potential biomaterial by its known similarity to 
bioactive glass, dissolving in simulated body fluids to release bioavailable soluble 
silicate species and spontaneously forming a calcium phosphate layer on the 
surface of nano-porous silicon wafers. 
 
Since the discovery of silicons essentiality to bone biology by Carlisle (1974) and 
the role that silica and soluble silicates play in the orthopaedic bioactivity of 
Bioglass® (Hench, 2006), research has focussed on the chemistry and biology of 
silicon in calcified tissues. This research has demonstrated that silicon has at least 
two separate effects on bone biology in nature: interacting with 
glycosaminoglycans and the GAG component of proteoglycans, and substituting 
for phosphorus and carbon in the crystal lattice structure of bone mineral. 
 
In addition, the dissolution products of bioactive glass which include soluble 
silicic acids have an effect on the molecular biology of osteoblasts in vitro, 
significantly up- or down-regulating the expression of several genes including key 
osteoblastic markers (Xynos et al, 2001). Localisation of silicon in the body has 
been identified to the growing areas of bone by electron microprobe analysis 
(Carlisle, 1972) and imaging ion microscopy (Landis et al, 1986). Furthermore, 
several studies have detected silicon within osteoblasts (Carlisle, 1975 & 1976), 
possibly in mitochondria and in other intracellular organelles. 
 
There is substantial evidence therefore that the release of silicic acid from 
Bioglass®-based biomaterials forms the basis of their bioactivity. Porous silicon  
which dissolves in water to form silicic acid as its only degradation product  is 
therefore a good candidate for biomaterials applications that require bone-
bonding and enhancement of osteoblastic activity. Like Bioglass®, porosified 
silicon has poor mechanical properties, particularly in comparison to bone and to 
existing orthopaedic implant materials such as stainless steel and titanium; this is 
even more apparent as the material dissolves. 
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To create a usable biomaterial therefore, porous silicon was formed into a 
composite with polycaprolactone (PCL), a polymer with existing uses in 
biomaterials and surgery, and which degrades over a period of 1  2 years in vivo 
through hydrolysis of its monomers. This approach has previously been used to 
form bioactive glass  polycaprolactone composites by Chouzori & Xanthos 
(2007) and Jiang et al (2006). Crucially,  these bioactive glass  polymer composites 
contain a relatively high proportion of Bioglass®, e.g. 30% - 50% by weight 
(Chouzori & Xanthos, 2007; Venugopal et al, 2008) and 40% in polylactide 
(Blakker et al, 2003). 
 
This high level of inclusion generates some bioactivity, although Chouzori & 
Xanthos (2007) indicate that the bioactivity is less than might be expected. Also, 
since the polymer phase functions in the composite to lend mechanical 
(particularly tensile) strength to the material, reducing the proportion of polymer 
lowers the mechanical strength of the material.  
 
In chapter two, it was shown that porous silicon can generate high levels of silicic 
acid in solution from relatively much smaller amounts of pSi, with composites 
containing 8% porous silicon in PCL releasing more than twice as much 
orthosilicic acid into solution than 8% bioactive glass-PCL composites. This 
ability to generate silicic acids from much smaller amounts of the bioactive 
component is a key advantage of pSi over Bioglass®. 
 
Research in porous silicon is ongoing in several disciplines, with substantial 
progress being made in the opto-electronic applications of the material (Canham, 
1997). For biological applications, the required properties were essentially 
unknown, and so the effect of silicon porosity and the size of particles in the 
composite was investigated.  
 
At pSiMedica, several porosities of pSi were created, hand-milled and sieved for 
evaluation in composites, from 49% porous to 82% porous with 38  150Ƭm size 
range. These particles were used for initial trials, but it was decided that greater 
uniformity and a smaller size range was required and so in subsequent 
experiments a standardised 70% porous silicon was used with 11Ƭm particles in a 
 216 
Chapter Seven 
narrow size range. This was also found to have the most beneficial effect on 
osteoblasts in vitro. 
 
Once the most appropriate porosity and particle size had been determined, the 
biodegradable polymer phase was considered. Polycaprolactone was chosen as the 
polymer phase for the reasons outlined in the introduction to chapter one, chiefly 
that the polymer has a slower degradation time than polylactides and 
polyglycolides. For many applications, degradation in excess of two years may be 
excessive, but co-polymerisation with more rapidly degrading polymers such as 
PLA or PGA can reduce this to a tailored timescale. 
 
It was found that the release of silicic acids from polycaprolactone, poly(D,L 
lactide-co-glycolide) and poly(3-hydroxybutyrate-co-hydroxyvalerate) was similar 
but not identical, attributed to the differences in surface chemistry, of the 
polymers. The degradation rate of PLGA was also significantly increased by the 
addition of pSi to the material, causing full degradation of two out of three 
samples tested within 8 weeks, compared to > 12 weeks for PLGA alone. 
 
Biodegradable polymers such as polycaprolactone are currently used in clinical 
applications, such as in resorbable screws, but concerns over the acidic 
degradation products and their affect on surrounding bone necrosis and 
resorbtion have limited their use in practice. Acidosis inhibits bone formation and 
stimulates osteoclastic resorbtion of bone (Frick and Bushinsky, 2003), and so 
limiting the acidification of orthopaedic wounds is important in designing 
degradable implants. As a material designed to elute orthosilicic acid, this was a 
concern from the beginning of the investigation.  
 
Whilst composites of PCL, PHBV and PLGA with pSi lowered the pH of 
incubating solutions, the composites were shown to stabilise the solutions over 
time, with volumes incubating composites increasing in pH after 8 weeks rather 
than decreasing. This is thought to be due to the polycondensation of silica which 
eliminates silicic acid from solution. 
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Porous silicon composites with polycaprolactone were shown to be effectively 
fully permeable to water, allowing the degradation of porous silicon and the 
release of silicic acids from throughout the polymer, as determined by the linear 
relationship of solution Si concentrations to the size of the composite.  
 
As the composite degrades, porous silicon dissolves to initially form orthosilicic 
acid. Orthosilicic acid is stable up to concentrations of ~ 2 x 10-3 M (Iler, 1979), 
approximately 56 Ƭg.ml-1 [Si], at which concentration it polycondenses into 
increasingly higher weight polysilicic acids which have correspondingly lower 
solubility. Silicic acid octomers are effectively insoluble in water (Iler, 1979) and 
condense to form a silicate gel layer on the surface of the material.  
 
In this investigation, the silicate gel layer was quantified by the mass gain caused 
by the deposition of this silica gel and found to be directly proportional to the pSi 
content of the disc. Scanning electron microscopy cross sections through the silica 
layer show it to have a pronounced internal architecture, with perpendicular 
striations between solid outer layers and indicating that silica chemistry continues 
following deposition.  
 
Several researchers (e.g. Hench, 2006) have suggested that the silica gel layer 
formed on the surface of bioactive glass-based materials acts as a nucleation bed 
for calcium phosphate, which is shown to spontaneously precipitate out of 
acellular simulated body fluids (SBFs). Porosified silicon wafers are also shown to 
spontaneously nucleate calcium phosphate from SBF on the surface of the wafer 
(Canham et al, 1996). The question of calcium phosphate nucleation on pSi-PCL 
composites was addressed.  
 
Calcium phosphate was detected on composites incubated in acellular simulated 
body fluid and found to be proportional to pSi content of the disc. Scanning 
electron microscopy operating in wet environmental mode (samples not coated), 
showed the calcium phosphate has the characteristic morphology of biological 
apatite, with a Ca:P ratio of ~1.5. The Ca:P ratio was proportional to the pSi in 
the disc, with increasing pSi in the disc resulting in a lower proportion of 
phosphate in the crystal. Due to the higher amount of silicates in the system here, 
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it is proposed that the apatite in these cases is silicate substituted (for some 
phosphate and carbonate).  
 
In chapter three, the response of human osteoblasts to porous silicon was 
evaluated by culturing the cells in vitro on porous silicon  polycaprolactone 
composites. Separately, the effect on osteoblasts of pSi-PCL degradation products 
and orthosilicic acid in the growth media was tested. 
 
As has been discussed, the physiological requirement for silicon and the bone-
bonding effects of Bioglass® are attributed to both stabilisation of the collagen 
and glycosaminoglycan components of the extracellular matrix and silicate 
substitution for phosphate and carbonate in the calcium phosphate crystalline 
structure in matrix mineralisation.  
 
The first stage in this investigation was to determine the response of osteoblasts 
to a range of porous silicon  polycaprolactone compositions and to observe the 
effect of pSi-porosity/degradation rate on cells in vitro. The results of this analysis 
show that 54% and 66% porous silicon microparticles do not appear to 
significantly enhance the proliferation or osteoblastic phenotype; whereas 82% 
microparticles degrade so rapidly the resulting accumulation of degradation 
products and effervescent hydrogen evolution is effectively toxic to cells. 
 
70% porous silicon particles in a smaller particle size range (11Ƭm rather than 38 
 150Ƭm) proved to be more compatible with osteoblasts, stimulating the 
progression of the osteoblast from de-differentiated and dividing preosteoblast-
like cells to mature secretory cells. Osteoblasts cultured on the surface of 8% w/w 
pSi-PCL composite discs produced significantly more collagen at 10 days in vitro 
than osteoblasts cultured on either PCL or tissue culture plastic. In addition, these 
cells were associated with a more than two-fold increase in glycosaminoglycan 
content of the extracellular matrix, which may be due to increased production of 
GAGs by the osteoblasts or by stabilisation of the ECM by soluble silicate 
species. Crosslinking of collagen by pyridinoline was demonstrated to be greater 
in the presence of porous silicon. 
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To examine the effect of the soluble degradation products of pSi on osteoblasts, 
porous silicon microparticles were added to cell culture medium to generate a 
solution containing known concentrations of silicic acid. When applied to 
osteoblasts, concentrations of silicic acids from 1  5 Ƭg.ml-1 appeared to increase 
the proliferation rate of cells and also their metabolic activity in terms of collagen 
production. Previous research has shown that silicic acid-releasing zeolite A has 
similar effect on osteoblasts, increasing the rate of proliferation in densely seeded 
cells by the autocrine TGF-Ƣ route (Keeting et al, 1992).  
 
This data supports previous studies which suggest a bioactive range of orthosilicic 
acid to be 280 ng.ml-1 to 2.8 Ƭg.ml-1 (Reffitt et al, 2003; Arumugram et al, 2004), 
although it was found that silicon supplementation of up to 25 Ƭg.ml-1 also had a 
positive effect on osteoblastic activity in vitro. In this investigation, 
supplementation with orthosilicic acid from sodium metasilicate generated a 
similar cell response to conditioning media with silicic acids released from pSi 
dissolution. Interestingly, there was effectively no significant increase in calcium 
deposition when cells were cultured in even high concentrations (up to 100 Ƭg.ml-
1) of silicic acid, indicating that a substantial silica gel layer is not formed to act as 
a nucleation bed for mineralisation. 
 
The bioactivity of Bioglass®- and pSi-based materials arises from two separate 
sources therefore: the silica-conditioned surface of the material which acts as a 
nucleation bed for apatite-like mineralisation, and the soluble silicate species 
which interact with the extracellular matrix.  
 
A major focus in porous silicon research and the core technology of pSiMedica 
Ltd. is the use of pSi microparticles as delivery vehicles for active pharmaceuticals 
(and radiotherapy agents). Substantial data exists in house at pSiMedica for the 
loading and release kinetics of a variety of molecules, and similar research at the 
University of California, San Diego (Anglin et al, 2008) has been published. 
However, the somewhat more complicated release kinetics of pSi microparticles 
embedded in polycaprolactone were unknown. 
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The aim of chapter four was to assess porous silicon as a carrier for active 
pharmaceuticals in a polycaprolactone matrix and evaluate the release kinetics of a 
range of substances from small organic molecules to large, enzymatically active 
glycoproteins. A method was developed for loading substances into pSi, derived 
from the technique used at pSiMedica, in which the substance is dissolved in a 
solvent  wherever possible an organic solvent such as ethanol or acetone. A 
combination of the large surface area of pSi and capillarity of the narrow pores 
adsorbs the substance onto the pore surface.  
 
To combine these substance-loaded particles with polycaprolactone, the polymer 
was dissolved in acetone and the microparticles added and stirred to distribute. At 
this point, the treatment of the composite was identical to non-loaded 
composites, although excess heating was avoided. Drug loading into the pSi 
microparticles was subsequently proved by confocal laser scanning microscopy of 
porous silicon microparticles loaded with fluorescein, which showed the 
fluorescein to be fully associated with pSi microparticles. 
 
The subsequent release of small, water-soluble molecules such as fluorescein and 
gentamicin were found to be similar, 6 -12 Ƭg.day-1 for 10mg of each substance 
loaded into pSi-PCL, allowing the amount of substance released to be broadly 
predicted from loading concentration. The release of proteins such as bovine 
serum albumin and alkaline phosphatase from pSi-PCL was more dependent on 
protein mass and structure, with BSA (MW 66 KDa) being released into solution 
in concentrations an order of magnitude greater than the very hydrophobic dimer 
alkaline phosphatase (MW 160 KDa).  
 
It was found that drugs loaded into pSi-PCL composites have similar release 
profiles to drugs loaded into polycaprolactone-only for most of the substances 
tested in this investigation. Therefore the results of this research can be directly 
compared to the wealth of published data on polycaprolactone drug delivery 
devices, microspheres, screws and sutures (e.g. Wu & Jin, 2008; Varde & Pack, 
2004). Some substances, such as alkaline phosphatase and gentamicin were aided 
into solution by pre-loading them into pSi. Crucially, the activity of alkaline 
phosphatase was unchanged following release from pSi, demonstrating that 
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although such large glycoproteins may be crosslinked by silicates generated in pSi 
dissolution (Bayliss et al, 2000), the enzymatic activity was not affected. Release of 
other substances, such as bovine serum albumin, appeared to be lower, although it 
was subsequently found that significant amounts of BSA in solution are adsorbed 
onto the surface of pSi-PCL composites.  
 
Adsorption of proteins onto the silica gel surface of Bioglass®-based  biomaterials 
has been postulated as a key method by which they achieve bioactivity (Kaufmann 
et al, 2000; Rosengren et al, 2003; Perry, 2009). In chapter five, 8% pSi-PCL was 
shown to significantly increase the amount of protein adsorbed from both 
concentrations of BSA at blood plasma concentrations (40 mg.ml-1) and foetal calf 
serum over adsorption onto polycaprolactone-only. Further, the adsorption of 
alkaline phosphatase did not denature the proteins structure, allowing the 
complex homodimer to retain phosphatase activity when bound to the surface.  
 
In discussing drug-releasing polymers used for orthopaedics, the most widely used 
such material - antibiotic-eluting bone cement - is considered. Poly(methyl 
methacrylate) bone cement (PMMA) has a long history of use in fixation of 
orthpaedic implants and arthroplasties, and has been loaded with aminoglycoside 
antibiotics such as gentamicin for revision treatment of infections almost since its 
inception. As a potential application of pSi drug delivery microparticles in chapter 
seven PMMA was loaded with fluorescein and added to PMMA. It was found that 
the pre-loading of fluorescein into pSi enhanced the release of the molecule by an 
order of magnitude over loading of fluorescein directly into PMMA. As is shown 
in chapter four, the release rates of gentamicin and fluorescein are very similar, 
indicating that the addition of up to 8% pSi microparticles will enhance the 
delivery of antibiotics in orthopaedic fixation whilst maintaining the bone-
bonding strength of the cement. 
 
In the experiments described above, porous silicon  polycaprolactone 
composites were incubated in water, PBS or SBF in a static system, i.e. the fluid in 
the experiment was neither circulated nor shaken. This is clearly not 
representative of the conditions an implant would experience in vivo, and so a 
 222 
Chapter Seven 
series of simulated bone models were established to test the behaviour of the 
composite. 
 
The results of exposing pSi-PCL to continuously flowing simulated body fluid 
was similar to that of incubating composites in a shaken water bath  under 
conditions of fluid flow, the release of silicic acids into solution is 200  300 times 
greater than in static systems. Interestingly, despite the increase in silicic acid 
removal from the solution (which did not exceed the 2 x 10-3 M orthosilicic acid 
stability threshold proposed by Iler (1979), a silica  calcium layer was formed on 
the surface of the material within 24 hours. 
 
In regard to the permeability of bone in vivo to silicic acids, an agarose hydrogel 
was successful in demonstrating that diffusion of silicic acids occurs through 
hydrated porous structures with pore sizes similar to those of canaliculi (259nm).  
 
In chapter six, the mechanical properties of the composite are compared to those 
of PCL alone. Numerous studies have been performed on potential and existing 
orthopaedic materials, but for the applications we are considering and the nature 
of the material, it was determined that tensile yield strength and elastic modulus 
were the most important components of the material which we wished to test. It 
was found that there was no significant difference between the tensile strength of 
PCL-only and 4% composite, but 8% composites were less strong. The failure 
mode of these materials was all identical  plastic deformation, or necking  but a 
larger number of the 8% composites failed by fracturing. Closer examination 
revealed these fracture regions to contain voids  effectively air bubbles 
introduced during fabrication. Several techniques were attempted to reduce the 
number and size of these microscopic voids but they remained a persistent 
problem in mechanical testing experiments. 
 
The other mechanical properties of the material were good. Whilst not explicitly 
tested, the hardness of the material (resistance to indentation) appeared to be 
greater than PCL  this is supported by the gradient of the stress-strain curves 
produced in mechanical testing experiments and reflected in the higher elastic 
modulus of composites. This is important in resisting deformation to sudden or 
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prolonged loading, particularly in restoring shape in reconstructive surgery, a 
major application for which these composites are being developed.  
 
Further mechanical testing is reported in the appendix to this thesis, in which 
potential applications of the composite material are considered. At an early stage 
in this investigation, it was decided that a potential use of this material would be 
in bioactive resorbable screws. Currently used screws for orthopaedic fixation are 
made from either titanium or stainless steel, with a small market for polylactide 
based resorbable screws which are supplied in the UK by Inion Ltd., Finland, but 
these screws are not bioactive. 
 
Whilst the development of novel polymer blends for optimised mechanical 
strength were far beyond the remit of this investigation, the effect of adding pSi 
microparticles to simple polycaprolactone screws was examined. Two moulds 
were used for fabricating screws  a purpose designed mould based on the size 
and thread profile of stainless steel screws marketed by SmitMedimed Pvt. Ltd. 
(Ahmadabad, India), and a stainless steel nut with internal threads. This latter 
mould was required for mechanical testing because it was found that the small 
diameter screws were too flexible and the threads too weak for use  supporting 
concerns voiced by surgeons consulted in this work (Mr Ian McVickar, Clinical 
Orthopaedics, University of Nottingham, UK).  
 
The push-out strength of the composite screw from the nut-mould was not 
significantly different to polycaprolactone up to 8% pSi inclusion in the material, 
demonstrating that further research in using pSi to render resorbable polymer 
screws bioactive would be worthwhile.  
 
In the introduction to chapter six, research is reported that indicates a role of 
electrical stimulation on bone healing. Whilst the clinical evidence for this is still 
both ambiguous and debated, a large number of researchers have focussed on this 
as a means to increase fracture healing rates and treat bone non-union. As the 
most important electrical semiconductor of the modern age, silicon and porous 
silicon were proposed to be beneficial in lowering the resistance of polymeric 
materials with the aim of creating an electrically conductive implant that can be 
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connected to an external power source and provide enhanced healing of the 
surrounding bone.  
 
In practice, the extremely high resistivity of the polymer remained too high for 
successful measurement (>1018 ȍ.m), but proof of principle was obtained by 
adding pSi microparticles to an agarose hydrogel. The addition of 2% pSi to 
agarose gels lowered the resistivity of the gel by an order of magnitude. pSi 
inclusion in the gel was then found to inversely proportional to resistance, such 
that the addition of 8% pSi lowered the resistivity of the gel from (34.53 ± 2.25 
Kƙ.m to 0.86 ± 0.69 Kƙ.m).  
 
Whilst polycaprolactone remains prohibitively resistive, several groups have 
achieved success in creating electrically conducting, biodegradable polymers for 
biomedical applications. Rivers et al (2002) fabricated a biodegradable copolymer 
based on pyrrole  thiophene monomers linked by hydrolysable ester bonds. The 
effect on the addition of porous silicon to these polymers in terms of their 
electrical conductivity and bioactivity would therefore be interesting to determine. 
 
In summary, porous silicon is potentially a very useful inclusion in 
polycaprolactone composite materials, able to outperform bioactive glasses in the 
release of bioavailable silicates and the spontaneous deposition of apatite-like 
minerals. Porous silicon stimulates the activity of osteoblasts in vitro and evidence 
suggests it enhances the stability of the extracellular matrix through crosslinking 
its component molecules and adsorbing serum proteins such as growth factors 
onto the cell substrate.  
 
As a drug delivery vehicle, porous silicon increases the rate at which small 
molecules and hydrophobic proteins are released into solution, whilst maintaining 
their biological and enzymatic activity. Other proteins such as bone serum 
albumin were effectively adsorbed onto the materials surface, a useful 
characteristic which could localise both drug-loaded and native growth factors to 
the osteoblast-supporting surface of the material.  
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The above characteristics were all achieved by composites containing no more 
than 8% porous silicon by weight, far lower than Bioglass® in comparable 
composites. The incorporation of porous silicon into polymers therefore forms 
excellent and useful biomaterials for orthopaedic tissue engineering. 
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1. Introduction. 
 
In this investigation, porous silicon-polycaprolactone composites have been 
evaluated for applications in orthopaedic tissue engineering, with the degradation 
and bioactivity characteristics tested and the material properties identified. 
Throughout this work, attention has been given to the potential applications of 
this technology, allowing the material to be tested in the most appropriate ways 
and reflecting the genesis of the project as a combination of empirical academic 
research and industrial sponsorship.  
 
This approach is becoming increasingly favourable in the field of biomaterials 
research and tissue engineering, as the number of patented biomaterials increases 
and companies are established to exploit this technology in relevant biomedical 
niches. With this in mind, at an early stage in the project the potential applications 
of pSi-PCL composites were researched and discussed, initially with Professor 
Leigh Canham and Dr Susan Anderson, and subsequently with consultant 
orthopaedic surgeons, Miss Brigitte Scammell (orthopaedic fixation), Mr Iain 
McVicar (maxillofacial reconstruction and fixation), and Dr Roger Bayston 
(antibiotic-eluting biomaterials). 
 
The most relevant applications for pSi-composites based on analysis of the 
current (2009) orthopaedics market were therefore considered to be: 
 
 Porous scaffolds for maxillo-facial reconstruction. 
 Biodegradable screws for plate fixation. 
 Enhancing the bone-bonding ability of bone cement. 
 
This appendix describes the preliminary research that was performed to assess the 
suitability of pSi-composites for these applications and describes the methods that 
were developed for creating 3-D porous scaffolds, biodegradable fixation screws 
and bioactive pSi-PMMA bone cements. 
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1.1. 3-Dimensional porous composites for tissue engineering.. 
 
For a material to function as a tissue engineering scaffold for therapeutic or 
reconstructive use it is essential that a network of inter-connected pores is 
available through the material through which osteoblasts can migrate and deposit 
extracellular matrix (reviewed in Stevens et al, 2008).  
 
The pore size diameter required to allow passage of osteoblasts and 
vascularisation is considered to be >300-500Ƭm (Chen et al, 2008), with the 
accompanying porosity required to be at least 60% in order for sufficient bone to 
grow to take transferred stresses as the resorbable scaffold degrades in strength. 
To enable osteoblast ingress through the material the pores must be continuously 
interconnected as pores forming internal voids do not permit tissue ingrowth and 
significantly weaken the material.  
 
A large array of techniques have been developed to porosify biomaterials, ranging 
in technical complexity from aeration of the polymer during formation to 
supercritical fluid degassing and rapid prototyping (Stevens et al, 2008), illustrated 
in fig. 1. Use of porogens such as salt or sugar crystals embedded in the matrix to 
create a two-phase composite is a common and inexpensive technique: as the 
salt/sugar phase is soluble in water, soaking of the composite results in the 
porogen being released into solution, leaving pores in the material with the 
dimensions of the porogen (e.g. cubic for salt crsytals). 
  
Problems with salt leaching are that the porogens, even when loaded in high 
density, are not contiguous and many crystals are left behind following leaching. 
Additionally, as shown in fig. 1.A, the cubic dimensions of the pores are not 
ideally suited to osteoblast colonisation  rounded, tubular pores with regular 
diameters and interconnections are preferable for vascularisation and tissue 
deposition in the scaffold (Stevens et al, 2008). 
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Fig. 1. Techniques used for porosifying biomaterials range from low-technology 
methods such as a) NaCl salt leaching from PLGA1 , b) sintering of 
hydroxyapatite and titanium microparticles2, and c) emulsification of PLGA 
containing 20% Bioglass®3,  to more advanced, controllable methods such as d) 
inkjet printing of collagen4, and e) computer controlled melt-plot rapid 
prototyping using polycaprolactone5. From 1The Royal Society of Chemistry 
webpages; 2Marcelo et al, 2006; 3Costa et al, 2007; 4Yeong et al, 2006; 5Park et al, 
2008.  
 
 
In this investigation, mostly two-dimensional composites have been tested, i.e. 
bulk materials without any internal architecture and with only exterior surfaces to 
support cell attachment and growth. To create three-dimensional materials with a 
network of internal spaces for cell ingrowth, a number of porogenic techniques 
were applied and evaluated, including: 
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 Sucrose leaching 
 Starch leaching 
 Inulin (a carbohydrate) 
 Gelatin granule leaching 
 PCL-Poly(vinyl alcohol) emulsion/admix 
 
It was determined that these techniques, whilst successful in developing pores in 
the material, resulted in an uninterconnected network and so subsequent 
development of 3-D materials focussed on the creation of a dissolvable pore 
template. In these experiments, rapidly soluble polymers were employed to create 
a solid negative of the pores, such that the casting of PCL or composite around 
the template and subsequent washing would result in a porous material with 
interconnected internal spaces (fig. 2). 
 
Fig. 2. Porosification using a soluble pore template. 1. Pore template is formed 
using a variety of methods, 2. PCL/composite is added either melted or in 
solution with acetone, 3. The template is removed by washing, leaving a 3-D 
network of interconnected pores. 
 
 
Several soluble pore templates were trialed, all of which were chosen for their 
solubility and ease of being drawn into fibres or deposited as strands, including: 
 
 Porcine skin collagen 
 Poly(vinyl alcohol) 
 Polymerised sucrose (caramel) 
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When heated to 170°C, sucrose undergoes caramelization, a series of complex 
reactions which results in a molten polymer which can be stretched or spun into 
fibres. A traditional use of this polymer has been to create spun sugar meshes and 
lattices for confectionery, meshes which comprise a network of strands which 
overlap, forming an interconnected mesh with strands 50-100 micrometers in 
diameter. 
 
This part of the investigation outlines  experiments which were performed to 
evaluate this method for porosifying PCL-based composite biomaterials.  
 
 
1.2. Composite orthopaedic fixation screw. 
 
Orthopaedic fixation is traditionally by means of stainless steel or titanium pins 
and screws, manufactured in a range of sizes to suit all applications from fixing 
long bones such as femur to attaching small plates in paediatric maxillo-facial 
surgery (Allgower & Perren, 1991). Metal screws can be manufactured in a wide 
range of shapes and sizes and tailored to quite specific uses and are regulated in 
the UK by Section 5 of British Standard BS 3531 (fig. 3). For plate fixation in 
maxillo-facial applications, however, metal screws are generally very similar, 
having the basic profiles illustrated in fig. 4. 
 
Fig. 3. Cross section of a standard (4mm) cortical bone screw with asymmetrical 
thread and spherical under-surfaces, based on the British Standard BS3531 
[British Standards Institution, Implants for osteosynthesis. Part 5, Bone screws 
and auxiliary equipment. Section 5.3, specification for the dimensions of screws 
having hexagonal drive connection, spherical under surfaces and asymmetrical 
thread, BSI, London (1991)]. From Zhang et al (2006). 
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Interest in using biodegradable screws has developed due to the potential for 
overcoming serious problems in metallic fixation, including the complications 
arising from the persistence of metal screws or the requirement for subsequent 
removal, interference with bone healing or interference with tissue growth and 
function, particularly in paediatric fixation (Moisala et al, 2008; Cavusoglu et al, 
2005).  
 
Fig. 4. Examples of small stainless steel orthopaedic screws manufactured by 
Smit Medimed Pvt. Ltd. (Ahmedabad, India) suitable for maxillo-facial fixation 
which formed the basis for the screw designed for this investigation. 
 
 
As such, numerous resorbable or integrative devices have been developed, 
patented, trailed and authorised for clinical use, including: 
 
 Screws manufactured from de-cellularised bovine or human cortical bone 
(Haje & Volpon, 2006) 
 Fully resorbable polylactide screws (marketed by Inion) 
 Polylactide-Hydroxyapatite/ Bioglass® composite screws (Lewandrowski et al, 
2002; Berry, 2008) 
 
Of the commercially available bioresorbable polymer screws, those marketed by 
Inion Ltd. (www.inion.com Tampere, Finland) have been most successful in the 
UK (discussed with Mr Iain McVicar, consultant oral and maxillofacial surgeon, 
Queens Medical Centre, Nottingham, UK) with a variety of screw and plate 
combinations available for almost all small fixation applications and authorised for 
use in National Health Service hospitals.  
 
Inion use a combination of four polymers  trimethylene carbonate (TMC), L-
polylactic acid (LPLA), D,L-polylactic acid (DLPLA) and polyglycolic acid (PGA) 
to create a co-polymer with optimised degradation and strength. The development 
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of a specific polymer blend is beyond the remit of this investigation, but the 
addition of pSi to a generalised polymer such as polycaprolactone provides an 
insight into the change in mechanical properties of the resulting polymer-
composite, with applications in enhancing the bioactivity of existing polymer 
blends for fixation. 
 
The tensile properties of composites are particularly important in fixation 
applications using screws, and those of pSi-PCL are discussed in Chapter 6. An 
important parameter  with regard to orthopaedic screws is push-out (or pull-out) 
strength  the force required to evict a screw from the plate or bone (Zhang et al, 
2006) which is also a measure of the materials shear strength, resistance to 
torsional forces during implantation and thread stability.  
 
Lewis et al (2008) and Windham et al (2008) show that in some applications, use of 
a polylactide-based screw is advantageous over the use of titanium or steel, as the 
tissue (in both cases laryngeal cartilage) is not stripped by metal screw threads 
when longitudinal forces are applied. Comparisons between titanium and 
resorbable screws (Lewis et al, 2008) showed that this increases the linear pull-out 
force required to remove the screw. 
 
This part of the investigation covers the work that was done in identifying the 
parameters of resorbable screw design and evaluates the effect of adding porous 
silicon to PCL on push-out strength of screws from a mould. 
 
 
1.3. Poly(methyl methacrylate) bone cement. 
 
Certain orthopaedic devices, particularly total knee and hip arthroplasties are 
secured in place using a bone cement based on poly(methyl methacrylate) 
(PMMA) to fix the artificial components to the living bone. However, this 
approach has become increasingly unfavourable for several reasons: 
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฀ The cement acts analogously to grout, forming a filler in spaces between 
the implant and the bone and is a common location for loosening of the 
implant and subsequent failure. 
฀ The cement is not osteoconductive and is non-porous, so no bone 
ingrowth secures the prosthesis. 
฀ Microfractures and bubbles in the cement create localised weaknesses in 
the join which can lead to failure. 
฀ During revision, the bone cement has to be chiselled out and replaced, 
leaving a much larger space to fill in subsequent implantations. 
 
These factors lead to the development of an alternative approach which involved 
surgeons drilling a slightly too small hole and using physical force to secure a 
titanium implant in place, as titanium is capable of bonding directly to the 
surrounding bone (Allgower & Perren, 1991). This technique has found less 
success in knee arthroplasty however, where the components of the artificial joint 
need to be securely fixed to the outside edges of the bone. Additionally after a 
decade of clinical use it was found that the failure rates of cemented and non-
cemented prostheses were similar (Hedley et al, 1987). Cemented prostheses are 
still favoured for most applications, particularly in elderly, osteoporotic patients 
and those undergoing undergoing revision. 
 
Despite the wide use of PMMA, the cement composition has remained largely 
unchanged since its clinical inception 30 years ago, being primarily poly(methyl 
methacrylate) (also known commercially as Perspex or acrylic) with residual 
polymerising agents (benzoyl peroxide and N,N-dimethyl-para-toluidine - DMPT) 
as well as barium sulphate to render the cement X-ray opaque.  
 
The cement is delivered to surgeons as a kit, composed of 40g powdered PMMA 
containing benzoyl peroxide and barium sulphate, and a liquid phase composed of 
20ml MMA monomer and DMPT. The liquid is added to the powder and mixed 
under vacuum to minimise air bubbles and injected into the implant site where 
polymerisation takes place to harden the cement, accompanied by an increase in 
temperature to ~50ûC.  
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Gentamicin- and other aminoglycoside- loaded bone cement was first used 
clinically in the 1970s, less than a decade after poly(methyl methacrylate) (PMMA) 
itself was first applied in prosthesis fixation (Gardner & Medcraft, 1974). The 
loading ratios and release kinetics of aminoglycoside-bone cements have been well 
characterised over the last four decades and the mechanical properties of adding 
such substances evaluated (Lautenshlager et al, 1977). Commercial products such 
as Depuy 1 Gentamicin Bone Cement (Depuy Orthopaedics, USA) and 
Simplex (releasing tobramycin, Stryker Orthopaedics, USA) contain 1g 
gentamicin mixed into the 40g powder component of the cement (approximately 
1.5% final concentration, w/w). Clinicians may choose to add gentamicin 
separately to the PMMA and favour a high-loading of gentamicin, commonly 
>9% w/w loading and up to 20% for treatment of active infections in revisions 
(Lautenshlager et al, 1977). 
 
PMMA bone cement is not biodegradable, osteoinductive or permeable to water 
and consequently only a small percentage of the antibiotic is released into the 
wound site in a burst release following would closure. PMMA is also weaker than 
bone in terms of tensile and compressive strength, but it has been found that 
addition of low-doses (up to ~9%) of antibiotics do not adversely affect the 
mechanical properties of the cement and indentation resistance is actually 
increased (Lautenshlager et al, 1977). The primary concerns with antibiotic-
releasing cements is developing an immune response to high-doses and the 
possibility of gentamicin-resistant bacterial infections developing. 
 
The quantity of antibiotic released is difficult to assess however, as the surfaces 
and flow rates of fluid around the wound are highly variable in each case. An 
additional complication is presented during prosthesis revisions as high doses of 
gentamicin have been found to be released as the PMMA bone cement is chipped 
off during removal of the implant (Powles et al, 1998). This can complicate further 
antibiotic treatment as systemic dosages must be recalculated with this in mind. 
 
To comply with ISO 5833:2002 (Lee, 2005), for set and cured acrylic bone 
cements with or without antibiotics or other inclusions, cement must meet or 
exceed the following specifications: 
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 Compressive strength  70 MPa 
 Bending modulus  1800 MPa 
 Bending strength  50 MPa 
 
Fig. 5. shows results from Lautenschlager et al (1976) comparing the compressive 
and tensile strength of increasingly higher doses of gentamicin in bone cement. 
This figure shows that whilst the mechanical properties are not dramatically 
affected up to 5g (~8-9% w/w), higher doses of antibiotics in the cement cause 
the material to fail the ISO standard. 
 
Despite this approach, bone cement is a poor releaser of antibiotics as it is non-
permeable to water, therefore antibiotics are only released from the surface in a 
large single dose lasting several days (Lee et al, 2005). A drug-loading mechanism 
which provides for a slower, more controlled release of antibiotics is 
advantageous, providing it can be shown that the mechanical properties of the 
cement are not lower than for a given quantity of antibiotic directly loaded into 
the cement. 
 
Compressive and tensile strength of gentamicin-PMMA bone cement
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Fig. 5. Compressive and tensile strength of PMMA bone cement loaded with 
gentamicin (adapted from Lautenschlager et al, 1976). ISO 5883 standard 
minimum compressive strength is 70 MPa, indicated by the horizontal line.  
 
 
Porous silicon may be a useful material to include in bone cement as not only has 
it been shown to gradually elute the aminoglycoside antibiotic gentamicin 
(Chapter 4), it also forms an osteoconductive coating to materials, enhancing the 
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rate of bone repair and may act to form a boney bridge from the living bone to 
the implant surface (fig. 6). 
 
 
Fig. 6. Schematic of anticipated action of bone cement containing pSi/gentamicin 
microparticles. Immediately following implantation the silicon begins to oxidise in 
the aqueous environment, releasing silicic acids which condense into a silica gel, 
trapping growth factors and forming a bed for mineral deposition.   
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2. Materials and methods. 
 
2.1. Fabrication of 3-D scaffolds. 
 
Several methods for porosifying PCL and pSi-PCL using water-soluble particulate 
and mesh-formed porogens were tested: 
 
2.1.1. Particulate porogens. 
 
10g PCL was dissolved in 5 ml acetone at 40°C and stirred until homogenous. 2g 
sucrose crystals, PVA powder, starch powder, porcine skin collagen (all Sigma, 
UK) or inulin (FibreSure, UK) were added and the mixture stirred until dispersed. 
The mixtures were cast inside a 10ml polypropylene syringe body and allowed to 
air dry at room temperature overnight. 
  
The cylinders were cut into discs and the porogens washed out in three changes 
of dH2O, stirred using a magnetic flea in water heated to 30°C for one hour per 
change. Discs were dried and gold coated using a sputter coater before being 
imaged in a Jeol JSM8340 scanning electron microscope. 
 
2.1.2. Porosification using soluble templates. 
 
Templates were formed using porcine skin collagen and poly(vinyl alcohol) (both 
sigma, UK) by dissolving 20g polymer in 5-10ml water at 30°C and stirring until a 
homogenous and viscous solution was formed. The solution was poured into a 
10ml polypropylene syringe which was fitted with a small-diamter nozzle 
fashioned from a 20Ƭm pipette tip. The solution was forced through the nozzle 
directly over a 250ml measuring colmn containing 200ml ethanol at -80°C. 
 
Rapid cooling plus substitution of ethanol for water in the polymer solution 
precipitated the polymer into a continuous strand which collected as a solid three-
dimensional coiled mesh at the base of the measuring cylinder. 
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The mesh was removed and dried at room temperature and placed into a vertical 
10ml polypropylene syringe body. 20g of PCL dissolved in 10ml acetone was 
added and allowed to permeate through down the mesh before being cooled to -
80°C to rapidly cast the PCL. The PCL-template was allowed to air dry overnight 
before being cut into discs and the pore template washed out in three changes of 
dH2O, stirred using a magnetic flea in water heated to 30°C for one hour per 
change. Discs were dried and gold coated using a sputter coater before being 
imaged in a Jeol JSM8340 scanning electron microscope 
 
2.1.3. Porosification using caramelised sucrose templates. 
 
Sucrose (Sigma, UK) was heated without stirring on a hotplate set to 180°C until 
melted and a colour change from colourless to light brown was observed. Sugar 
was spun in two ways, firstly by flicking the caramel from the end of a spoon in a 
random patttern onto siliconised paper.  
 
The second method was by immersing a purpose-made 16-prong fibre spinning 
tool in the caramel and passing it across a siliconised sheet as shown in fig. 7. 
Secured filter paper pads acted as anchoring points for the fibres which were 
stretched across the sheet and fixed onto a second pad. The tool was moved to a 
third side and the process repeated. Caramel was reapplied every 15-20 passes and 
each pass was performed as quickly as possible to prevent cooling and breakage of 
the fibres. Once a sufficent amount was deposited the central region containing 
strands running in both directions was removed and used as a pore template 
 
10mg polycaprolactone was dissolved in 10ml acetone at room temperature and 
stirred until homogenous. The caramel pore template was placed on a sheet of 
siliconised paper and the polmer solution poured over and allowed to dry. Once 
set, the edges of the polymer were removed to expose the caramel-contaning 
region and the material placed in 500ml water, stirred at 30°C for 24 hours until 
all the caramel had removed.  
 
In a second experiment, porous silicon (70% porous, 10Ƭm particle size) 
microparticles were added to polycaprolactone in acetone at 8% composite weight 
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(20mg per 250mg PCL). The above process was repeated to provide a porosified 
composite. Analysis was by scanning electron microscopy. 5.0 mm sections of the 
material were cut, gold-coated and mounted on aluminium stubs for imaging.  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7. Diagram of caramel porogen spinning technique. Caramelised fructose at 
160-180°C is applied to the fibre spinning tool which is then touched to a 
reservoir pad and fibres stretched to an opposing pad. The tool is moved to a an 
adjacent pad (90°) and the process repeated to form a cross-hatched region in the 
middle of the paper which is subsequently used for porogenesis. 
 
 
 
2.2. Screw fabrication. 
 
Example screws were manufactured from either extruding melted 
polymer/composite into a custom made composite mould based on 
measurements taken from a similarly sized titanium screw (2.5mm diameter, 6mm 
length) or melt-cast inside a stainless steel nut (internal diameter  12mm, length 
14mm). Mechanical testing was performed using screws cast inside stainless steel 
nuts using an Instron 5569 compressive testing system with a 50 KN load cell.  
 
The nut was held in a recessed block over a central hole and a 6mm diameter steel 
dowel clamped in the upper grip. The dowel was lowered to touch the 
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polymer/composite surface and then pushed out through the nut at 2 mm/min. 
The force (N) required to push out the screw was measured for PCL and 4% or 
8% composites and the failure mode determined by SEM of sections through the 
pushed-out material. 
 
 
2.3. PMMA bone cement incorporating pSi. 
 
2.3.1. Characterisation of pSi-PMMA in water. 
 
Composites containing 8% pSi in PMMA were made by mixing PMMA in 
acetone (66% w/v) with pSi microparticles and casting in the body of a 5ml 
polypropylene syringe. Whilst residual acetone was present in the composite, discs 
were cut from the cylinder and air-dried overnight at room temperature before 
weighing, resulting in 250mg ± 10mg discs. PMMA discs were made by the same 
process without the addition of pSi. Discs were incubated in 50ml dH2O at 37°C 
for 24 weeks in 50ml polypropylene screw-capped tubes. 400Ƭl of the incubation 
solution was removed, replaced and tested for silicic acid using the molybdenum 
blue assay every week for 8 weeks.  
 
At 4, 8, 12 and 24 weeks the discs were removed from the solution and allowed to 
air dry overnight at room temperature before being observed and reweighed to 
assess mass loss/gain. At 4 and 8 weeks the pH of the solution was measured 
using a Hannah 120 bench top pH meter. 
 
2.3.2. Response of osteoblasts to pSi-PMMA composites in vitro. 
 
pSi-PMMA composite discs were formed using acetone and containing 0, 1, 10 or 
20 mg pSi weighing 250mg ± 10mg and sterilised in 70% ethanol before being 
dried completely overnight in 24-well plates (Nunc) in a sterile fume hood.  
 
Osteoblasts were cultured to passage 30 - 35 in DMEM supplemented with 10% 
FCS, 2mM L-glutamine, 1% non-essential amino acids, 0.2mM HEPES, 
150Ƭg.ml-1 ascorbic acid, 2% penicillin/streptomycin and with 10mM sodium ฀-
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glycerophosphate and 10-7M dexamethasone (all Sigma, UK). Cells were seeded at 
a density of ~105 cells.ml-1 directly onto the disc surface with a disc-free well used 
as a control. 
 
1ml media was added per well which was replaced daily for 28 days. One plate was 
analysed every 7 days by rinsing each well carefully in PBS followed by freeze-
thawing the plate with 1.0ml H2O per well for three cycles between -80°C and 
20°C. DNA and collagen were quantified and alkaline phosphatase activity was 
measured at each time point. At 28 days, osteoblasts growing on 54% composite 
discs were stained and assayed for calcium only. 
 
Cell lysates and discs/wells were analysed for DNA and collagen content, alkaline 
phosphatase content and calcium deposition as described in section 3.2.2. 
 
2.3.3 Drug release from PMMA-pSi composites. 
 
A 66% (w/v) solution of PMMA / acetone was made and fluorescein added to 
create 250mg polymer discs containing 1mg, 5mg or 10mg fluorescein. PMMA in 
acetone was also mixed in with 8% (w/w) porous silicon containing the same 
quantities of fluorescein and formed into 250mg discs. 
 
The discs were air-dried at room temperature overnight to evolve residual solvent 
and reweighed before being placed in wells of a 24-well plate and 1ml dH2O 
added. The plate was incubated at 37°C for 24 days. The solution was exchanged 
daily, with the well being rinsed each time with dH2O to remove residual 
fluorescein. The solution was assayed for fluorescein content by placing 200Ƭl 
into a clear-bottomed 96-well plate and measuring the fluorescence of the sample 
in an automated plate reader at 360nm / 460 nm (excitation/emmission). The 
results were compared to fluorescence of known concentrations of fluorescein.  
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3. Results. 
 
3.1. 3-D scaffold fabrication. 
 
3.1.1. Particulate porogens. 
 
Porosification using soluble particulate porogens such as sucrose crystals (fig. 8), 
powdered starch (fig. 9), inulin (fig. 10) and porcine skin collagen (fig. 11) results 
in unconnected pores. The pores, or voids, have the same shape as the particle 
which formed them, e.g. cubic when sucrose crystals were used. Admixed PVOH 
(fig. 12) generated a pore network, some of which appeared to be continuous. 
 
  
Fig. 8. Porosification using sucrose crystal leaching results in the formation of 
cubic voids in the material which are not interonnected. 
 
 
  
Fig. 9. Porosification using powdered starch results in a material which appears 
spongy and formed from polymer filaments with little microscopic architecture or 
detail and large aggregations of unporosified material. 
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Inulin-porosified PCL showed a much more open network initially with large 
pores forming as the material was cast. Scanning electron microscopy of inulin-
porosified PCL (fig. 10) shows large pores are formed, with distinctivly textured 
pore walls caused by inulin particles beneath the surface. Interestingly, the 
polymer coating of the inulin particles appears to restrict dissolution of the 
polysaccharide. 
 
  
Fig. 10. Scanning electron micrographs of polycaprolactone porosified with 40% 
w/w inulin.   
 
 
  
Fig. 11. Porosification using porcine skin collagen results in irregular pores, some 
of which interconnect through the thin walls between spaces. 
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Fig. 12. Admixtures of PCL/PVA produced a porous network which appeared to 
be continuous, with a variety of pore sizes from 10 - 100Ƭm in diameter. 
 
 
 
3.1.2. Porosification using soluble templates. 
 
Use of dissolvable poly(vinyl alcohol) (fig. 13) and collagen (fig. 14) templates to 
create interconnected pores were partially successful. The templates were 
recovered from being precipitated in cold ethanol and retained their 3D form 
during casting of PCL around them, although it was noted that PVA was very 
brittle and collagen softened rapidly at room temperature through the thawing of 
internal water which had been frozen during precipitation. 
 
 A                              B  
 
 
 
 
 
 
Fig. 13. PVA was formed as a 3D template (A) by precipitating PVA/water into 
cold ethanol through a fine nozzle. The resulting mesh was used as a template 
around which PCL was cast. After 2 hours in 1M HCl solution and following 
drying, residual PVA remained in the pores in the material (B) whilst the PCL 
matrix was also degraded by the acid. 
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A further difficulty was experienced in removing the template. Some collagen 
remained in the material even after 72 hours continuous stirring in warm water, 
whilst PVA became hydrated and pliable but did not readily dissolve from inside 
the material. Lowering pH of the removal solution by addition of HCl (to create a 
1M HCl solution) was successful in solubilising the PVA but degraded the PCL. 
 
 
Fig. 14. Gelatin (collagen) meshes formed a comprehensive network of pores, but 
as shown from this SEM image, collagen was not washed out from the material 
despite extendive washing and dessicated to remain inside the pores. 
 
 
 
3.1.3. Porosification using caramelised sucrose templates. 
 
The first method for producing pores using this method (randomly flicked 
strands) resulted in an uneven network of pores and larger spaces resulting from 
globules of sugar, but demonstrated the proof of principle. The second method 
(fibre-spun mesh) produced a dense mat of strands which were evenly spaced in 
all three dimensions and free of large globules. SEM images of the porogen 
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strands are shown in fig. 15, fig. 16 and fig. 17 illustrating the fibre diameter, and 
connections between the fibres. 
 
  
Fig. 15. Spun sugar fibres used as a three-dimensional template for pore 
formation. Fibres here have been aligned in one direction during formation using 
the fibre-spinning tool. Interconnections are visible between strands in image B, 
developed during formation through the fibres sticking together and being pulled 
apart. 
 
 
    
Fig. 16. A larger image of an interconnection between sugar strands. 
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Fig. 17. A larger image of several interconnections between sugar strands. 
 
 
Rapid and minimal handling of the material was necessary as atmospheric 
humidity rendered the strands adherent and longer periods (>2 hours) resulted in 
the collapse of the 3-dimensional form. Addition of PCL in acetone did not 
deform the matrix and no mould was required  the strength and density of the 
spun fibre network was sufficient to contain the polymer solution. 
 
Drying of the polymer and removal of the porogen was effected within 24 hours 
in 500ml agitated warm water; sections through the material demonstrated that 
~95% of the sugar had been removed.  
 
The pore walls of caramel-porosified PCL are smoother and more uniformly 
rounded with smoothly contoured pore interfaces. The addition of 8% (w/w) pSi 
to the polymer phase results in a harder composite as seen in previous studies 
pores at cut surfaces.  
 
with the result here of more defined edges to pore interfaces and preservation of 
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Fig. 18. Caramelised spun-sugar porosified polycaprolactone (A-C) and pSi-PCL 
composite (D) showing pore and surface morphology and rounded pore-
interfaces.  
 
 
 
3.2. Mechanical testing of orthopaedic screws.  
 
The screw which was manufactured to the specifications for metal bone screws 
(fig. 19) and BS3531 was considered to be too flexible and the thread too weak 
for testing (fig. 20). The screws moulded directly from nuts were strong enough 
to unscrew out of the mould (using a hexagonal key) and imaged using SEM (fig. 
21). The PCL-only screw has uneven threads caused by deformation on removing 
from the mould, whereas the pSi-containing screws showed a more defined 
thread, corresponding to the enhanced hardness and indentation resistance 
displayed by the composite.  
 
Appendix 
    
Fig. 19. Titanium maxillo-facial / mandible cortical bone screw. 
 
 
    
Fig. 20. Screw fabricated from mould designed to specifications detailed above
llowing screw threads in fig. 19 (above). 
 
fo
 
 
The failure mode of all screws during the push-out test was by plastic deformation 
of the thread  screw threads did not shear or break at any part at the composite 
ratios used here (up to 8% pSi) as shown in fig. 21.D. 
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Fig. 21. Scanning electron micrographs of screw threads cast inside nuts: A. PCL, 
B. 10mg (4%) pSi composite, C. 20mg (8%) composite. D. shows the failure 
mode of the PCL screw recovered after testing which was the same for all 
materials tested. 
 
 
he force required to push out the screw from the mould was slightly lower for 
 requiring 1078 N to fully 
ush out the screw from the mould, higher than the mean for PCL (1035 N), 
plying that the poorer mechanical properties may result from inconsistencies in 
fabrication of the composites and the presence of voids. 
T
composites than for PCL, being 96.8% (for 10mg) and 96.3% (for 20mg) of the 
force required to fully push out PCL screws (fig. 22). Greater variability in 
composite strength was observed, with one 20mg screw
p
im
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Fig. 22. Force required to push-out screw from nut. Error bars are standard error 
of the mean, n = 4. 
 
 
 
3.3. pSi-PMMA bone cement. 
 
3.3.1. Characterisation of PMMA bone cement incorporating pSi. 
ond order line of best fit 
(R2) for the data of 0.9701. The pH of solutions incubating composites were 
lower than those incubating PMMA alone. 
 
PMMA bone cement composites were made containing 8% pSi. Fig. 23 shows 
the results of incubating the composite in dH2O for 24 weeks in comparison to 
PMMA-only discs. Initial gain in mass for all discs (attributed to water ingress into 
the material) diminishes over time, resulting in net mass loss observed for all discs 
at 24 weeks, although this is less for composites due to silica deposition. Silicic 
acid release was almost linear over the first 8 weeks (linear R2 = 0.9524) with a 
slight increase in silicic acid release rate indicated by a sec
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Fig. 23. PMMA and 8% pSi-PMMA incubated in dH2O. The change in mass of 
both PMMA and pSi-PMMA over 24 weeks was similar, showing an initial 
increase in mass followed by decrease (A). Silicic acid release into 50ml dH2O 
over the first 8 weeks was linear (B) with a linear regression coefficient of 0.9524 
(compared to the slightly better polynomial line of best fit, R2 = 0.9701) showing 
a slight increase in silicic acid release rate over time. pH of solutions incubating 
both PMMA and pSi-PMMA at 4 and 8 weeks were acidic, with composite pH 
significantly lower at both time points (C). 
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3.3.2. Response of osteoblasts to pSi-PMMA composites in vitro. 
 
e amount of calcium detected on the 
iscs after 4 weeks. Cell growth (C) was comparable on all discs, but osteoblast 
opulations were lower on 20mg composites. Alkaline phosphatase (D) per Ƭg 
NA was similar at each time point for all discs except 20mg pSi which was 
ignificantly lower throughout. Collagen per Ƭg DNA (E) was also not 
ignificantly different at each stage for any of the discs. 
Fig. 24. Osteoblast response to PMMA-pSi composites over 4 weeks in vitro. A 
and B show the concentration of silicic aid which was detected in a parallel study 
using 1ml H2O as dissolution media and th
d
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3.3.3. Drug release from PMMA bone cement incorporating pSi. 
 
Release of an example drug, fluorescein, from PMMA and from pSi 
microparticles in a PMMA matrix shows a marked increase in release of the 
molecule when pre-loaded into pSi (fig. 7.25.B). Release of the molecule is linear 
until depleted (fig.7.25.A), although only a maximum of 0.1% of the total 
fluorescein loaded was detected in the solution, indicating that a small region of 
the PMMA-pSi was permeable to water to allow fluoresein dissolution and release. 
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Fig. 25. Fluorescein release from 8% PMMA-pSi is proportional to the loading 
concentration of fluorescein into the microparticles (A) and is significantly greater 
than release from PMMA controls (B). Release rate of fluorescein is directly 
proportional to loading concentration (coefficient of linear regression, R2 = 
0.9998) Error bars are standard error of the mean, n = 4. 
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4. Discussion. 
 
Numerous methods have been developed for porosifying biomaterials, from basic 
techniques such as gas-evolution and particulate leaching to high-technology 
solutions such as rapid prototyping and supercritical fluid degassing. Advanced 
techniques however often require specialised and expensive apparatus and 
although successful are more appropriate for larger research groups and well-
characterised materials. Simpler techniques are required for smaller and less well-
funded groups and as such, numerous methods have been developed but few of 
these produce contiguous pores, high-density/strength materials or can achieve 
porosity without cytotoxic chemicals (e.g. salt, residual solvents). 
 
It was discovered during early experiments that spun sugar meshes could be used 
as a pore template for cast polymers as PCL and PCL-pSi can be cast at 
temperatures much lower than the melting point for spun sugar without the use 
of solvents. Spun sugar has several advantages over other porogens tested here: 
 
 Viscosity determines fibre size and is dependent on caramel temperature. 
 Typical fibre size is 50-100Ƭm. 
 Touching fibres stick together, forming a connection betweeen subsequent 
pores. 
 Humidity softens the sugar at the connections, increasing the interfacial area 
between strands and the diameter of pore connections. 
 Caremelised sugar is fully soluble in water, allowing easy extraction and 
porogenesis at low temperatures. 
 
The method described here is able to produce continuous pores through a 
polymer material without use of harmful chemicals or expensive apparatus and 
only a limited amount of experience is required. Further developments of this 
romise 
technique would focus on the ability of the porosified composites to induce 
osteoblast colonisation of the scaffold. 
 
The wide range of sizes in which orthopaedic screws are currently available have 
been optimised by consultation with surgeons to offer the best comp
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between strength and size. Consequently, the surgeon consulted during this work 
as aware of a number of limitations for biodegradable screws, chiefly that small 
d bioactivity) on 
e screws strength and failure mode. The results show that the addition of pSi to 
er 
CL, providing greater resistance to plastic deformation. To support this, further 
ty years of clinical use, fundamental 
r fixation have so far 
no published research has highlighted 
ethods for improving the osteointegration of the prosthesis-cement system with 
echanical strength (based of data using PCL as the polymer phase).  
w
plastic screws can never be strong enough for fixation. In fact, the smallest sizes 
of maxillo-facial screw were too weak and flexible to be tested in this 
investigation. 
 
Companies such as Inion have successfully manufactured and commercialised a 
range of small, strong screws based on unique co-polymers, but the research 
behind developing such an advanced composite were far beyond the remit of this 
project. The aim of this part of the investigation was to assess the impact of 
adding pSi particles to a PCL bone screw (in ratio with a define
th
polycaprolactone screw do not significantly affect the mechanical properties of 
the screw (up to 8% w/w pSi as tested) and the morphology of the screw threads 
is preserved to a greater extent in the composite. This is supported by the results 
in chapter 6, indicating that the elastic modulus is higher for pSi-composites ov
P
investigation into impact resistance are required. 
 
Poly(methyl methacrylate) continues to be used as the main form of fixation for 
articular prostheses. Despite over thir
inadequacies regarding failure and lack of biological compatibility remain inherent 
to its use. Mechanisms which strengthen cement used fo
focused on eliminating voids in the material and optimising the duration with 
which the cement can be applied, but 
m
living bone. 
 
Addition of porous silicon microparticles may present such an opportunity. This 
investigation has shown that PMMA can be loaded with sufficient pSi to render 
class I bioactivity (formation of a calcium phosphate layer) without compromising 
m
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Addition of pSi in known ratios results in a predictable release rate of orthosilicic 
acid from the composite. Due to the non-permeable nature of PMMA, pSi 
degrades from the surface regions only, resulting in a linear, first order 
relationship between loading and release.  
 
Bone cement / pSi composites were not shown to exhibit increased bioactivity in 
 eluted from the water-available 
olume within 7 days. The amount released is equal to 8.3 x 10-3% of the total 
ne cements with pharmaceuticals whilst maintaining a mechanically 
trong bond between bone and the metal prosthesis. 
this investigation however. 1mg and 10mg composites exhibited similar levels of 
cell proliferation, alkaline phosphatase activity and collagen deposition as PMMA 
controls. 20mg composites showed markedly lower cell activity than controls. 
 
Fluorescein was used here as an example of an API which could be loaded into 
pSi and released from PMMA bone cement. As discussed in chapter 3, fluorescein 
displays similar chemical properties to aminoglycoside antibiotics such as 
gentamicin and was used here to simulate such pharmaceuticals. The release 
profile generated was similar to the silicic acid release profiles described above. 
Due to the non-permeable matrix, fluorescein was eluted from a thin surface layer 
of composite and displayed a predictable profile based on known initial amounts 
of pSi and fluorescein. 1mg fluorescein was fully
v
loaded, indicating that the layer available for dissolution is very small.  
 
Despite this, the amount of fluorescein eluted from PMMA without the pSi 
vehicle was an order of magnitude less than when pSi was used. This data suggests 
that current dosages of gentamicin in bone cement may be reduced by a factor of 
10 if pSi is used as a drug delivery vehicle in the cement; alternatively, larger doses 
of antibiotics (and other drugs) may be added, increasing the effective loading 
ability of bo
s
